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Abstract 
 
The inner lining of the vasculature is a monolayer of endothelial cells that 
performs a multitude of functions with importance for cardiovascular health. 
Many of the functions are regulated by or are dependent on the calcium ion 
(Ca2+), a major intracellular signalling factor.  
 
The overall aim of this thesis was to investigate molecular mechanisms and 
pharmacology of Ca2+ entry mechanisms and their downstream signalling in 
endothelial cells. Molecular, biochemical and electrophysiology techniques and 
cell functional assays were used to address two main objectives. The first 
objective was to investigate putative Ca2+ channel regulator proteins, 
CRACR2A and golli-MBP. Based on previous reported studies, it was 
hypothesised that both of these proteins would have a role in regulating 
endothelial cell store-operated Ca2+ entry. However, unexpectedly these 
proteins had Ca2+ channel-independent functions, leading to alternative 
hypotheses about their roles in endothelial cells. The second objective was to 
generate new information about pharmacology targeted to a Ca2+ channel 
subunit, TRPC6, which has been suggested to be important in endothelial cell 
biology. Specifically, it was hypothesised that the anti-cancer agent 
carboxyamidotriazole (CAI) and the flavanol galangin and its derivatives, which 
have previously been shown to inhibit intracellular Ca2+, were TRPC6 channel 
inhibitors. 
 
Endothelial cells did not express CRACR2A as reported for T cells (Srikanth et 
al., 2010) but did express a longer splice variant arising from the same gene, 
EFCAB4B isoform a (EFCAB4B-a). CRACR2A and EFCAB4B-a have the same 
putative Ca2+ binding domains at their N termini but EFCAB4B-a, unlike 
CRACR2A, had no role in the regulation of Ca2+ release-activated Ca2+ (CRAC) 
channels. Instead, EFCAB4B-a contained a predicted Rab domain in its C 
terminus and was therefore a putative monomeric G protein. It localised to 
endothelial cell specific Weibel-Palade bodies and influenced the abundance of 
the pro-thrombotic agent von Willebrand factor. Golli-MBP was found expressed 
iv 
 
in endothelial cells but again there was little effect on CRAC channel activity. 
Instead golli-MBP was identified as a positive regulator of the important 
endothelial growth factor receptor, VEGFR2.  
 
The small-molecule CAI, was identified as an inhibitor of TRPC6 channels 
without effect on TRPC5 or TRPV4 channels. A range of flavonol compounds 
was also identified as TRPC6 inhibitors. 
 
In summary, this research has generated new information and hypotheses 
about a putative Ca2+-regulated Rab protein of Weibel-Palade bodies, a novel 
regulator of a key endothelial growth factor receptor, and a molecular target for 
CAI. It has, therefore, led to understanding of molecular mechanisms and 
pharmacology in endothelial cells which may be useful for devising strategies to 
treat life-threatening conditions such as cardiovascular disease and cancer. 
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CHAPTER 1. INTRODUCTION 
 
Lining the inner surface of the entire vasculature is a monolayer of endothelial 
cells which together make up the endothelium. The endothelium forms a semi-
permeable barrier between the blood and tissues and performs vital 
physiological functions such as regulation of blood flow and blood pressure, 
haemostasis, inflammatory responses and angiogenesis (Khazaei et al., 2008). 
Endothelial cells also play a key role in pathophysiological processes such as 
tumour angiogenesis (Hoeben et al., 2004) and endothelial dysfunction is a 
hallmark of many cardiovascular diseases such as atherosclerosis and 
hypertension (Khazaei et al., 2008). Endothelial cells have therefore become an 
attractive therapeutic target. Many endothelial cell processes depend on 
calcium, an important signalling factor in endothelial cells. Research in our 
laboratory is focused on calcium entry mechanisms and the downstream effects 
of calcium on endothelial cell processes in the context of cardiovascular disease 
and cancer. This introductory chapter will provide a short background on 
endothelial cell anatomy and physiology; endothelial cell dysfunction and 
cardiovascular disease; calcium regulation in endothelial cells with a particular 
focus on store-operated calcium entry (SOCE) channels, and therapeutic 
targeting of endothelial cell calcium.  
1.1. The vascular endothelium: physiology and function  
 
The human endothelium is a dynamic, multifunctional ‘organ’ composed of 
approximately 1x1013 endothelial cells (ECs) with a combined mass of around 1 
kg, which is approximately 1% of body mass (Galley and Webster, 2004, 
Khazaei et al., 2008). Lining the inner surface of the vasculature, ECs have an 
important role in regulating the transfer of molecules between the circulating 
blood and tissues. In this regard the endothelium is often referred to as the 
‘blood-tissue barrier’. Being in direct contact with the circulating blood, ECs are 
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responsible for detecting and responding to changes in hemodynamic forces via 
membrane receptor mechanisms and the synthesis and release of vasoactive 
substances (Khazaei et al., 2008). In the same way, ECs contribute to the 
regulation of blood flow and blood pressure through the release of vasodilator 
and vasoconstrictor substances, which are important for controlling vascular 
tone (Khazaei et al., 2008). A major vasodilator synthesised and released by 
ECs is nitric oxide (NO). NO has several beneficial effects on the cardiovascular 
system including inhibition of platelet aggregation, smooth muscle cell 
proliferation and anti-atherosclerotic effects (Khazaei et al., 2008). ECs release 
vasoconstrictors and these include endothelin (ET)-1 and prostaglandin H2. 
Other important vasomotor factors are shown in Figure 1-1. In addition to 
hemodynamic functions, ECs also regulate thrombosis and thrombolysis. An 
important substance involved in thrombosis and coagulation is von Willebrand 
factor (vWF), which is synthesised by ECs and stored in organelles, unique to 
ECs called Weibel-Palade bodies (Valentijn et al., 2011). These are rod-shaped 
secretory-like granules that release large multimers of vWF during inflammatory 
processes or infection (Sumpio et al., 2002). ECs are involved in a number of 
other key processes, including platelet activation and aggregation, inflammation 
and immune modulation, vascular smooth muscle cell proliferation, vascular 
permeability, vasculogenesis and angiogenesis, some of which will be 
discussed in more detail below. Figure 1-2 shows schematically the general 
organisation of the endothelial cell.  
1.1.1. Angiogenesis 
 
One of the most important EC functions is angiogenesis. Angiogenesis is 
defined as the growth of new blood vessels from pre-existing ones and is vital 
for physiological processes such as wound healing, growth and reproduction 
(Hoeben et al., 2004, Khazaei et al., 2008). Pathologically, angiogenesis is 
important for tumour growth, psoriasis, diabetic retinopathy and rheumatoid 
arthritis (Hoeben et al., 2004). Angiogenesis involves endothelial cell migration 
and proliferation, the selective breakdown of the extracellular matrix by 
proteases such as collagenase, further migration and sprout formation (Khazaei 
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et al., 2008). During normal physiological conditions a delicate balance of pro 
(stimulatory) and anti (inhibitory) angiogenic factors circulate in the blood 
(Hoeben et al., 2004).  A change in the balance of these circulating factors can 
result in a switch to a pro-angiogenic phenotype. The most potent stimulators of 
angiogenesis are growth factors, of which one of the most important is vascular 
endothelial growth factor (VEGF).  
 
VEGF 
VEGF was first discovered in the late 1970s as a tumour-secreted protein which 
was found to greatly increase microvascular permeability to circulating 
macromolecules and hence was given the name vascular permeability factor 
(VPF) (Dvorak et al., 1979). VPF was shown to increase permeability at 
concentrations as low as 1 nmol/L, 50,000 times more potently than histamine 
(Dvorak et al., 1999, Dvorak, 2002).  
 
VEGF family 
VPF (also known as VEGF-A) is member of the platelet-derived growth factor 
(PDGF) superfamily of growth factors (Dvorak, 2002). Other members of this 
family include VEGF-B, VEGF-C, VEGF-D and placenta-derived growth factor, 
PIGF (Hoeben et al., 2004). All of these growth factors are dimeric 
glycoproteins and all contain a conserved VEGF homology domain (Hoeben et 
al., 2004). VEGF-A is the most well characterised of the VEGF proteins. VEGF-
A is a 34 - 45 kDa protein with highest mRNA levels found in the adult lung, 
heart, kidney and adrenal gland and lower levels in the gastric mucosa, spleen 
and liver (Hoeben et al., 2004). There are different isoforms of VEGF-A but 
VEGF-A165 is often the predominant form (Hoeben et al., 2004). VEGF-A has 
several unique properties: it is essential for the development of a vascular 
system as evidenced by both the null (VEGF-A-/-) and heterozygote (VEGF-A+/-) 
animals that are embryonic lethal (Carmeliet et al., 1996, Ferrara et al., 1996); it 
is selective for ECs since its major receptor, VEGFR2, is selectively expressed 
on vascular endothelium, compared to other growth factors that are 
comparatively less selective for ECs (Dvorak, 2002), it can increase vascular 
permeability (Dvorak et al., 1979) and it is up-regulated in many human cancers 
(Duncan et al., 2008).  
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VEGF receptors 
In the early 1990s the VEGF receptors were characterised (reviewed by 
(Shibuya and Claesson-Welsh, 2006). The 3 tyrosine kinase receptors identified 
are structurally highly related; they are: VEGFR1, VEGFR2 (also known as KDR 
in humans) and VEGFR3 (Hoeben et al., 2004). VEGFR2 and VEGFR3 are 
more active kinases than VEGFR1, which has 10 times lower kinase activity 
than VEGFR2 (Shibuya and Claesson-Welsh, 2006). VEGFR2 binds VEGF-C 
and VEGF-D but is most important for its role in VEGF-A-induced vascular 
permeability and angiogenesis (Hoeben et al., 2004). VEGF-A binding to 
VEGFR2 results in the autophosphorylation of various tyrosine residues on 
VEGFR2 (Hoeben et al., 2004). Autophosphorylation of Tyr1175 results in the 
binding of phospholipase C (PLCγ1) which generates an increase in inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) leading to a rise in 
intracellular Ca2+ but also activating protein kinase C (PKC), which 
subsequently activates Ras, which is involved in downstream gene transcription 
events (Hoeben et al., 2004).  
 
Tumour angiogenesis 
For a tumour to grow beyond 1-2 mm3 it must develop its own blood supply – a 
process which is termed tumour angiogenesis (Hanahan and Weinberg, 2000). 
When a tumour reaches 1-2 mm3 the balance of pro- and anti-angiogenic 
factors is shifted in favour of angiogenesis. ECs isolated from tumour blood 
vessels are phenotypically and genetically different from ‘normal’ endothelial 
cells and are often described as dysfunctional (Dudley, 2012). Tumour blood 
vessels are often chaotic and leaky and no longer form a single layer of regular 
shaped cells, but instead take on an irregular shape and size with cytoplasmic 
protrusions stretching across the lumen of the vessel (Dudley, 2012). There still 
remains some debate as to the origin of tumour blood vessels - whether they 
have developed from pre-existing ‘normal’ vessels or whether stem-like tumour 
cells have trans-differentiated to form an endothelium (Hendrix et al., 2003). 
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However, regardless of origin, the endothelial lining of these vessels is 
morphologically and genetically distinct from ‘normal’ vessels.  
1.1.2. Endothelial permeability 
 
ECs form a barrier between the circulating blood and tissues (Goddard and 
Iruela-Arispe, 2013) The integrity of this barrier is regulated in various ways 
including intercellular junctions such as tight junctions and adherence junctions 
(Goddard and Iruela-Arispe, 2013). Tight junction proteins include claudin-5, 
occludin and junctional adhesion molecules and vascular permeability is 
increased when these proteins become phosphorylated (Goddard and Iruela-
Arispe, 2013). Adherence junctions are mainly composed of the calcium-
dependent VE-cadherin proteins (Goddard and Iruela-Arispe, 2013). When ECs 
become exposed to permeability factors such as thrombin, VEGF and 
histamine, VE-cadherins become phosphorylated and internalise, which 
disrupts the integrity of the barrier (Goddard and Iruela-Arispe, 2013). Different 
adherent proteins exist in different vascular beds. In particular, in tumour blood 
vessels, junctions are very weak and hence vessels are very leaky (Dudley, 
2012). VEGF is the most potent permeability factor and the mechanisms 
involved in VEGF-induced increases in permeability include junctional 
remodelling, induction of fenestrae and other downstream signalling events 
such as PLC-dependent increase in intracellular Ca2+, phosphorylation and 
internalisation of junctional proteins, eNOS signalling and dissociation of VE-
cadherin complexes (Goddard and Iruela-Arispe, 2013). Other permeability 
factors include the inflammatory mediators histamine, thrombin and bradykinin, 
all of which evoke a transient increase in vascular permeability followed by 
barrier stabilisation (Goddard and Iruela-Arispe, 2013).  
1.1.3. Haemostasis 
 
Another important role of ECs is in haemostasis, a physiological process that 
allows bleeding to stop. Circulating in the blood is a balance of prothrombotic 
and antithrombotic factors (Figure 1-1), which maintain haemostasis. During 
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normal physiological conditions, ECs produce prostacylin and NO, which work 
to prevent the adhesion of platelets and subsequent aggregation (Khazaei et 
al., 2008). However, during vessel damage and wound healing ECs increase 
their release of pro-thrombotic factors such as von Willebrand factor (vWF) 
through Ca2+-dependent exocytosis, which interacts with the platelet 
glycoprotein complex allowing platelet adhesion and aggregation resulting in 
clot formation (Khazaei et al., 2008).  
1.2. Endothelial dysfunction 
 
Endothelial dysfunction occurs as a result of phenotypic changes to healthy 
ECs and is characterised by an increase in contracting factors combined with 
an overall shift towards a proinflammatory, procoagulatory and proliferative 
environment along with an increase in vascular permeability (Bonetti et al., 
2003, Widlansky et al., 2003). These phenotypic alterations mark an early step 
in the development of atherosclerosis, a major precursor of cardiovascular 
disease, which is the main cause of death in Europe responsible for over 4 
million deaths each year (European Cardiovascular Disease Statistics 2012 
edition) (Widlansky et al., 2003).  
 
Atherosclerosis is a disease of the arterial vessels, which involves the 
thickening of the vessel wall through accumulation of fatty material and 
importantly low density lipoprotein (LDL) (Singh et al., 2002). Lipoproteins, 
monocytes and macrophages are able to accumulate in the vessel due to an 
increase in vessel permeability, a key characteristic of endothelial dysfunction 
(Khazaei et al., 2008). The build-up of fatty material or ‘streaks’ in the vessel 
wall is a trigger for an inflammatory response (Weber and Noels, 2011, Esper et 
al., 2006). When the LDL becomes oxidised within the vessel wall by reactive 
oxygen species or enzymes, this triggers further immune response including 
expression of adhesion molecules and secretion of chemokines by the ECs, 
which results in T cells and macrophages travelling to the damaged site and 
absorbing the oxidised LDL (Weber and Noels, 2011, Esper et al., 2006). Since 
the oxidised LDL cannot be effectively broken down, it builds-up and can 
rupture releasing cholesterol into the circulation, triggering further immune 
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responses, amplifying the problem. If the process continues then eventually a 
cholesterol plaque is formed as a result of the inflammation and vascular 
smooth muscle cells form a hard cover over the affected area, which ultimately 
narrows the vessel, decreases blood flow and increases blood pressure. During 
this inflammatory cascade, the normal antithrombotic milieu is disrupted, 
decreasing the anticoagulatory potential of the endothelium and increasing 
procoagulatory mediators resulting in a thrombotic vascular environment (Esper 
et al., 2006). 
 
Hypertension represents another risk factor for cardiovascular disease, however 
there remains some debate as to whether hypertension is the cause or result of 
endothelial dysfunction (Dharmashankar and Widlansky, 2010, Panza et al., 
1993). 
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1.3. Endothelial cell signalling pathways 
 
For endothelial cells to effectively communicate and perform the range of 
functions that they do, many different signalling mechanisms exist. Signalling 
cascades are often initiated by extracellular signalling molecules that bind and 
activate cell surface receptors. The signalling of one molecule often signals to 
another and then to another and so on, amplifying the signal as it goes and 
finally distributing the signal to the appropriate effector molecule for example 
gene regulatory proteins or ion channels (Alberts et al., 2008). There are two 
key families of cell-surface receptors that are important in endothelial cells - G-
protein-coupled receptors and enzyme-coupled receptors. In addition, there are 
several principal intracellular signalling pathways activated by these receptors 
that are important for endothelial cell function including the RAS/Raf/MEK/ERK, 
PI3K/AKT, and IP3/DAG pathways (Figure 1-3). The first two of these pathways 
will be discussed below and the third will be discussed in greater detail in 
section 1.4.  
1.3.1. RAS/Raf/MEK/ERK pathway 
 
The RAS/Raf/MEK/ERK pathway is a conserved signal transduction pathway 
involved primarily in cell growth and proliferation. This pathway is stimulated by 
growth factors acting on their target receptor tyrosine kinase (RTK) at the 
plasma membrane (Alberts et al., 2008). RAS is part of a superfamily of 
monomeric GTPases and is involved in relaying signals from the cell surface 
through to effector molecules such as transcription factors and thereby affecting 
gene expression (Alberts et al., 2008). As with all small GTPases, RAS 
switches between an active GTP-bound state and an inactive GDP-bound state. 
Regulating this switch are numerous effector and adaptor molecules called 
guanine-nucleotide exchange factors (GEFs) that speed up the activation of 
RAS and GTPase activating proteins (GAPs) that increase the rate of hydrolysis 
and inactivate RAS (Colicelli, 2004) (Figure 1-4). RTKs couple to RAS via 
adaptor molecules called Grb2 and Shc and a GEF called “son of sevenless” 
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SOs (Alberts et al., 2008). Activation of RAS then phosphorylates the effector 
molecule Raf, which subsequently phosphorylates MEK and ERK. The ERK 
kinase then enters the nucleus and is involved in gene transcription. RAF, MEK 
and ERK are all mitogen-activated protein (MAP) kinases and therefore this 
signalling pathway is often referred to as the MAP kinase signalling pathway. 
Mutations in RAS are common in cancer and around 15% of human cancers 
have activating RAS mutations, which lead to aberrant cell growth (Malumbres 
and Barbacid, 2003). Evidence for the importance of this signalling pathway in 
endothelial cells is clear; MEK1 knockout mice show defective angiogenesis in 
the placenta and are embryonic lethal (Giroux et al., 1999). Two studies use a 
dominant negative (DN) approach and show that DN Raf results in endothelial 
cell apoptosis and inhibits tumour growth (Hood and Cheresh, 2002), and that 
DN MEK1 results in a decrease in the vascularisation of a tumour (Mavria et al., 
2006). In addition the ERK-MAPK pathway is essential for proliferation 
(Meadows et al., 2001).  
1.3.2. PI3K/Akt pathway 
 
Akt is a serine/threonine protein kinase, activated by a range of different growth 
factors including angiogenic growth factors such as VEGF, in a PI3 kinase 
(PI3K)-dependent manner (Shiojima and Walsh, 2002). Upon growth factor 
stimulation, the pleckstrin homology (PH) domain of Akt binds to the lipid 
products of PI3K, resulting in recruitment of Akt to the plasma membrane. Akt 
then becomes phosphorylated, yielding a fully activated kinase. The Akt/PI3K 
pathway is most widely known for its role as a cell-survival pathway since 
studies have shown that constitutive activation of this pathway is able to block 
cell death induced by a range of apoptotic stimuli, and that mutation of Akt in 
Drosophila results in embryonic lethality. However, this signalling pathway is 
also important for angiogenesis, since activating mutations in the PI3K pathway 
can suppress tumour vascularisation (Yuan and Cantley, 2008, Graupera and 
Potente, 2013). 
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1.4. The calcium ion – a major signalling ion in ECs 
 
Calcium (Ca2+) can be described as the chief intracellular signal, as it regulates 
a diverse range of cellular processes from rapid processes such as exocytosis 
(within microseconds), to longer-acting processes such as transcription (over 
several hours) (Berridge et al., 2003). In ECs, Ca2+ is required for many vital 
functions such as vasodilation and constriction, angiogenesis, vessel 
permeability and haemostasis (Khazaei et al., 2008, Tran et al., 2000). Control 
of cellular Ca2+ is carefully regulated so that the intracellular Ca2+ concentration 
is maintained at ~100 nM, whereas extracellular Ca2+ concentration is in the 
mM range creating a concentration gradient of around 20,000-fold (Clapham, 
2007a). With Ca2+ being so avidly extruded from the cytosol, the cell has 
evolved ways to exert control over Ca2+ levels, such as chelation, 
compartmentalisation and extrusion (Clapham, 2007a). This requires a balance 
of ‘on’ reactions that allow Ca2+ into the cytoplasm and ‘off’ reactions that 
remove Ca2+ (Berridge et al., 2003). Figure 1-5 schematically shows the 
mechanisms that a cell uses to control Ca2+ homeostasis. The details in this 
diagram such as major storage sites for intracellular Ca2+ and the various 
mechanisms that endothelial cells use to carefully control the balance of Ca2+ in 
the cell will be discussed in the next sections. 
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be carefully controlled. Increases in cellular Ca2+ arise through various ‘on’ reactions such 
as Ca2+ entry through membrane ion channels or the release of Ca2+ from the endoplasmic 
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receptor; ER/SR: endoplasmic reticulum/sarcoplasmic reticulum; NCX: Na2+/Ca2+ 
exchanger; SERCA: sarcoendoplasmic reticulum ATPase. Adapted from Berridge et al 
(2003).  
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1.4.1. Storage sites of Ca2+ 
 
Endoplasmic reticulum 
The endoplasmic reticulum (ER) is a multifunctional signalling organelle 
involved in the synthesis and packaging of proteins, but is also essential for 
many signalling processes (Berridge, 2002). With regard to the latter, the ER is 
the major intracellular store of Ca2+, where the Ca2+ concentration is maintained 
at 100-500 µM but can reach as high as 3 mM (Berridge, 2002, Tran et al., 
2000). In endothelial cells, 75% of the total intracellular Ca2+ is stored in the ER 
(Tran et al., 2000). It is vital that the ER maintains a constant luminal level of 
Ca2+ for the post-translational processing, folding and export of proteins 
(Berridge, 2002). In order to maintain a constant Ca2+ concentration, the ER 
contains buffers such as calreticulin that have a large capacity for Ca2+. In 
addition the ER contains Ca2+-sensitive chaperones such as GRP94 and 
calnexin which act in concert with the buffers to maintain a constant level of 
Ca2+ (Berridge, 2002). Should the ER Ca2+ level decline, this can have 
catastrophic effects due to activation of ER stress signalling pathways 
(Berridge, 2002). 
 
Mitochondria 
The remaining 25% of intracellular Ca2+ in ECs is contained in the mitochondria 
(Tran et al., 2000). The ER and the mitochondria are intimately connected and 
the two organelles cooperate to generate Ca2+ signals (Berridge, 2002). The 
mitochondria are important in sequestering Ca2+ that has been released from 
the ER but if large amounts of Ca2+ move from the ER to the mitochondria, a 
number of stress signals are induced (Berridge, 2002).  
 
Other intracellular Ca2+ stores 
Whilst the ER and mitochondria are the best-characterised cellular 
compartments for storing and releasing Ca2+, other vesicular compartments 
have been shown to accumulate Ca2+ including the Golgi, secretory vesicles 
and lysosomes (Dickson et al., 2012). Since these organelles are highly 
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localised within the cell, they have the capacity to take up or release Ca2+ in 
select ‘microdomains’, the importance of which is still under investigation.  
1.4.2. Regulation of Ca2+ 
 
Pumps and exchangers 
A number of Ca2+ pumps and exchangers are important for maintaining the 
resting level of Ca2+ in the cell at ~100 nM and ensuring that internal stores are 
kept loaded (Berridge et al., 2003). In order to perform these functions, the 
pumps are located on the plasma and ER membranes. For example, the 
plasma membrane Ca2+-ATPase (PMCA) removes Ca2+ from the cell to the 
extracellular environment (Holton et al., 2010). The PMCA operates with high 
Ca2+ affinity and low transport capacity such that one Ca2+ is removed for each 
ATP hydrolysed (Moccia et al., 2012) which means the PMCA is efficient at 
maintaining low levels of intracellular Ca2+ over long durations (Clapham, 
2007a). PMCA1, 2 and 4 are expressed on the vascular endothelium but 
PMCA1 appears to be the predominant isoform (Szewczyk et al., 2007).  
 
Also localised on the plasma membrane, and responsible for extruding Ca2+ 
from the cell are members of the sodium/calcium exchanger family, NCX. 
(Berridge et al., 2003). This family comprises NCX1-3 and functions by 
extruding one Ca2+ ion for the uptake of 3 Na+ ions. The NCX therefore 
operates with low Ca2+ affinity and high transport capacity, which makes it 
suitable for making rapid adjustments in Ca2+ concentration (Clapham, 2007a).  
 
Unlike the PMCA and NCX, which extrude Ca2+ from the cell, the 
sarco(endo)plasmic reticulum ATPase (SERCA) located on the ER membrane 
functions to pump Ca2+ against a concentration gradient into the ER at the 
expense of ATP (Berridge et al., 2003). Uniporters on mitochondria also serve 
to rapidly sequester Ca2+ that is then released more slowly back into the cytosol 
where it is sequestered by the SERCA and PMCA (Berridge et al., 2003).  
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1.4.3. Intracellular Ca2+ permeable ion channels 
 
Ca2+ release and uptake channels on the ER 
In ECs, the predominant Ca2+ release channels on the ER are the IP3Rs 
(Berridge, 2002), of which there are 3 forms (Moccia et al., 2012, Tran et al., 
2000). The second messenger IP3 activates these channels and this allows 
Ca2+ to be released from the intracellular store into the cytoplasm (Tran et al., 
2000). In addition to Ca2+ release from the ER through IP3Rs, Ca2+ can also 
leak out of the ER down its concentration gradient into the cytosol (Tran et al., 
2000). This Ca2+ leak is often compensated for by uptake of Ca2+ by ER Ca2+ 
ATPases such as SERCA which is faster at taking up Ca2+ than the leak 
channels are at releasing it, thereby maintaining Ca2+ homeostasis (Tran et al., 
2000).  
1.4.4. Plasma membrane Ca2+ permeable ion channels 
 
ECs express a multitude of Ca2+ permeable ion channels on their cell surface, 
all of which open and close in response to various stimuli. The next section will 
discuss voltage-operated Ca2+ channels and the Transient Receptor Potential 
(TRP) family of ion channels that act as cellular sensors for various stimuli.  
 
Voltage-gated Ca2+ channels 
Voltage-gated Ca2+ channels (VGCCs) have a high selectivity for Ca2+ and open 
in response to cell membrane depolarisation. VGCCs are predominantly found 
in neurons and muscle, where they are involved in excitation and contraction 
(Vinet and Vargas, 1999). ECs are generally considered ‘electrically non-
excitable’ and to not express VGCCs, however a number of reports have shown 
expression and function of these channels in ECs (Bossu et al., 1992a, Bossu 
et al., 1992b, Bossu et al., 1989, Zhou and Wu, 2006). Interestingly, all of these 
publications report expression in microvascular ECs and the publication by 
Zhou et al shows almost no expression in macrovascular ECs, suggesting a 
possible specific role of VGCCs in small diameter blood vessel ECs (Zhou and 
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Wu, 2006). Further studies are needed in this area to determine the significance 
of this finding. 
 
Endothelial Ca2+-permeable TRP channels 
The TRP family of ion channels were discovered in the Drosophila 
melanogaster visual system in 1989 (Montell and Rubin, 1989) and many are 
expressed in mammalian ECs. These include all known members of the 
canonical (TRPC) family, 3 members of the vanilloid (TRPV) family including 
TRPV1, TRPV2 and TRPV4, all of the melastatin (TRPM) family except 
TRPM5, and 2 members of the polycystin (TRPP) family, TRPP1 and TRPP2. 
All of these channels except TRPM4 are Ca2+ permeable ion channels (Kwan et 
al., 2007) that act as cellular sensors for a variety of different internal and 
external stimuli. The literature around endothelial TRP channels is vast, and so 
the next sections will focus on three important endothelial Ca2+-permeable TRP 
channels that have distinct mechanisms of activation: TRPC6, TRPV4 and 
TRPM2. 
 
TRPC6: a receptor-operated Ca2+ channel 
Activation of receptor-operated channels occurs as a result of plasma 
membrane G-protein coupled receptor (GPCR) stimulation, leading to activation 
of phospholipase C (PLC) and the hydrolysis of PIP2 into IP3 and diacylglycerol 
(DAG). Generation of IP3 activates IP3 receptors on the ER that results in Ca2+ 
release from the ER and this triggers Ca2+ entry through receptor-operated 
channels (Janssen and Kwan, 2007). Alternatively, DAG can directly activate 
receptor-operated channels in the plasma membrane for example TRPC6 
(Estacion et al., 2004). The muscarinic family of GPCRs are an example of 
GPCR that couple to ROCs (Shapiro et al., 2001).  
 
TRPV4: an arachidonic acid-sensitive Ca2+ channel 
TRPV4 is activated endogenously by arachidonic acid (Nilius et al., 2004). 
Stimulation with arachidonic acid causes a robust Ca2+ influx which has been 
found important in migration and angiogenesis of tumour-derived endothelial 
cells (Fiorio Pla et al., 2010). 
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TRPM2: a cellular redox sensing Ca2+ channel 
TRPM2 is expressed on endothelial cells and has been shown to contribute to 
endothelial cell permeability through its sensing and responding to oxidative 
stress for example through the generation of reactive oxygen species such as 
hydrogen peroxide (Hecquet et al., 2008). However, TRPM2 not only acts as a 
cellular redox sensor but also uniquely behaves as an enzyme, via a region with 
homology with the ADP-ribose pyrophosphatase NUDT9 at its C terminus 
(Perraud et al., 2001). When ADP-ribose binds to this region, TRPM2 becomes 
activated, but the enzymatic function of TRPM2 remains to be determined. For 
this reason, TRPM2 is sometimes referred to as a ‘chanzyme’ due to its 
potential dual roles as an ion channel and an enzyme.  
 
Store-operated Ca2+ entry (SOCE) channels 
The first evidence for SOCE came from Casteels and Droogmans in 1981 
(Casteels and Droogmans, 1981), but it was Jim Putney in 1986 who coined the 
term ‘capacitiative calcium entry’. This was following experiments which showed 
that Ca2+ entry triggered by muscarinic receptor agonists was more closely 
linked to the emptiness of the ER Ca2+ store than to increases in IP3 or 
occupation of the muscarinic receptor (Putney, 1986). Today, SOCE is 
recognised as a major pathway in nearly all animal cells, both excitable and 
non-excitable, and the defining feature of SOCE channels is their activation by 
the reduction of Ca2+ concentration in the lumen of the ER rather than by 
receptor-associated signalling molecules such as G-proteins, PLC or IP3 (Lewis, 
2011, Park et al., 2009). Physiologically, this often occurs when phospholipase-
C (PLC) coupled receptors in the plasma membrane become activated which 
leads to the production of inositol 1,4,5-triphosphate (IP3), and the activation of 
IP3 receptors on the ER membrane, causing release of Ca2+ from stores (Lewis, 
2011).   
 
Identifying the molecular nature of SOCE channels has been the subject of 
much research over the last 25 years. The development of fluorescent Ca2+ 
indicator dyes such as Fura-2 (Grynkiewicz et al., 1985) and the identification of 
sarcoendoplasmic reticulum Ca2+-ATPase (SERCA) inhibitors (that have the 
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ability to deplete ER Ca2+ stores independently of receptors and IP3) such as 
thapsigargin (Thastrup et al., 1989) have had a significant positive impact on 
determining the molecular make-up of these channels. TRPC channels have 
long been associated with SOCE, however whether they are truly store-
dependent is still under debate (Lewis, 2011). 
 
In 1992 a major breakthrough was made in the search for the channel 
underlying SOCE. Hoth and Penner identified an inwardly-rectifying ion channel 
current in mast cells, activated during whole-cell patch recordings either 
spontaneously (by Ca2+ chelators) or by IP3 or ionomycin, that was highly Ca2+-
selective. They called this current the ‘Ca2+ release-activated Ca2+ (CRAC) 
current (ICRAC) (Hoth and Penner, 1992). Research efforts over the subsequent 
13 years led to the identification of the genes underlying ICRAC and in 2005 and 
2006, STIM1, the ER Ca2+-sensor and Orai1, the CRAC channel protein were 
discovered (Zhang et al., 2005, Roos et al., 2005, Vig et al., 2006a, Vig et al., 
2006b). These important discoveries have greatly advanced our understanding 
of the role of these channels in physiology and disease, and have created new 
directions for research (Lewis, 2011). In addition to Orai1, two other Orai 
homologues exist, Orai2 and 3, both of which also form SOCE channels (Lis et 
al., 2007). However the role of Orai2 and 3 in physiology and pathophysiology 
remains to be determined. The functions of STIM1 and Orai1 and their 
relevance to health and disease will be discussed in the next section. 
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1.5. CRAC channel composition and function 
 
1.5.1. ER Ca2+ sensors: STIM1 and STIM2 
 
Mammalian cells ubiquitously express the Ca2+ binding proteins STIM1 and 
STIM2 (Williams et al., 2001). STIM1 was originally identified as a tumour 
suppressor gene called GOK (Sabbioni et al., 1999) but was later identified as a 
molecular component of store-operated Ca2+ signalling through RNAi screening 
by two independent research groups, and is now recognised as the primary ER 
Ca2+ sensor (Liou et al., 2005, Roos et al., 2005). In addition, a close family 
member (STIM2, which shares 61% sequence similarity with STIM1) is also an 
ER Ca2+ sensor but has lower Ca2+ binding affinity compared to STIM1 and has 
been suggested to activate CRAC channels following mild store depletion (Thiel 
et al., 2013, Soboloff et al., 2012). Studies revealed that whilst STIM1 could 
trigger SOCE, it did not form the CRAC channel itself. It was only in the next 
year through genetic and RNAi studies, that Orai1 was identified as the pore 
forming protein of the CRAC channel. Orai1 and CRAC channel function will be 
discussed below. STIM1 is predominantly localised in the ER, but 20-30% is 
detected at the plasma membrane (Manji et al., 2000). STIM1 is an ER 
membrane protein with one transmembrane region (Cahalan, 2009). The amino 
terminal of STIM1 resides in the lumen of the ER and has a pair of low affinity 
EF-hands that sense ER Ca2+ levels (Zhang et al., 2005). This Ca2+ binding 
domain has since proven critical for STIM1 function as an ER Ca2+ sensor. In 
addition, STIM1 also contains a sterile alpha motif or SAM domain located on 
the ER luminal side of the protein that is important for its function, since SAM-
deletion mutants are unable to form ER-PM punctae required for SOCE 
(Cahalan, 2009, Stathopulos et al., 2008). In the resting cell when ER Ca2+ 
stores are filled, STIM1 exists as a dimer, stabilised by C-terminal coiled-coil 
interactions (Penna et al., 2008).  
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STIM1 mRNA is widely expressed and can be found in the heart, central 
nervous system, skeletal muscle and platelets (Feske, 2010). Genetic ablation 
of the STIM1 gene is lethal and mice die perinatally due to skeletal muscle 
myopathy (Oh-Hora et al., 2008). In comparison, STIM2 knockout mice survive 
to 4-5 weeks after birth (Oh-hora et al 2008). T cells derived from STIM1 
knockout mice have smaller and shorter Ca2+ influx responses and impaired 
interleukin-2 production compared to cells derived from wild-type mice (Oh-Hora 
et al., 2008).  This is in contrast to T cells derived from STIM2 knockout mice 
that have relatively normal Ca2+ influx responses and interleukin-2 production. 
Despite this however, overexpression of STIM2 is unable to fully compensate 
for the loss of STIM1 in T cells derived from STIM1 knockout mice compared to 
overexpression of STIM1 (Oh-Hora et al., 2008). Ablating both STIM1 and 
STIM2 in mice leads to a lymphoproliferative phenotype characterised by signs 
of autoimmunity (Oh-Hora et al., 2008).  
 
Studies in endothelial cells have shown that knockdown of STIM1 using short 
interfering RNA (siRNA) results in a smaller CRAC channel response compared 
to controls (Abdullaev et al., 2008).  
 
1.5.2. CRAC channels and the Orai family of ion channels 
 
The Orai family of ion channels comprises 3 homologues: Orai1, 2 and 3 (Feske 
et al., 2006). Like STIM1, the Orai family (named after the Greek keepers of 
Heaven’s gate and also known as CRACM channels), was discovered in RNAi 
based screens, and was found to include the molecular components that form 
the CRAC channel. At the same time a linkage analysis study in patients with 
severe combined immune deficiency (SCID, which is caused by a defect in Ca2+ 
entry of T cells), identified Orai1 (also called CRACM1 or TMEM142a), 
suggesting a role for the Orai1 gene product in SOCE (Feske et al., 2006). 
Importantly, in T cells obtained from SCID patients, a SOCE response could be 
restored by overexpression of Orai1. The SOCE defect in SCID patients was 
subsequently found to be due to a mutation (encoding the amino acid change 
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R91W) in the Orai1 gene on chromosome 12, highlighting the importance of this 
gene in the immune system. Further studies clarified Orai1 was an ion channel 
by demonstrating that the R91W mutation could significantly affect ion 
selectivity (Feske et al., 2006, Prakriya et al., 2006, Vig et al., 2006b, Yeromin 
et al., 2006). Orai proteins have no sequence homology with other Ca2+ 
permeable ion channels, and therefore represent a structurally unique family of 
ion channels (Rothberg et al., 2013).  
 
A key characteristic of CRAC channels is their high selectivity for Ca2+ over 
monovalent ions (PCa/PNa > 1000) (Yamashita et al., 2007), which renders 
them functionally unique (Rothberg et al., 2013). Biophysically, CRAC channels 
are highly Ca2+ selective ion channels producing inwardly-rectifying currents 
with a calculated single channel conductance of <1 pS (Parekh and Putney, 
2005). The CRAC channel current can be blocked by micromolar La3+ and 2-
aminoethoxydiphenyl borate (2-APB) (Parekh and Putney, 2005). Other 
blockers of the current include the non-selective Ca2+ channel blocker 
SKF96365, a 3,5-trifluoromethyl pyrazole derivative BTP2 (YM-58483) and a 
structurally similar compound Synta 66 (3-fluoropyridine-4-carboxylic acid (2′,5′-
dimethoxybiphenyl-4-yl)amide) which blocks ICRAC with an IC50 of approximately 
3 µM in immune cells, and with 100-fold greater potentcy in ECs with an IC50 of 
approximately 25 nM (Li et al., 2011, Parekh, 2010). 
 
Sequence analysis predicts that Orai1 has four transmembrane helices (M1 to 
M4; Figure 1-6) and multiple studies have indicated that Orai1 channels are 
multimers, with most studies predicting a tetrameric configuration (Ji et al., 
2008, Penna et al., 2008, Zhou et al., 2010). However the crystal structure of a 
large component of the Drosophila melanogaster Orai channel has been solved 
(Hou et al., 2012), revealing an unexpected hexameric assembly of Orai 
proteins (Hou et al., 2012). This structure shares 73% sequence similarity with 
the human version within its transmembrane region (Hou et al., 2012). Figure 1-
7 shows the newly solved crystal structure of dOrai. 
 
Orai1 knockout mice are smaller than their wild-type litter-mates and have 
eyelid irritation and sporadic hair loss (Gwack et al., 2008). Despite T cells 
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developing normally in the Orai1 knockout mouse, their function is impaired 
(Gwack et al., 2008).  
 
In endothelial cells, knockdown of Orai1 using siRNA resulted in smaller store-
operated Ca2+ responses and an inhibition of VEGF-mediated Ca2+ signalling 
and endothelial cell tube formation (Abdullaev et al., 2008, Li et al., 2011). 
 
Both Orai2 and Orai3 are also able to complex with STIM1 and form Ca2+ 
channels (DeHaven et al., 2007, Lis et al., 2007). The Ca2+ channels involving 
Orai2 and Orai3 have similar biophysical properties to those involving Orai1, but 
differ in their activation and inactivation kinetics. For example, Ca2+ entry via 
Orai3 channels is potentiated by 2-APB, which is the opposite of the effect seen 
on Orai1 channels (Lis et al., 2007). Despite these similarities, it has been 
shown that Orai2 is unable to compensate for the loss of Orai1 in T cells 
derived from SCID patients, and overexpression of Orai3 is only able to partially 
compensate (Gwack et al 2007).  
 
There is little information regarding the physiological role of Orai2 or Orai3 
channels in endothelial cells however in smooth muscle cells Orai3 knockdown 
in vivo inhibited neointimal formation (Gonzalez-Cobos et al., 2013). Orai3 also 
underlies SOCE in estrogen receptor positive breast cancer cells compated to 
estrogen receptor negative cells where Orai1 underlies the SOCE response 
(Motiani et al., 2013).  
 
Orai3 is also suggested to complex with Orai1 to form arachidonic-acid 
activated channels, and these channels have been shown to function in a store-
independent manner (Mignen and Shuttleworth, 2000, Mignen et al., 2008). 
Both Orai1 and Orai3 are expressed on ECs but the existence or physiological 
relevance of the Arc channel remains to be determined.  
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Figure 1-6 Functional domains in Orai1 and STIM1. 
Orai1 comprises 4 transmembrane domains M1-M4. The M1 transmembrane helix 
lines the channel pore. Orai1 has a calmodulin binding site on the cytoplasmic side. 
L273 is a region important for STIM1 binding. The R91W mutation is shown and is 
important for Orai1 function. STIM1 has an N-terminus that resides in the ER and 
contains 2 EF-hand domains responsible for Ca2+ binding. STIM1 also contains a 
sterile alpha motif (SAM) located in the ER. The CAD/SOAR/OASF/CCb9 region, which 
is important for Orai1 binding is located in the cytoplasm. Adapted from Feske (2010). 
27 
 
 
 
 
 
 
 
 
 
 
Figure 1-7 The structure of the Orai1 channel hexamer.  
View from the extracellular side showing the four transmembrane helices of 
each of the Orai1 subunits (M1-M4) with the M1 helices lining the channel pore 
(Hou et al., 2012). Reprinted with permission from AAAS. 
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1.5.3. Orai1, STIM1 and CRAC channel function 
 
During resting conditions STIM1 binds to Ca2+ via its EF-hands that lie in the ER 
lumen, and Orai1 resides in the plasma membrane (Hogan et al., 2010). When 
cells become stimulated in such a way that IP3 is increased, IP3 interacts with 
IP3 receptors on the ER membrane allowing Ca2+ release. This Ca2+ release is 
detected by STIM1 through its EF hands. Depletion of Ca2+ from the ER causes 
Ca2+ to dissociate from the EF hands (Hogan et al., 2010). It is the dissociation 
of Ca2+ that causes a conformational change in STIM1 by unfolding the 
adjacent EF-SAM domains, allowing it to oligomerise (Liou et al., 2005, Muik et 
al., 2008, Stathopulos et al., 2006). STIM1 dimers translocate to regions of the 
ER membrane that are in close association with the plasma membrane (10-25 
nm) forming large aggregates or ‘puncta’ (Wu et al., 2006). In response to this 
movement, Orai1 accumulates in these ER-PM junctions where it can interact 
with STIM1 (Luik et al., 2006, Muik et al., 2008, Park et al., 2009, Xu et al., 
2006, Yuan et al., 2009, Kawasaki et al., 2009) The recent breakthrough with 
the crystal structure of Drosophila Orai suggests that Orai1 subunits form a 
hexameric assembly around a central pore lined by the M1 transmembrane 
helices (Hou et al., 2012, Rothberg et al., 2013). It is the clustering of Orai1 and 
STIM1 that allows the entry of Ca2+ into the cell in a process termed SOCE. 
Ca2+ that enters the cell is then used to replenish Ca2+ ER stores and for 
downstream signalling pathways. The mechanism of STIM1/Orai1 CRAC 
channel activation is shown schematically in Figure 1-8. 
1.5.4. Regulation of CRAC channel activity 
 
In immune T cells, 2 novel regulatory proteins of CRAC channels, called 
CRACR2A and junctate have been identified by protein affinity purification 
(Srikanth et al., 2012, Srikanth et al., 2010). CRACR2A is a cytosolic protein 
that has been shown to interact with both Orai1 and STIM1 to regulate Ca2+ 
entry through Orai1 channels.  The role of these proteins in non-immune cells 
remains to be determined. Junctate is an ER-Ca2+-sensing protein that has 
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been found to be part of the ER-PM complex made up of Orai1 and STIM1 
during CRAC channel activation in immune T cells (Srikanth et al., 2012).  
 
Also described in immune T cells is a negative regulator of CRAC channels, a 
protein called Golli (gene of oligodendrocyte lineage), which is an isoform of 
myelin basic protein (Walsh et al., 2010). Overexpression of Golli in immune 
cells inhibits Ca2+ entry through CRAC channels. Further studies are required to 
understand the physiological relevance of this protein.  
1.5.5. Ca2+ channels in EC physiology and pathophysiology 
 
The function of Orai1 and STIM1 in SOCE in ECs was first described in 2008 
(Abdullaev et al., 2008). Knockdown of Orai1 and STIM1 in human umbilical 
vein endothelial cells (HUVECs) and in human pulmonary artery endothelial 
cells (HPAECs) resulted in an inhibition of EC proliferation (Abdullaev et al., 
2008). Subsequent studies have identified CRAC channels as a major Ca2+ 
entry route in ECs: knockdown of Orai1 using siRNA significantly inhibited the 
Ca2+ entry and inhibited angiogenesis both in vitro (in the co-culture tube 
formation assay) and in vivo (in the chick chorioallantoic membrane) (Li et al., 
2011). A CRAC channel blocker called Synta66 was found to also inhibit VEGF-
stimulated angiogenesis, further supporting a role of CRAC channels in 
angiogenesis. A study by Antigny et al found no effect of Orai1 in in vitro tube 
formation, but found that TRPC1 and TRPC4 were important (Antigny et al., 
2013).  
 
Hamdollah Zadeh et al  (2008) were the first to report TRPC channel 
involvement in the VEGF induced microvascular endothelial cell proliferation 
and tube formation (Hamdollah Zadeh et al., 2008). Using a dominant negative 
TRPC6 (DNTRPC6) lentivirus, they showed a significant inhibition of VEGF-
induced human microvascular endothelial cell tube formation in vitro. These 
results were later confirmed by Ge et al, who demonstrated that DNTRPC6 
could inhibit VEGF-induced tube formation in human umbilical vein endothelial 
cells (HUVECs; (Ge et al., 2009). To date there are no in vivo data which 
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support this role of TRPC6 in tumour angiogenesis, although this may be partly 
due to a lack of selective tools to study TRPC channels. Ge et al (2009), 
however, did demonstrate an inhibition of blood vessel growth in in vivo 
chorioallantoic membrane (CAM) using the non-selective blocker SKF 96365 
that has previously been shown to block TRPC6 (Inoue et al., 2001, Ge et al., 
2009).  
 
A recent report has shown for the first time an important role for TRPC1 in 
angiogenesis (Yu et al., 2010). The authors showed that knockdown of TRPC1 
by antisense morpholino oligonucleotides severely disrupted angiogenic 
sprouting of intersegmental vessels in zebrafish larvae. In addition they showed 
that TRPC1 acted synergistically with VEGF in controlling vessel growth, and 
that TRPC1 appeared to be downstream of VEGF in controlling angiogenesis. 
This study supports an earlier study by Jho et al (2005), who showed that 
blocking TRPC1 inhibits VEGF-induced permeability in endothelial cells (Jho et 
al., 2005). 
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Figure 1-8 CRAC channel function. 
In the resting state, STIM1 resides in the ER membrane and Orai1 subunits in the 
plasma membrane. When cells are stimulated, IP3 activates IP3Rs on the ER 
membrane releasing Ca2+, which depletes the ER of Ca2+ and causes a conformational 
change in the STIM1 protein. STIM1 clusters at ER-PM junctions where it interacts with 
hexameric assemblies of Orai1 channels leading to CRAC channel activation and Ca2+ 
entry into the cell. 
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1.6. Downstream signalling as a result of Ca2+ entry 
 
Ca2+ is important for both short- and long-term cellular responses. The next 
section will discuss recent studies linking Ca2+ entry through Ca2+ permeable 
ion channels with downstream signalling events: gene transcription and small 
GTPase activity. 
1.6.1. Ca2+-regulated gene transcription 
 
Accumulating evidence suggests that Ca2+ entry through CRAC channels is not 
only important for short-term cellular responses such as exocytosis and muscle 
contraction but also for long-term responses such as gene transcription (Kar et 
al., 2012). A common mechanism for the activation of gene transcription in non-
excitable cells involves Ca2+ entry followed by stimulation of the Ca2+-
calmodulin-dependent protein phosphatase calcineurin (Macian, 2005). 
Calcineurin dephosphorylates the highly phosphorylated nuclear factor of 
activated T cells (NFAT) that resides in the cytosol (Macian, 2005). This 
dephosphorylation exposes a nuclear localisation motif in NFAT, which causes 
it to be imported into the nucleus where it interacts with other transcription 
factors to initiate the transcription of genes such as interleukin 2 and 4 (Hogan 
et al., 2003, Kar et al., 2011, Parekh and Putney, 2005). It has been shown that 
in immune cells, CRAC channels are responsible for this Ca2+ entry required for 
NFAT activation (Parekh and Putney, 2005). Further evidence for an important 
role of Ca2+ entry through CRAC channels in NFAT translocation and 
transcription comes from SCID patients who carry a mutation in their Orai1 
gene; these patients fail to activate the IL-2 and and IL-4 genes (Feske et al., 
2000).  
 
NFAT activation in endothelial cells is critical for vascular development and 
function (Hernandez et al., 2001). VEGF activates NFATc translocation and 
transcription, which is important for endothelial cell migration and angiogenesis 
since the NFAT inhibitor cyclosporin-A inhibits these processes (Hernandez et 
33 
 
al., 2001). There is evidence linking Ca2+ entry through CRAC channels to 
NFAT translocation and transcription in HEK293 cells (Kar et al., 2011) which 
suggests this might also be true in other cell types, however there is currently 
no definitive study investigating this in endothelial cells. Despite this, three lines 
of evidence support a role for CRAC channels and NFAT activation in 
endothelial cells: firstly, NFAT activation is not evoked by Ca2+ release from the 
ER but involves Ca2+ entry via a SOCE channel (Rinne et al., 2009); secondly, 
Ca2+ entry into endothelial cells occurs via CRAC channels (Li et al., 2011); and 
finally VEGF, through activation of VEGFR2, causes Ca2+ entry through CRAC 
channels, which is important for cell migration and angiogenesis. An 
independent study shows that VEGF can activate NFATc translocation and 
transcription in ECs (Hernandez et al., 2001).  
1.6.2. Ca2+ entry channels and small GTPases 
 
The Rho family of small GTPases are important regulators of cytoskeletal 
dynamics in events such as cell migration, vesicle trafficking and endocytosis 
(Etienne-Manneville and Hall, 2002, Pertz, 2010). Members of the Rho family 
include cdc42 and Rac1, which have been found at the leading edge of 
migrating cells and are important in the formation of filopodia and lamellipodia 
respectively (Lamalice et al., 2007, Pertz, 2010) and RhoA, which regulates cell 
motility through activation of kinases such as phosphatidyinositol 3-kinase 
(PI3K) (Lamalice et al., 2007). Ca2+ is important for cell migration and it has 
been shown that Ca2+ flickers appeared at the leading edge of migrating cells, 
and that the stretch-activated ion channel TRPM7 was responsible for these 
flickers (Wei et al., 2009). A more recent study showed a direct link between 
Ca2+ influx and small GTPase activity in cell motility (Tian et al., 2010). The 
authors showed that TRPC5 exists in a molecular complex with Rac1, and that 
Ca2+ entry through TRPC5 channels promotes cell migration (Tian et al., 2010). 
Conversely, it was found that TRPC6 worked in an antagonistic manner in a 
complex with RhoA to inhibit cell migration.  
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1.7. Therapeutic targeting of Ca2+  
 
1.7.1. Ca2+ channel blockers  
 
With cardiovascular disease and cancer being two of the biggest causes of 
death worldwide, there is a growing need to develop new drugs to treat these 
life-threatening conditions. Targeting intracellular Ca2+ is a promising 
therapeutic avenue to explore since Ca2+ channel blocking drugs have already 
proven successful in treating hypertension. Drugs such as verapamil and 
nifedipine inhibit voltage-gated Ca2+ channels in the heart and increase 
vasodilation (McDonagh et al., 2005). These drugs indicate that calcium 
channels represent druggable targets, and set a precedent for the development 
of other Ca2+ channel blocking drugs for other therapeutic uses.  
1.7.2. Rationale for targeting Ca2+ permeable ion channels in cancer  
 
It is widely accepted that Ca2+ is an important signalling factor in tumour 
progression, as it is needed for cell migration, proliferation and angiogenesis 
(Monteith et al., 2012). Increasing numbers of studies are showing altered 
expression levels of Ca2+ channels or pumps in cancer. A recent review 
provided a table of examples of ion channels and pumps that are differentially 
regulated in cancer (Monteith et al., 2012). In the TRPC family of non-selective 
Ca2+ channels, TRPC3 is up-regulated in breast cancer and ovarian cancer 
compared to healthy controls (Aydar et al., 2009, Yang et al., 2009); TRPC4 is 
down-regulated in renal cell carcinoma cells (Veliceasa et al., 2007) and TRPC6 
was found to be the predominant Ca2+ channel expressed in breast cancer but 
was absent in normal breast tissue (Aydar et al., 2009). TRPC6 was also found 
elevated in specimens from oesophageal squamous cell carcinoma patients 
compared to normal oesophageal tissue (Shi et al., 2009). In the TRPM family, 
TRPM8 is up-regulated in prostate, pancreatic, breast, colorectal and lung 
cancers (Dhennin-Duthille et al., 2011, Schmidt et al., 2006, Tsavaler et al., 
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2001, Yee et al., 2010) whilst TRPM7 is involved in pancreatic and breast 
cancer (Dhennin-Duthille et al., 2011, Rybarczyk et al., 2012). TRPV1 is down-
regulated in bladder and up-regulated in prostate (Czifra et al., 2009, Kalogris et 
al., 2010) and TRPV6 in breast, prostate, thyroid, colon and ovarian cancers 
(Bolanz et al., 2008, Dhennin-Duthille et al., 2011, Fixemer et al., 2003). In 
addition both Orai1 and Orai3 are over-expressed in breast cancer (McAndrew 
et al., 2011, Motiani et al., 2010).  
 
1.7.3. Targeting downstream Ca2+ pathways 
 
One example of a pathway downstream of Ca2+ signalling that was discussed 
earlier was NFAT activation. In cancer, NFAT isoforms have been found to be 
upregulated (Jauliac et al., 2002, Mancini and Toker, 2009, Medyouf et al., 
2007, Ryeom et al., 2008). It is predicted that inhibiting NFAT activation using 
small molecule inhibitors could suppress tumorigenesis (Mancini and Toker, 
2009). 
 
In summary, targeting Ca2+, either by inhibiting Ca2+ entry pathways or by 
targeting its downstream effectors, is a potential route to develop novel 
therapeutics to inhibit tumour progression. 
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1.8. Aims and objectives 
 
The aim of this research was to develop a better understanding of the molecular 
mechanisms and pharmacology of Ca2+ entry and its downstream signalling in 
endothelial cells, with the overall purpose of devising new strategies to treat 
major health problems such as cardiovascular disease and cancer. 
 
Specifically, this project addressed 3 main objectives. The first objective was to 
investigate the novel EF-hand protein, CRACR2A. CRACR2A was identified as 
a binding partner for Orai1 and STIM1, and is involved in CRAC channel activity 
in immune T cells. Emerging evidence suggests that Orai1 and STIM1 are 
important in endothelial cell function, and it was therefore hypothesised that 
CRACR2A may also be important. RT-PCR and Western blotting will be used to 
investigate the expression of CRACR2A in endothelial cells and where 
CRACR2A is expressed, Ca2+ measurement and functional cell assays will be 
used to characterise its function. 
 
The second objective was to investigate the expression and function of golli-
MBP in endothelial cells. Golli-MBP has been identified as a novel binding 
partner for STIM1. It was therefore hypothesised that Golli-MBP may interact 
with STIM1 in endothelial cells and be an important regulator of store-operated 
Ca2+ entry. RT-PCR and Western blotting will be used to investigate the 
expression of golli-MBP in endothelial cells and should golli-MBP be expressed, 
Ca2+ measurement and functional cell assays will be used to characterise its 
function. 
 
The final objective was to investigate the anti-cancer agent 
carboxyamidotriazole (CAI) as a potential TRPC6 channel inhibitor. CAI is a 
small molecule, Ca2+ influx inhibitor with anti-cancer properties. CAI has been 
tested in numerous clinical trials as an anti-cancer drug, but the mechanism of 
action remains to be determined. Several lines of evidence suggest that TRPC6 
is an important Ca2+ channel involved in angiogenesis and cancer progression. 
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In this section, the hypothesis that CAI is a TRPC6 channel inhibitor is 
proposed. Using a recombinant mouse TRPC6 cell line, pharmacological 
experiments involving Ca2+ measurements and whole-cell voltage patch clamp 
will be used to determine whether CAI is a TRPC6 channel inhibitor.  
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CHAPTER 2.  MATERIALS AND METHODS 
 
2.1. Ionic solutions 
2.1.1. Standard Bath Solution (SBS) for Ca2+ imaging experiments  
 
SBS contained (mM): NaCl 130, KCl 5, MgCl2 1.2, CaCl2 1.5, D-Glucose 8, 
HEPES 10; Osmolarity adjusted to 290 mOsm with NaCl; pH was titrated to 7.4 
with 4 M NaOH. 
 
Ca2+-free SBS was prepared by omitting CaCl2. 
 
For TRPV4 FlexStation experiments, 0.1% BSA was added to the SBS during 
washing and recording stages. 
 
2.1.2. Solutions for Whole Cell Patch Clamp  
 
For TRPC5 whole cell recordings the bath solution contained (mM): NaCl 130, 
KCl 5, MgCl2 1.2, CaCl2 1.5, D-Glucose 8, HEPES 10; Osmolarity was adjusted 
to 290 mOsm with NaCl; pH was titrated to 7.4 with 4M NaOH.  
 
TRPC5 patch pipette solution contained (mM): EGTA 1, CsCl 135, MgCl2 2, 
HEPES 10, Na2ATP 5, Na2GTP 0.1; Osmolarity adjusted to 290 mOsm with 
CsCl; pH was titrated to 7.2 with 4M CsOH. 
 
For TRPC6 whole cell recordings the bath solution contained (mM): NaCl 140, 
KCl 5, MgCl2 1.2, BaCl2 1, HEPES 10, D-Glucose 10; Osmolarity was adjusted 
to 290 mOsm with 4M NaOH; pH titrated to 7.2 with Tris Base. 
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TRPC6 patch pipette solution contained (mM): CsOH (monohydrate) 48, L-
Glutamic acid 48, Hepes 10, Na2ATP 1, NaCl 8, MgCl2 2, CaCl2 17, EGTA 40; 
Osmolarity adjusted to 300 mOsm. pH 7.2. 
 
2.1.3. Chemicals and reagents 
 
All general salts and solutions were purchased from Sigma along with the 
following chemicals: N-Methyl-D-glucamine (NMDG), gadolinium chloride, 
carbachol, vascular endothelial growth factor A (VEGF-A165), thapsigargin, 
histamine, 2-aminoethoxydiphenyl borate (2-APB) and 4α-phorbol 12,13-
didecanoate (4αPDD). Carboxyamidotriazole (L,651,582) was purchased from 
Tocris. 1-Oleoyl-2-acetyl-sn-glycerol (OAG) was purchased from Cayman 
Chemical.   
 
OAG was supplied as a solution in acetonitrile. To change solvent to DMSO, the 
OAG was evaporated under a gentle stream of nitrogen and DMSO immediately 
added to make a final concentration of 50 mM. OAG aliquots were stored at -
80°C. 
2.2.   Cell culture 
2.2.1. Stably-expressing TRPC6 Human Embryonic Kidney (HEK) Cells 
 
Stably expressing mouse TRPC6 HEK293 cells (Boulay, 2002) were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) supplemented with 
10% Fetal Bovine Serum (FBS) and 100 unit ml penicillin-streptomycin. The 
selection antibiotic G418 (0.4 mg/ml; Sigma) was used to maintain TRPC6 
channel expression.  
2.2.2. TRPC5-Inducible HEK Cells 
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A stable cell line for the tetracycline-regulated expression of full length human 
TRPC5 (accession number AF054568), previously developed within this 
laboratory (Zeng et al., 2004), was used to investigate TRPC5 function.  
 
 
This cell line includes a TRPC5 expression vector that has been modified to 
include two tetracycline operator sequences (TetO2) between the CMV 
promoter site and the transcription start site, and a regulator vector that 
constitutively expresses the tetracycline repressor protein (TR). In the absence 
of tetracycline, the TR protein binds to the TetO2 sequence and inhibits the 
initiation of transcription of the TRPC5 gene.  
 
24 hours prior to experiments TRPC5 expression was switched on by adding 
tetracycline (1 µg/ml) to the culture medium. TRPC5 cells were maintained in 
DMEM-F12 + Glutamax (GIBCO) supplemented with 10% FBS, 100 U/ml 
penicillin and 100 µg/ml streptomycin (Gibco) and the selection antibiotics (10 
µg/ml blasticidin and 400 µg/ml zeocin). 
2.2.3. Stably-expressing TRPV4 chinese hamster ovary (CHO) cells 
 
Wild-type CHO cells or stably expressing human TRPV4 CHO K1 cells were 
maintained in Hams F12 glutamax medium (Gibco) supplemented with 10% 
FBS and 100 unit ml-1 penicillin-streptomycin. The selection antibiotic geneticin 
(G418; Sigma; 1 mg/ml) was used to maintain TRPV4 channel expression.  
2.2.4. HEK-Macrophage-scavenging receptor (MSR) cells 
 
HEK-MSR cells are a genetically engineered cell line derived from the HEK293 
parent line that are more adherent than their parent HEK293 cells making them 
more suitable for transfection. The macrophage scavenging receptor is 
expressed on a pCMV.SPORT6MSR.neomycin plasmid, whose expression is 
controlled by the SV40 promoter. Geneticin (G418) is used routinely in the 
culture of HEK-MSR cells to maintain selection. Cells were maintained in 
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DMEM-F12 + Glutamax (GIBCO) supplemented with 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin (Gibco) and the selection antibiotic G418 (50 
µg/ml). 
2.2.5. Human Umbilical Vein Endothelial Cells (HUVECs) 
 
Pooled HUVECs were purchased from Lonza. Cells were maintained in 
Endothelial Growth Medium (EGM-2) supplemented with 2% Fetal Calf Serum 
(FCS) and growth factors (supplied as a bullet kit; Lonza). Experiments were 
performed on passage 2-10 cells. 
2.2.6. Normal Human Dermal Fibroblasts (NHDFs) 
 
NHDFs were purchased from Promocell and maintained in Fibroblast Growth 
Medium (Promocell). Experiments were performed on passage 1-12 cells. 
2.2.7. Human Colonic Microvascular Endothelial Cells (HCoMECs)  
 
HCoMECs were purchased from Sciencell and maintained in endothelial cell 
medium (Sciencell). 
  
All cells were maintained in a humidified incubator gassed with 95% air and 5% 
CO2. 
 
2.3. Transfections 
2.3.1. cDNA Transfection 
 
HUVECs and MSR-HEK cells were transfected using Lipofectamine™ 2000 
(Invitrogen) or FuGene HD transfection reagent (Roche) according to the 
manufacturer protocols.  
 
Fugene 
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Briefly, 3 µl of FuGene and 1 µg of cDNA were added to 150 µl Opti-MEM 
medium (Gibco) and this was incubated at room temperature for 20 minutes 
before adding it onto 90-95% confluent cells in one well of a six well plate 
containing 2 ml of cell culture medium. Alternatively cells plated onto glass 
cover slips in a 24 well plate were transfected with 200 ng cDNA/well of a 24 
well plate. Experiments were performed 24-48 hrs post-transfection.  
 
Lipofectamine™2000 
Briefly, 2 µl Lipofectamine™2000 was added to 150 µl Opti-MEM medium 
(Gibco) in tube 1 and 0.5 – 1 µg of cDNA was added to 150 µl Opti-MEM 
medium in tube 2. Tubes were incubated at room temperature for 5 minutes 
then tubes 1 and 2 were combined and left to incubate at room temperature for 
20 minutes. The transfection mixture was added to 90-95% confluent cells in 1 
well of a six well plate containing 2 ml of cell culture medium. 4-6 hours after 
transfection the medium was removed and fresh cell culture medium added. 
Alternatively, cells plated onto glass coverslips in a 24 well plate were 
transfected with 200 ng cDNA/well of a 24 well plate. Experiments were 
performed 24-48 hours post-transfection. 
2.3.2. Short-interfering RNA (siRNA) transfection 
 
HUVECs were transfected with 20 nmol/L of siRNA (Ambion) using 
Lipofectamine™2000. Briefly, for 1 well of a 6 well plate: 0.42 µl siRNA (stock 
concentration 50 µM in water) was added to 210 µl Opti-MEM in tube 1 and 4.2 
µl LipofectamineTM2000 was added to 210 µl Opti-MEM in tube 2. The tubes 
were incubated at room temperature for 5 minutes. After this time, 200 µl of 
tube 1 was added to 200 µl of tube 2 and the mixture was incubated at room 
temperature for 20 minutes. The 400 µl transfection mixture was added to 90-
95% confluent HUVECs in 1 well of a 6 well plate containing 600 µl of cell 
culture medium. After 4-6 hours the medium was removed and replaced with 
fresh cell culture medium. Experiments were performed 48-72 hours post-
transfection. siRNA sequences are shown in Table 2-1. The scrambled control 
siRNA (sc.si) was a 19 bp scrambled sequence Lipofectamine™2000 with no 
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significant homology to human gene sequences (Silencer Negative Control 
number 1, Ambion). Knockdown efficiency was quantified by qPCR as 
described in section 2.9 or Western blotting as described in section 2.7.
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Gene siRNA Sequence 5’ – 3’ 
hCRACR2A.si.1 CAACAAAUCAAAAGUGAGAtt 
hCRACR2A.si.2 GGAGUUCACUACUGGAUUUtt 
hGolli.si.1 GUUUCUUUAUUCAAAAGCAtt 
hGolli.si.2 GAAUAGUGAAACUAACAGAtt 
hOrai1.si. GGGAAGAGGAUUUUUAUAAtt 
hSTIM1.si. CAAUUCGGCAAAACUCUGCtg 
 
Table 2-1 List of siRNA target sequences.  
Table showing siRNA target sequences used to knockdown CRACR2A, Golli, Orai1 
and STIM1. 
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2.4. Intracellular Ca2+ measurement 
2.4.1. Fluo-4 acetoxymethyl ester (Fluo-4 AM) 
 
Fluo-4 is a Ca2+ indicator dye (Gee et al., 2000) with an acetoxymethyl moiety 
that confers membrane-solubility. Once inside the cell, nonspecific esterases de-
esterify the compound, generating a charged and active form of fluo-4 that 
exhibits increased fluorescence when bound to Ca2+. Fluo-4 AM is excited at 
485 nm and emits at 525 nm. Fluo-4 AM was purchased from Invitrogen and 
made up to 1 mM in DMSO. Cells were loaded with 2 µM Fluo-4 AM in the 
presence of 0.01% pluronic acid (Biotium) and 2.5 mM probenecid (Sigma) in 
SBS for 1 hour at 37°C. Cells were washed for 30 minutes in SBS prior to 
FlexStation recordings. 
 
Pluronic is a non-ionic surfactant that is used with Fluo-4 AM and Fura-2 AM to 
increase their aqueous solubility. Pluronic was made up as a 10% solution in 
water. Probenecid inhibits organic anion transporters located in the cell 
membrane. These transporters can prevent dyes and indicators getting across 
the membrane and into the cell, which contributes to poor dye loading or high 
background signal in FlexStation II384 assays. Probenecid was made up fresh 
each day in 1M NaOH to a stock concentration of 0.5 M. The final concentration 
in SBS was 2.5 mM. This was titrated with concentrated HCl to pH 7.4. 
2.4.2. Fura-2 acetoxymethyl ester (Fura-2 AM) 
 
Fura-2 AM is often the preferred choice when choosing a Ca2+ indicator dye 
since it is ratiometric and has high Ca2+ binding affinity. Fura-2 AM is excited at 
340 and 380 nm wavelengths and emits at 510 nm. Use of a ratiometric dye 
minimises experimental error due to uneven loading of dye, dye leakage from 
the cell and photobleaching (Grynkiewicz et al., 1985). Fura-2 AM (Invitrogen) 
was made up to 1 mM in DMSO. Cells were loaded with 2 µM Fura-2 AM in the 
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presence of 0.01 % pluronic acid for 1 hour at 37°C. Cells were washed for 30 
minutes in SBS prior to FlexStation recordings. 
2.4.3. Ca2+ measurements using the FlexStation II384 
 
Intracellular Ca2+ measurements were made using the Flexstation II384 
(Molecular Devices). The FlexStation II384 is a bench-top high throughput 
fluorescence plate reader that has the ability to read 96 and 384 well plates. The 
Flexstation II384 has 3 drawers for tips, a cell plate and compound plate and has 
a built in 8-head dispenser that can be programmed to deliver compounds to the 
cell plate at designated time points. The Flexstation II384 is programmed to read 
across the plate, column by column. Cells were grown to 90-100% confluence in 
96 well plates (for HUVECs, non-coated plates (NUNC) were used and for HEK 
and CHO cell experiments poly-D-lysine coated plates (Corning) were used). 
Cells were loaded with a Ca2+ indicator dye for 1 hour at 37°C, washed and 
placed in the lower drawer of the FlexStation II384. The compounds were 
prepared at 5x final concentration and placed in the middle drawer. The tip box 
was placed in the upper drawer. Experimental setup and data collection was 
performed using the software program Softmax® Pro 4.7.1. All experiments 
were performed at room temperature. 
 
2.5. Whole cell patch clamp electrophysiology 
2.5.1. Patch pipettes 
 
Borosilicate glass capillaries with an outside diameter of 1 mm and an inside 
diameter of 0.58 mm (Harvard Apparatus) were pulled into patch pipettes using 
a PP830 vertical 2-stage pipette puller (Narishige, Tokyo, Japan). Pipette 
resistances were between 2 and 6 MΩ. Immediately before patching, pipettes 
were fire-polished. In all experiments series resistance was 5-15 MΩ. All 
recordings were made at room temperature, which was 21 ± 2 °C. 
47 
 
2.5.2. Whole cell voltage patch clamp 
 
A silver wire electrode was coated with chloride using a battery and 
concentrated NaCl solution. Cells were seeded onto glass coverslips 24 hours 
before recording. For TRPC5, cells were induced with 1 µg/ml tetracycline. 
Whole cell configuration was achieved by gentle suction on the cell to obtain a 
gigaseal followed by a small increase in pressure to result in breakthrough. 
Resulting series resistances were around 5-15 MΩ. Voltage ramps of 200 ms 
duration spanning the voltage range of -100 to +100 mV were delivered 
continuously every 10s.  pClamp software was used to capture data which was 
analysed using Clampfit and Origin 7 software (OriginLab corporation). Currents 
at -80 mV and +80 mV were measured before and after drug application.  
 
Compounds were administered to the bath using a ‘push-pull’ syringe 
mechanism to ensure rapid bath exchange. To calculate the time to 90% bath 
exchange, recordings were made using tetracycline-induced TRPC5 cells. 
TRPC5 currents were activated with gadolinium and whilst keeping gadolinium 
constant, Na+ in the extracellular solution was exchanged for NMDG+ (Figure 2-
1). NMDG+ is larger than Na+ and so does not pass through the channel 
resulting in a rapid inhibition of gadolinium-induced current. Figure 2-1 shows a 
recording where Na+ was replaced with NMDG+ 5 times repeatedly. The time to 
90% bath exchange was calculated for each of the 5 repeats as shown in Fig 2-
1. The mean time to 90% bath exchange for the on rate was calculated as 56 ± 
7.6 s and for the off rate calculated as 31 ± 4 s.  
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Figure 2-1 Time taken for bath exchange to occur during whole-cell voltage-clamp 
patch experiments.  
A. Example patch clamp trace showing Gd3+ activated TRPC5 currents in tet + TRPC5 
cells in Na+ containing SBS followed by a switch to NMDG containing SBS. B. 
Enlargement of the highlighted region in A. Time to 90% change for ‘on rate’ = 56 ± 7.6 
s and for ‘off rate’ = 31 ± 4 s (n=5 repeats). 
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2.6. Co-culture tube formation assay 
 
Normal Human Dermal Fibroblasts were seeded into a 96 well plate (Greiner) at 
a density of 2 x 103 cells/well and incubated at 37°C in a 5% CO2 incubator for 
72 hours. The cell culture medium was removed and HUVECs at a density of 
5.4 x 104 cells/well were seeded on top of the fibroblasts in endothelial cell 
growth medium containing 3 ng/ml VEGF-A165 and 2% FBS. Co-cultures were 
incubated for 7 days then fixed with ice-cold methanol for 10 minutes. Non-
specific binding sites were blocked with 5% donkey serum (in PBS) for 30 
minutes at 37ºC. HUVEC tubes were visualised by staining with a primary 
monoclonal mouse anti-human CD31 antibody (1:500 in 1% donkey serum for 1 
hour at room temperature). After 3 washes in PBS a secondary Alexa Fluor 488 
antibody was added for 1 hour at room temperature. Plates were imaged using 
an IncuCyte (Essen Bioscience) and tube formation was quantified using the 
IncuCyte angiogenesis v2.0 software. Parameters measured included tube 
length, tube area and number of branching points. 
2.7. Western blotting 
2.7.1. Sample preparation 
 
Cells were washed in PBS and harvested in lysis buffer containing: 0.5% NP40, 
10 mM Tris (pH 7.5), 150 mM NaCl, 0.5 mM EDTA and a 1:100 protease 
inhibitor cocktail (Fermentas). Lysates were centrifuged at 16,000g at 4°C for 5 
minutes. The supernatant containing the soluble fraction was retained while the 
in-soluble fraction was discarded. For quantitative experiments, the protein 
concentration in each sample was measured using a detergent compatible Bio-
Rad Assay (Bio-Rad Laboratories) as per the manufacturer’s protocol. Protein 
concentrations in each sample were estimated by comparison against serial 
dilutions of BSA protein.  
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2.7.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Western blotting is a biochemical method used to detect specific protein 
expression in cells. SDS-PAGE separates denatured proteins by their 
electrophoretic mobility. SDS linearises proteins and coats them with an overall 
negative charge, which means that the proteins are then separated by 
approximate size. Reducing conditions were used to break disulphide bonds. 
 
Equal amounts (10-20 µg) of samples were mixed with a 4x SDS running buffer 
(containing: 200 mM Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 400 mM DTT, 
traces of bromophenol blue) and boiled for 5 minutes at 95°C to fully denature 
the proteins. Samples were loaded onto a 10% acrylamide gel alongside a 
protein marker (ThermoScientific) and run for 50 minutes at 170 V in running 
buffer, which allowed full separation of proteins in the sample. The composition 
of the SDS gels were as follows: 
 
Resolving gel (10%): 4050 µl water, 3300 µl 30% acrylamide/bis-acrylamide 
(Sigma), 2500 µl 1.5M Tris pH 8.8, 50 µl 20% SDS, 100 µl 10% ammonium 
persulphate (APS), 8 µl TEMED. 
 
Stacking gel: 4120 µl water, 1000 µl 30% acrylamide/bis-acrylamide, 750 µl 
0.5M Tris pH 6.8, 60 µl 10% SDS, 100 µl 10% ammonium persulphate, 8 µl 
TEMED. 
 
The separated proteins in the gel were then transferred onto PVDF membranes 
(Millipore) for 80 minutes at 50 mA, using a semi-dry transfer unit (BioRad). The 
transfer buffer contained: Tris Base 48 mM, glycine 39 mM, SDS 20%, methanol 
20%.  
2.7.3. Western blotting 
 
The transferred membrane was incubated in 5% non-fat milk (in 0.1% Tween, 
150 mM NaCl, 10 mM Tris, pH 7.4) for 1 hour at room temperature to block non-
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specific binding sites. The membrane was then incubated either overnight at 4°C 
or for 1 hour at room temperature, in primary antibody diluted in 2.5% milk (For 
antibodies and dilutions see Table 2-2). Membranes were washed three times at 
room temperature in TBS-Tween, and then incubated for one hour at room 
temperature with secondary antibody, which was conjugated with horseradish 
peroxidase. Membranes were washed again in TBS-Tween (as above) and 
treated with Supersignal West Femto (Thermoscientific) for 5 minutes. This 
chemiluminescent substrate is made up of an enhancer solution and a stable 
peroxide solution and serves for detection of horseradish peroxidase activity. 
The blots were exposed to photographic paper (Kodak), developed and fixed 
(Photosol) to detect chemiluminescence. 
2.8. Immunocytochemistry 
 
Cells seeded onto glass coverslips were fixed with 2% paraformaldehyde (in 
PBS) for 10 minutes at room temperature, then permeabilised with 10% Triton-X 
solution for 10 minutes at room temperature. Non-specific binding sites were 
blocked with 5% donkey serum (in PBS) for 1 hour at room temperature. All 
antibodies were made up in 2.5% donkey serum and incubated at room 
temperature (For antibodies and dilutions see Table 2-3). Donkey serum was 
used since all secondary conjugated antibodies were raised in donkey. Cells 
were incubated in primary antibody for 1 hour followed by three washes in PBS 
and secondary antibodies for 1 hour. Cells were washed three times in PBS and 
briefly incubated in DAPI (nuclear stain) before being mounted onto imaging 
slides using Prolong Gold Anti-fade reagent (Invitrogen). Cells were imaged on 
either the Delta Vision microscope (Applied Precision) or confocal microscope 
(Zeiss). Images were prepared using Biophotonics ImageJ software 
(Opensource).  
2.8.1. Delta Vision wide-field deconvolution microscopy 
 
Delta vision (Applied Precision) microscopy uses white light from a mercury 
lamp, which is passed through an optical filter to give the correct excitation 
wavelength to illuminate the sample. To take an image, the sample is focused 
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by looking down the microscope then the upper and lower limits of the focus are 
set on the DV (Z-series) along with the number of images to take and how far 
apart the images should be (lowest is 1 µm). The DV then takes a series of 
images. Many of the images will be blurred. Once the images have been 
acquired the Delta Vision performs a restorative deconvolution or ‘nearest 
neighbour’ algorithm, which means it extracts information out of the blurred 
regions of an image in order to clean it up. The filter sets used were DAPI 
(excitation 360/40 and emission 457/50); FITC/GFP/Cy2 (excitation 490/20 and 
emission 528/38) and TRITC/Rhodamine/Cy3/DsRed (excitation 555/28 and 
emission 617/73). The objectives used were 40x/1.35 Oil Iris and 60x/1.4 Oil. 
Image acquisition and analysis was performed using SoftWoRx software.  
 
2.8.2. Confocal laser scanning microscopy 
 
Images were taken on a Zeiss laser scanning (LSM510) META Inverted 
confocal microscope, which was controlled using Zen 2009 imaging software. 
Confocal laser scanning microscopy uses point illumination and a spatial pinhole 
to get rid of out-of-focus light in a sample this in contrast to conventional wide-
field microscopy that uses either a mercury or xenon lamp to flood the entire 
sample with light resulting in background blur. Since only a single point in the 
sample is illuminated during confocal microscopy, scanning over a regular raster 
is required. Confocal microscopy takes thin optical sections between 0.5-1.5 µm 
thick. The objectives used were the 40x/1.3 Oil Plan-Neofluar and the 63x/1.4 
Oil Plan-Apochromat. The lasers used were the 405 nm Diode lase; Argon/2 
(458, 477, 488, 514 nm); HeNe 543 nm and HeNe 633 nm. Figure 2-2 is a 
schematic illustrating the principle of confocal laser scanning microscopy.  
53 
 
Photomultiplier 
detector 
Detector pinhole aperture 
Out-of-focus light rays 
Fluorescence 
barrier filter 
In-focus light rays 
Dichromatic mirrors 
Objective 
Sample 
Focal 
planes 
Excitation light rays Excitation 
filter 
Light 
source 
pinhole 
aperture 
Laser excitation 
source 
Figure 2-2 Laser scanning confocal microscopy.  
The diagram shows the set-up of a confocal microscope. Adapted from 
http://www.olympusmicro.com. 
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2.9. RNA isolation, cDNA preparation and real-time polymerase chain 
reaction (PCR) 
2.9.1. RNA isolation 
 
HUVECs were grown to confluence in six well tissue culture plates and total 
RNA was extracted from HUVECs using a standard TRI-reagent protocol: 
briefly, medium was removed and the cells were washed twice with phosphate 
buffered saline (PBS). 1 ml TRI reagent (Sigma) was added to each well for 1 
minute, and the cell suspension was carefully transferred to a 1.5 ml eppendorf 
tube then placed immediately on ice. Phenol and guanidine thiocyanate in Tri-
reagent quickly lyse the cells and inactivate endogenous RNases. 12.5 µl 
Glycogen (Roche) was added to bind the RNA, and the mixture was vortexed 
thoroughly. 100 µl 1-bromo-3-chloro-propane (BCP) was then added, and the 
mixture vortexed once more before being left at room temperature for 15 
minutes. Tubes were centrifuged at 13, 000 rpm at 4°C for 15 minutes, which 
separated the RNA (found in the top aqueous layer) from the DNA (in the middle 
layer) and the protein (bottom layer). The RNA was carefully separated from the 
DNA and protein and an equal volume of ice-chilled isopropanol was added in 
order to precipitate the RNA. This was vortexed again and left on ice for 15 
minutes. Meanwhile, fresh 75% ethanol was made up in RNase free water. 
Following the 15 minute incubation, tubes were centrifuged at 13,000 rpm at 4°C 
for 20 minutes. The isoproponol was decanted and all residual isoproponol was 
removed from the pellet using a pipette. Each pellet was washed in 750 µl of 
75% ethanol and centrifuged at 13,000 rpm at 4°C for 5 minutes. Supernatants 
were removed and the pellets were left to air dry for 5 minutes. Each pellet was 
resuspended in 10 µl of RNase free water and left on ice ready for DNase I 
digestion. 
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2.9.2. DNase I Digestion 
 
To 10 µl of RNA solution, 1.3 µl of 10x DNase buffer (Ambion) and 3 µl of 
DNase I enzyme (Ambion) were added. This was incubated for 1 hour at 37°C. 
This was spun down using a bench-top centrifuge and 3 µl of Inactivation 
Reagent (Ambion) was added to pellet the DNA. This was gently mixed and left 
on ice for 2 minutes then bench-centrifuged again for 1 minute and supernatants 
containing the RNA were removed to fresh tubes.  
2.9.3. Ribogreen Assay 
 
The RNA concentration in each sample was measured using Ribogreen assay. 
Ribogreen is a dye that fluoresces upon nucleic acid binding. It is excited at 470 
nm of light and emits light at 530 nm when it is nucleic acid bound. The 
Ribogreen assay gives an absorbance reading that can be converted into a 
concentration of RNA in a sample. A 1:200 dilution of Ribogreen solution and a 
1:100 dilution of RNA solution were prepared in a 1x Tris-EDTA buffer. 10 µl of 
the diluted Ribogreen solution was added to 10 µl of the diluted RNA solution 
and loaded into glass capillaries (Roche). As a control 10 µl of Tris-EDTA buffer 
and 10 µl of the diluted Ribogreen solution were loaded into capillaries. Samples 
were mixed by centrifugation and left at room temperature for 5 minutes before 
fluorescence emission was measured in a real-time fluorimeter (Roche). In order 
to determine RNA concentrations in the samples, slope equation values from a 
standard curve were used. The following straight-line equation was used to 
determine the concentration of RNA: 
 
Straight-line equation: y = mx+c, where m is the slope, c is the Y intercept, x is 
RNA concentration in µg/µl. 
 
This equation rearranged to determine the RNA concentration is: 
x = (y-c)/m 
58 
 
The m value obtained for the Ribogreen solution used in this study was 15.96. 
Therefore to convert the readings into RNA concentrations in µg/µl, the following 
equation was used: 
x (µg/µl) = (y- (-0.2607))/15.96 * 0.2 
where, 
y = emission of the test sample at 530 nm (background subtracted) 
x = RNA concentration (µg/µl) 
(multiplied by 0.2 because of the Ribogreen and RNA dilutions) 
2.9.4. Reverse Transcription  
 
To generate cDNA from the RNA samples, a high capacity RNA-to-cDNA 
master-mix was used (Applied Biosystems). 600 ng of RNA was reverse 
transcribed using 4 µl of a reverse transcription master-mix (Applied 
Biosystems) and a calculated volume of water to bring the total volume to 20 µl. 
A separate control with no reverse transcriptase (‘no RT’) was carried out for 
each reaction. The mix was incubated at 42°C for 30 minutes followed by a 
heat-inactivating step at 85°C for 5 minutes. 
2.9.5. Real-time polymerase chain reaction (PCR)  
 
Real-time PCR was used to quantify messenger RNA (mRNA) using the Roche 
Light Cycler II system and SYBR Green I (Roche). cDNA template (0.5 µl) was 
added to the reactions in glass capillaries containing 0.5 µM of each primer 
(forward and reverse; Table 2-4), 4 mM MgCl2 and 1x SYBR Green I master mix 
(Roche, UK) to make up a final volume of 5 µl. DNA was amplified using the 
following protocol: 10 minute hot start at 95°C; 40 cycles of 10 seconds at 95°C, 
6 seconds at 55°C, and 16 seconds at 72°C.  
2.9.6. Agarose gel electrophoresis 
 
Real time PCR products were analysed by 2% agarose gel electrophoresis. 
Briefly, 5 µl of PCR product was mixed with 1 µl loading buffer (Promega) and 
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resolved against a 100 bp DNA ladder on a 2% agarose gel containing 0.5 
mg/ml ethidium bromide. Ethidium bromide intercalates between DNA base-
pairs and allows DNA bands to be visualised under UV light. Electrophoresis 
was performed at 70 V for 70 minutes in a 1x TAE buffer.  
 
2.9.7. Quantification of siRNA knockdown 
 
Real time PCR crossing point (CP) values were used to determine the % gene 
knockdown achieved following siRNA transfection. The fold difference in gene 
expression in siRNA (target gene) treated versus scrambled siRNA treated cells, 
was determined using the following formula: 
 
Fold Difference = 2-ΔCP 
 
Where ΔCP is the difference in the crossing point values between test and 
control samples (i.e. CP in test sample - CP in control sample). 
 
Target gene expression was normalised to actin.  
 
2.9.8. Primer design 
 
Real-time PCR primers were designed using Lightcycler Probe Design Software 
(Roche). Primers used in this study are shown in Table 2-4. 
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Table 2-4 List of RT-PCR primers used in this study.  
Table showing primers for CRACR2A and EFCAB4B-a (detects both isoforms), 
EFCAB4B-a, CRACR2A, Orai1, β actin, and STIM1 along with their predicted amplicon 
size (bp). F, forward; R, reverse.  
 
Gene 
(accession no.) 
Primer 5’ – 3’ 
 
Predicted 
amplicon (bp) 
CRACR2A &  
EFCAB4B-a 
F GAGATGGAACAACAAATCAAAAG 
R CGCTGTAGACTCTCCGT 
365 
EFCAB4B-a 
(NM_001144958.1) 
F CGTCATGTACGATCTCAC 
R GTGACCAGAGTAGGCG 
214 
 
CRACR2A 
(NM_032680.3) 
F GGTCATCCTTGCCTACG 
R GCTCGCATGAGATCAAGT 
222 
 
Orai1 
(NM_032790.3) 
F GCACAATCTCAACTCGG 
R GCGAAGACGATAAAGATCAG 
300 
 
βactin 
(NM_001101.3) 
F TCGAGCAAGAGATGGC 
R TGAAGGTAGTTTCGTTGGATG 
194 
 
STIM1 
(NM_001277961.1) 
F CTCTCTTGACTCGCCA 
R GCTTAGCAAGGTTGATCT 
276 
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2.10. Cloning EFCAB4B-a  
 
2.10.1. Generation of EFCAB4B-a-enriched cDNA using an EFCAB4B-a-specific 
primer 
 
Reverse transcription of HUVEC total RNA (isolated as per above protocol) was 
performed using Superscript II Reverse Transcriptase (Invitrogen) and an 
EFCAB4B-a gene specific primer (GSP; Crac2rainsertR; Table 2-5) following the 
manufacturers guidelines. Briefly, 2 pmoles EFCAB4B-a GSP was added to 600 
ng HUVEC RNA, 2 µl dNTP mix (Promega) in a final volume of 50 µl. The 
mixture was heated to 65ºC for 5 minutes and quickly chilled on ice. Reaction 
buffer was added to the mixture, which was then heated to 42ºC for 2 minutes. 
200 units of Superscript II enzyme was then added followed by incubation at 
42ºC for 50 minutes. The reaction was inactivated at 70ºC for 15 minutes. DNA 
concentration was measured at 260 nm wavelength on a spectrophotometer.  
2.10.2. Amplification of EFCAB4B-a 
EFCAB4B-a was amplified from the enriched cDNA (described above) using 
GoTaq Green (Promega) and cloning primers (Crac2rainsertF and 
Crac2rainsertR; Table 2-5) designed to be compatible with the Infusion-HD 
vector (Clontech). PCR reaction conditions were as follows: 95ºC for 2 minutes 
(initial denaturation stage) followed by 40 cycles of: 95ºC for 30 seconds, 53ºC 
for 30 seconds, 73ºC for 2.5 minutes followed by a final extension at 73ºC for 5 
minutes.   
 
The resulting PCR product was resolved on a 1% agarose gel (at 80 V for 1 
hour; Figure 2-3) then excised and the DNA was extracted using a 
Zymoclean™Gel DNA Recovery Kit (Zymo Research). The extracted DNA was 
sequenced and confirmed to be EFCAB4B-a (NM_001144958.1) before being 
further amplified by a second round of PCR using the high fidelity DNA 
polymerase Phusion (Thermoscientific). 
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2.10.3. Linearising the eGFP-C1 plasmid by inverse PCR 
 
The aim was to make constructs expressing either untagged EFCAB4B-a or 
GFP-EFCAB4B-a fusion. To generate these constructs the eGFP-C1 plasmid 
(kanamycin resistant; Clontech; 4731 bp) was used, with inverse PCR to delete 
the GFP portion of the plasmid as needed. 
2.10.4. Linearisation of plasmid with deletion of eGFP: 
 
To make the plasmid expressing EFCAB4B-a alone, the 798 bp eGFP sequence 
was removed from the eGFP-C1 plasmid by inverse PCR using the DNA 
polymerase Phusion and inverse PCR using primers designed so that the 
forward primer (eGFP2Inverse-F) started at the 3’ end of the GFP sequence and 
the reverse primer (eGFP2-Inverse-R) at the 5’ end of the GFP sequence, 
meaning that only the vector backbone (minus eGFP) was amplified. The 
reaction contained: 0.5 µl eGFP-C1 cDNA, 1 µl dNTPs, 3 µl DMSO, 1 µl forward 
primer, 1 µl reverse primer, 0.5 µl Phusion, 10 µl Phusion reaction buffer and 34 
µl water. The PCR reaction conditions were: initial denaturation at 98°C for 1 
minute followed by 25 cycles of: 98°C for 30 seconds, 59°C for 30 seconds and 
72°C for 2.5 minutes followed by a 5 minute extension step at 72°C. The PCR 
product was resolved on a 1% agarose gel, the band was excised and the DNA 
extracted using the Zymoclean™Gel DNA Recovery Kit.  
2.10.5. Linearisation of plasmid without deletion of eGFP  
 
To make the plasmid expressing N-terminal eGFP-tagged EFCAB4B-a, primers 
eGFP2Inverse-R and GFPinverse-R were designed to linearise the eGFP-C1 
plasmid whilst retaining the eGFP gene. The EFCAB4B-a primers were 
CRACR2AsGFPF and CRAC2rainsertR (Table 2-5). 
2.10.6. Infusion reaction to generate eGFP- EFCAB4B-a plasmids 
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The small overhangs on the EFCAB4B-a primers were used to combine the 
EFCAB4B-a PCR product with the eGFP-C1 vector backbone using an In-
Fusion HD (Clontech) reaction. The Infusion reaction is a ligation independent 
cloning method. The Infusion enzyme has 3’-5’ exonuclease activity and attacks 
exposed ends of broken double stranded DNA resulting in single stranded 
stretches of the vector and EFCAB4B-a insert allowing complementary pairing 
during the Infusion reaction. For this reaction 4 µl 5x Infusion HD enzyme premix 
(Clontech), 8 µl linearised eGFP-C1 vector, 4 µl EFCAB4B-a product and 4 µl 
water were mixed and incubated at 50°C for 15 minutes. 
2.10.7. Transformation 
 
XL10 Gold ultracompetent cells (Agilent Technologies) were used for 
transforming the EFCAB4B-a plasmids. Briefly, 2 µl of β-mercaptoethanol was 
incubated with 45 µl of cells for 10 minutes on ice 2.5 µl of the Infusion reaction 
mixture was added and incubated on ice for 30 minutes. The cells were then 
heat-shocked for 45 seconds at 42°C and put back on ice. 400 µl of LB broth 
was added and incubated in a 37°C shaker oven for 1 hour. 200 µl of the cell 
mixture was spread onto kanamycin agar plates and incubated overnight at 
37°C. 
2.10.8. Colony PCR 
 
The following day, colony PCR was performed to identify clones containing the 
correct insert. For this, 10 colonies were selected from each plate and mixed 
with 5 µl water in PCR tubes. The residual left on the tip was used to streak onto 
labelled kanamycin plates for subsequent culture as needed. Tubes were boiled 
for 5 minutes at 95°C and small volume PCR was performed using the following: 
12.5 µl GoTaqGreen, 5 µl of water/colony mix, 0.5 µl of primers and 6.5 µl water; 
95°C for 2 minutes followed by 40 cycles of: 95°C for 30 seconds, 53°C for 30 
seconds, 73°C for 30 seconds, followed by an extension at 73°C for 5 minutes. 
The primers used for the colony PCR were the eGFP2 reverse primer and 
EFCAB4B-a forward primer. PCR products were run on a 2% agarose gel at 100 
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V for 30 minutes. Colonies that contained the desired insert were identified by a 
correct band size. The correct colonies were selected from the streaked 
kanamycin plate the following day and grown up using a mini-prep kit (Qiagen). 
The clones were then sequenced (Beckman Coulter) to verify the presence and 
orientation of the correct insert, and plasmid Maxi-preps (Qiagen) were prepared 
from verified clones. Maxi-prep DNA was fully sequenced.  
 
2.10.9. Generation of C-terminal tagged EFCAB4B-a -GFP construct 
 
To make the EFCAB4B-a-GFP (C-terminal tagged) construct, the EFCAB4B-a 
plasmid was linearised using the following primers: CRACR2ALinverseR and 
CRACR2ALinverseF (Table 2-5). eGFP was cloned from the eGFP-C1 vector 
using the following primers: GFP forward primer and GFP reverse primer (Table 
2-5). eGFP was then inserted into the linearised plasmid by an Infusion reaction 
(as described above).  
2.10.10. Cloning CRACR2A 
 
CRACR2A (NM_032680.3) clone (clone ID 3531511) was purchased from 
Thermo Fisher. Inverse PCR was performed to linearise the eGFP-C1 vector. 
Insertion of CRACR2A into the eGFP-C1 vector was performed as above for 
CRACR2A- but using CRACR2A primers as shown in Table 2-5.  
2.11. EFCAB4B-a mutagenesis 
 
Site-directed mutations encoding single amino acid changes (Q604L and N658I) 
were introduced into the EFCAB4B-a gene using a Quikchange Lightning site-
directed mutagenesis kit (Agilent technologies) according to the manufacturer’s 
protocol. Mutagenic primers are shown in Table 2-6.  Phusion DNA polymerase 
was used for the reaction. PCR products were treated with the enzyme Dpn1 to 
digest any (non-mutated) methylated DNA strands. The mutated plasmid was 
transformed as per the protocol above and grown up using the mini-prep kit 
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(Qiagen). The presence of each desired mutation was confirmed by sequencing 
(Beckman-Coulter).  
 
2.12. von Willebrand factor (vWF) Enzyme-linked immunosorbent 
assay (ELISA) 
 
The concentration of secreted vWF was measured using an IMUBIND ELISA kit 
(American Diagnostica) according to the manufacturer’s protocol. This ELISA is 
a ‘sandwich’ ELISA and uses a goat polyclonal vWF antibody as the capture 
antibody. When samples are incubated with pre-coated test plates pre-coated 
with this antibody, the vWF in the sample binds to the antibody, and is 
subsequently detected using a second, horse-radish peroxidase (HRP)- 
conjugated antibody. In brief, HUVECs were seeded into 6 well plates. The 
following day, cells were transfected with siRNA using the protocol described 
above. 72 hours later, the medium was removed and cells were washed once 
with pre-warmed, serum- and growth factor-free endothelial medium (EGM-2, 
Lonza) and then incubated in 1 ml of the same pre-warmed medium for 30 
minutes at 37°C and 4% CO2. VEGF-A165 made up in the same medium was 
then added to the wells and incubated for 30 minutes at 37°C and 4% CO2. A 
100 µl sample was removed for each well and diluted in the same volume of 
medium. Two 100 µl samples were then added to the ELISA plate and the assay 
was performed as per the manufacturer’s protocol. The concentration of vWF in 
each sample was determined by comparison with a standard curve. Values 
obtained from wells that had no VEGF-A165 treatment were used as controls and 
subtracted from the sample values so that only VEGF-stimulated release was 
measured.  
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Figure 2-3 EFCAB4B-a amplified from HUVEC cDNA.  
The figure shows an electrophoresis gel of EFCAB4B-a product that was amplified 
from EFCAB4B-a enriched HUVEC cDNA. Amplification of EFCAB4B-a was not 
successful from random-primed cDNA (first 2 columns). The band was excised 
sequenced to confirm it was EFCAB4B-a. Expected size of product: 2,795 bp.    
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Primer 5’ – 3’ sequence 
EFCAB4B-a 
Crac2rainsertF GATCCGCTAGCGCTACACCATGGCTGCCCCTGACGGG 
Crac2rainsertR GGTATGGCTGACCTTGTAGGACCCTATCA 
eGFP2Inverse-F TCAGCCATACCACATTTGTAGAGG 
eGFP2Inverse-R GTAGCGCTAGCGGATCTG 
GFP- EFCAB4B-a 
eGFP2Inverse-F TCAGCCATACCACATTTGTAGAGG 
GFP Inverse-R CGAAGCTTGAGCTCGAGAT 
CRACR2AsGFP-F GAGCTCAAGCTTCGGGTGGTATGGCTGCCCCTGAC 
Crac2rainsertR GGTATGGCTGACCTTGTAGGACCCTATCA 
EFCAB4B-a-GFP 
CRACR2ALinverseR GCCACAGCAGGATTTCTTCT 
CRACR2ALinverseF TGATAGGGTCCTACAAGGTCAG 
GFP forward primer TCCTGCTGTGGCGGTGGTGTGAGCAAGGGCGA 
GFP reverse primer TAGGACCCTATCACGAAGCTTGAGCTCG 
CRACR2A 
eGFP2Inverse-F TCAGCCATACCACATTTGTAGAGG 
eGFP2Inverse-R GTAGCGCTAGCGGATCTG 
Crac2rainsertF GATCCGCTAGCGCTACACCATGGCTGCCCCTGACGGG 
CRACR2As Insert-R GGTATGGCTGATTAGACTGGTCCTTCCGAC 
GFP-CRACR2A 
eGFP2Inverse-F TCAGCCATACCACATTTGTAGAGG 
GFP Inverse-R CGAAGCTTGAGCTCGAGAT 
CRACR2AsGFP-F GAGCTCAAGCTTCGGGTGGTATGGCTGCCCCTGAC 
Table 2-5 Cloning primers.  
Table showing cloning primers used in this study 
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Table 2-6 List of primers for EFCAB4B-a mutagenesis.  
Table showing primer sequences used to generate Q604L and N658I mutations in 
EFCAB4B-a. F, forward primer; R, reverse primer.  
 
Mutation Primers (5’-3’) 
Q604L 
F: TGGGACACGGCTGGGCTGGAGAGGTACCGGTGC 
R: GCACCGGTACCTCTCCAGCCCAGCCGTGTCCCA 
N658I 
F: TGTTCTTCTGCTGGGTATTAAGCTTGACAACGAG 
R: CTCGTTGTCAAGCTTAATACCCAGCAGAAGAACA 
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2.13. Wound assay 
 
HUVECs were transfected with siRNA as per above protocol. Transfected cells 
were seeded into a 96 well Essen ImageLock plate and incubated at 37ºC/4% 
CO2 overnight. A 96-pin Woundmaker (Essen) was then used as per the 
manufacturer’s protocol to create a wound in a confluent monolayer of cells. 
The plate was then placed into the IncuCyte and wound images were taken 
every hour for up to 48 hours. The integrated IncuCyte technology calculated 
the Relative Wound Density, which was then used for data analysis.  
2.14. Data analysis 
 
Data were analysed and figures prepared using Origin 7.5 software (OriginLab 
Corporation). For FlexStation and cell migration experiments data are 
presented as ‘n/N’, which represents the ‘number of independent 
experiments/number of individual wells used in 96-well plates across all 
experiments’. For patch-clamp data ‘n’ represents the total number of individual 
cells from which recordings were made. For Western blot and ELISA data ‘n’ 
represents the number of independent experiments.  
 
Data sets were compared using two- tailed Student’s t-tests and expressed as ± 
standard error of the mean (SEM). For tube formation assays the mean ± 
standard error of the mean (SEM) was generated for each individual experiment 
due to variation in tube growth between assays. A difference where P<0.05 was 
judged to be significant (*). Any difference where the P-value was greater than 
0.05 was deemed not significant (n.s). 
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CHAPTER 3. EFCAB4B-A: A NOVEL PUTATIVE CALCIUM-
REGULATED RAB PROTEIN IN ENDOTHELIAL CELLS 
 
3.1. Introduction  
 
Store-operated Ca2+ entry involving Orai1 and STIM1 is an important signalling 
mechanism in many cell types including immune and endothelial cells (Feske et 
al., 2006, Li et al., 2011). In 2010, a novel Ca2+ binding protein called 
CRACR2A (also called EFCAB4B) was identified as a binding partner for Orai1 
(Srikanth et al., 2010). This came about through a study looking for novel 
regulators of the CRAC channel. In this study, HeLa cells stably expressing 
Orai1 and STIM1 were stimulated with the SERCA inhibitor thapsigargin (TG) to 
trigger store-depletion, and a macromolecular complex that contained putative 
interactors (one of which was CRACR2A) was identified through immunoaffinity 
purification (Srikanth et al., 2010).  
 
CRACR2A is a cytosolic EF-hand protein (Srikanth et al., 2010). The EF-hand is 
one of the most common structural motifs in the human genome and constitutes 
a helix-loop-helix domain. EF-hand proteins bind Ca2+ and are important 
regulators of Ca2+ signalling events, having diverse roles ranging from the 
opening and closing of Ca2+ channels to the transduction of biochemical 
responses (Chazin, 2011). CRACR2A has 2 EF-hands at its N terminus and 
Srikanth et al showed that mutating the second EF-hand abolished Ca2+ 
binding. In addition, results from this study showed that the binding of Ca2+ to 
CRACR2A was important for its interaction with Orai1 in Jurkat T cells (Srikanth 
et al., 2010). It was found that in the absence of extracellular Ca2+, CRACR2A 
had a strong association with Orai1 and that this was reduced in the presence 
of 2 mM extracellular Ca2+. Figure 3-1 illustrates the role of CRACR2A in 
SOCE, as evidenced in Jurkat T cells and HEK293 cells. In addition, it was 
shown that knocking down CRACR2A with siRNA reduced Orai1 clustering - an 
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important mechanism involved in CRAC channel activation. Interestingly, 
CRACR2A could also bind to Orai2, Orai3 and STIM1. A second EF-hand 
protein named CRACR2B (also called EFCAB4A) that shares 36% sequence 
similarity with CRACR2A was also found to be an effective modulator of SOCE 
(Srikanth et al 2010).  
 
Orai1 has been identified as the main ion channel underlying SOCE in 
endothelial cells (Li et al., 2011). The aim of this chapter was to investigate 
whether CRACR2A was expressed and functional in endothelial cells. RT-PCR 
and Western blotting was used to investigate expression of CRACR2A. Ca2+ 
imaging on HUVECs transfected with either scrambled or CRACR2A siRNA 
was used to address whether CRACR2A had any effect on SOCE in endothelial 
cells. Results from this chapter showed no expression of the CRACR2A protein 
in endothelial cells. However, a novel long isoform of CRACR2A that contains a 
putative Rab domain was discovered. This chapter reveals for the first time the 
expression and function of this novel putative Ca2+-regulated Rab protein in 
endothelial cells.  
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Figure 3-1 CRACR2A (CR2A) interacts with Orai1 and STIM1 and regulates Ca2+ 
entry through Orai1 channels in Jurkat T cells.  
1. At rest, CR2A resides in the cytoplasm; 2. Upon release of Ca2+ from the 
endoplasmic reticulum, CR2A binds to Orai1 and STIM1; 3. Orai1 and STIM1 cluster 
together in a complex with CR2A and Ca2+ enters the cell via Orai1 channels; 4. CR2A 
dissociates from Orai1 and STIM1 at elevated Ca2+ levels returning to resting state. 
Adapted from Srikanth et al (2010). 
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3.2. Endothelial cells express a longer isoform of CRACR2A 
 
First, to determine if endothelial cells expressed CRACR2A, total RNA was 
isolated from human umbilical vein endothelial cells (HUVECs) and reverse 
transcribed to generate cDNA. Real-time PCR (RT-PCR) was performed using 
CRACR2A primers that were designed using the LightCycler software (Roche) 
and products were resolved on a 2% agarose gel by electrophoresis. Since 
CRACR2A interacts with Orai1 and STIM1, RT-PCR was performed to confirm 
their expression. The gel image shows the mRNA expression of CRACR2A, 
Orai1 and STIM1 in HUVECs (Figure 3-2).  
 
To determine whether CRACR2A was expressed at the protein level, Western 
blotting was performed using HUVEC lysate. The lysate was probed with a 
commercially available polyclonal anti-CRACR2A antibody (antibody details in 
Table 2-2). The antigen peptide used to generate the anti-CRACR2A antibody 
was the full length CRACR2A protein (395 amino acids). Since CRACR2A has 
already been detected in Jurket T cells, a Jurkat T cell lysate was used as a 
positive control. Surprisingly, the blots showed no expression of the 46 kDa 
CRACR2A protein in HUVECs compared to Jurkat T cells using a 1:400 
antibody dilution and a 10 second exposure (Figure 3-3). However in both 
lysates the antibody detected a further 3 protein bands, one with a significantly 
greater abundance with an approximate molecular weight of 100 kDa (Figure 3-
3). The same band could be detected using four times less lysate and a 1:800 
antibody dilution, demonstrating its relatively higher abundance (Figure 3-5).  
 
Because of this unexpected result, sequence analysis and BLAST searches 
were performed on the CRACR2A gene sequence. These searches revealed 
that the CRACR2A gene (Ensembl number: ENSG00000130038, located on 
humans chromosome 12p.13.32) is alternatively spliced giving rise to a possible 
seven predicted variants. Four of the variants are predicted to be protein coding 
but only two are verified and recorded in the consensus coding DNA sequence 
(CDS) database. These are CRACR2A, and a putative longer isoform (isoform 
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A; accession number NP_001138430.1) that has a predicted mass of 83 kDa. 
This longer isoform shares 52% sequence similarity with CRACR2A (Figure 3-
4), but its expression has not been confirmed experimentally.  
 
Therefore to determine if the larger protein detected by Western blot was the 
longer isoform of CRACR2A, short interfering RNA (siRNA) that targets both 
long and short isoforms was used to knock down gene expression. Two 
different siRNAs (CR2A.si.1 and CR2A.si.2) were individually transfected into 
HUVECs using Lipofectamine 2000TM and 72 hours post-transfection the cells 
were lysed and Western blotting was performed. Figure 3-5a shows that there 
was no expression of the 46 kDa-CRACR2A protein and that both CR2A.si.1 
and CR2A.si.2 significantly reduced the amount of protein in this larger band by 
80% and 95% respectively (Figure 3-5). Actin was used as a loading control to 
demonstrate equal protein amounts in scrambled and siRNA samples (Figure 3-
5b). These data confirm that a longer isoform of CRACR2A is present in 
HUVECs, and from this point on the longer isoform will be referred to as 
EFCAB4B-a. 
 
To further confirm that EFCAB4B-a was expressed, RT-PCR primers were 
designed in the C-terminal region of the EFCAB4B-a nucleotide sequence so 
that they were specific for EFCAB4B-a over CRACR2A. RT-PCR was 
performed using these primers on HUVEC cDNA. Electrophoresis gel images 
show that EFCAB4B-a was expressed at the mRNA level (Figure 3-6). In 
addition, these primers were tested on cDNA from a range of other micro- and 
macro-vascular endothelial cells, and the mRNA gel confirmed that EFCAB4B-a 
was widely expressed across a large range of endothelial cell types (Figure 3-
6).  
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Figure 3-2 Expression of CRACR2A, Orai1 and STIM1 in HUVECs.  
Gel electrophoresis showing products from RT-PCR analysis of RNA isolated from 
HUVECs. Reactions were performed with (+) or without (-) reverse transcriptase (RT). 
Expected sizes of the products were 365 bp (CRACR2A), 300 bp (Orai1) and 276 bp 
(STIM1), 194 bp (β actin). 
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Figure 3-3 46 kDa CRACR2A is not detected in HUVECs.  
Representative Western blots of whole-cell lysate from HUVECs and Jurkat T cells 
using an anti-CRACR2A antibody (1:400) and a 1 (a) and 10 (b) exposure times (sec) 
showing a band at 46 kDa corresponding to CRACR2A in Jurkat T cells but not in 
HUVECs (black arrows). A larger band at around 100 kDa was detected in both 
HUVEC and Jurkat T cell lysates (grey arrows).  
 
  
72
95
55
43
26
130
HUVEC Jurkat5T
15sec
a
72
95
55
43
26
130
HUVEC Jurkat5T
105sec
b
Exposure
Time:
kDa kDa
77 
 
 
 
 
 
Figure 3-4 CRACR2A has a longer isoform.  
Protein sequence alignment of CRACR2A isoform c (EFCAB4Biso.c) and the predicted 
longer isoform a (EFCAB4Biso.a.), which has yet to be confirmed experimentally. The 
2 isoforms share 52% sequence similarity (highlighted). EFCAB4biso.a. has a 
predicted mass of 83 kDa.  
 
EFCAB4Biso.c      MAAPDGRVVSRPQRLGQGSGQGPKGSGACLHPLDSLEQKETQEQTSGQLVMLRKAQEFFQ 60 
EFCAB4Biso.a      MAAPDGRVVSRPQRLGQGSGQGPKGSGACLHPLDSLEQKETQEQTSGQLVMLRKAQEFFQ 60 
                  ************************************************************ 
 
EFCAB4Biso.c      TCDAEGKGFIARKDMQRLHKELPLSLEELEDVFDALDADGNGYLTPQEFTTGFSHFFFSQ 120 
EFCAB4Biso.a      TCDAEGKGFIARKDMQRLHKELPLSLEELEDVFDALDADGNGYLTPQEFTTGFSHFFFSQ 120 
                  ************************************************************ 
 
EFCAB4Biso.c      NNPSQEDAGEQVAQRHEEKVYLSRGDEDLGDMGEDEEAQFRMLMDRLGAQKVLEDESDVK 180 
EFCAB4Biso.a      NNPSQEDAGEQVAQRHEEKVYLSRGDEDLGDMGEDEEAQFRMLMDRLGAQKVLEDESDVK 180 
                  ************************************************************ 
 
EFCAB4Biso.c      QLWLQLKKEEPHLLSNFEDFLTRIISQLQEAHEEKNELECALKRKIAAYDEEIQHLYEEM 240 
EFCAB4Biso.a      QLWLQLKKEEPHLLSNFEDFLTRIISQLQEAHEEKNELECALKRKIAAYDEEIQHLYEEM 240 
                  ************************************************************ 
 
EFCAB4Biso.c      EQQIKSEKEQFLLKDTERFQARSQELEQKLLCKEQELEQLTQKQKRLEGQCTALHHDKHE 300 
EFCAB4Biso.a      EQQIKSEKEQFLLKDTERFQARSQELEQKLLCKEQELEQLTQKQKRLEGQCTALHHDKHE 300 
                  ************************************************************ 
 
EFCAB4Biso.c      TKAENTKLKLTNQELARELERTSWELQDAQQQLESLQQEACKLHQEKEMEVYRVTESLQR 360 
EFCAB4Biso.a      TKAENTKLKLTNQELARELERTSWELQDAQQQLESLQQEACKLHQEKEMEVYRVTESLQR 360 
                  ************************************************************ 
 
EFCAB4Biso.c      EKAGLLKQLDFLR----------------------------------------------- 373 
EFCAB4Biso.a      EKAGLLKQLDFLRERNKHLRDERDICFQKNKAAKANTAASRASWKKRSGSVIGKYVDSRG 420 
                  *************                                                
 
EFCAB4Biso.c      --------------------------------------CVGGHWP--------------- 380 
EFCAB4Biso.a      ILRSQSEEEEEVFGIPRRSSLGLSGYPLTEEEPGTGEPGPGGPYPRPLRRIISVEEDPLP 480 
                                                          ** :*                
 
EFCAB4Biso.c      ----------------------------VLRAPPRSLGSEGPV----------------- 395 
EFCAB4Biso.a      QLLDGGFEQPLSKCSEEEEVSDQGVQGQIPEAPPLKLTPTSPRGQPVGKEALCKEESSPS 540 
                                              : .*** .* . .*                   
 
EFCAB4Biso.c      ------------------------------------------------------------ EFCAB4Biso.c      ------------------------------------------------------------ EFCAB4Biso.a      APDRLFKIVFVGNSAVGKTSFLRRFCEDRFSPGMAATVGIDYRVKTLNVDNSQVALQLWD 600 
                                                                               
 
EFCAB4Biso.c      ------------------------------------------------------------ 
EFCAB4Biso.a      TAGQERYRCITQQFFRKADGVIVMYDLTDKQSFLSVRRWLSSVEEAVGDRVPVLLLGNKL 660 
                                                                               
 
EFCAB4Biso.c      ------------------------------------------------------------ 
EFCAB4Biso.a      DNEKEREVPRGLGEQLATENNLIFYECSAYSGHNTKESLLHLARFLKEQEDTVREDTIQV 720 
                                                                               
 
EFCAB4Biso.c      ----------- 
EFCAB4Biso.a      GHPAKKKSCCG 731 
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Figure 3-5 HUVECs express CRACR2A isoform a.  
HUVECs were transfected with 2 different CRACR2A siRNAs and lysed after 72 hours. 
Western blots using an anti-CRACR2A antibody did not detect the 46 kDa CRACR2A 
protein (arrow; a) but did detect a larger protein that was down-regulated following 
siRNA knockdown with CRACR2A siRNA 1 (CR2A.si.1; a; n=3) and CRACR2A siRNA 
2 (CR2A.si.2; b; n=3). Protein levels were quantified by densitometry and the mean 
levels of CRACR2A (large isoform) are shown in c (CR2A.si.1; *P<0.05) and d 
(CR2A.si.2; *P<0.05).   
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Figure 3-6 EFCAB4B-a mRNA is expressed in a range of macro- and micro-
vascular endothelial cells.  
The image shows an electrophoresis gel of PCR products showing expression of 
EFCAB4B-a in: HPAEC (pulmonary artery); HDBEC (dermal blood); HUVEC (umbilical 
vein); HUAEC (umbilical artery); HCoMEC (colonic microvascular); HCMEC (cardiac 
microvascular); HPMEC (pulmonary microvascular; HDMEC (dermal microvascular) 
and HBdMEC (bladder microvascular). Reactions were performed with (+) or without (-) 
reverse transcriptase (RT). Expected size of the EFCAB4B-a product was 214 bp.  
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3.3. EFCAB4B-a has no effect on store-operated Ca2+ entry in 
endothelial cells 
 
CRACR2A was found to interact with Orai1 and STIM1 to regulate Ca2+ entry 
into cells via the Orai1 ion channel (Srikanth et al., 2010). To determine whether 
EFCAB4B-a shared a similar function with CRACR2A, the effect of EFCAB4B-a 
knockdown on store-operated Ca2+ entry (SOCE) was investigated. Since 
HUVECs showed no expression of CRACR2A at the protein level, it was 
assumed that any effect observed with the CRACR2A siRNA (which target the 
identical N-terminus of both isoforms) was an effect mediated by EFCAB4B-a. 
Two different siRNAs and a scrambled control siRNA were individually 
transfected into HUVECs. Seventy-two hours post-transfection, cells were 
loaded with the Ca2+ indicator dye Fura-2 AM and SOCE was measured in 
multi-well intracellular Ca2+ ([Ca2+]i) measurement experiments using the 
FlexStation. To measure SOCE, cells were treated with the SERCA inhibitor 
thapsigargin (TG), in the absence of extracellular Ca2+ in order to evoke a 
release of Ca2+ from intracellular stores. Extracellular Ca2+ was then added 
back and the Ca2+ entry response measured. Interestingly, siRNA mediated 
knockdown of EFCAB4B-a had no effect on SOCE in HUVECs. As a control, 
Orai1 and STIM1 siRNA-transfected cells showed a significant inhibition of the 
SOCE response (Figure 3-7).  
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Figure 3-7 EFCAB4B-a has no effect on SOCE.  
siRNA transfected HUVECs loaded with Fura-2 AM were treated with TG (1 µM) in the 
absence of extracellular Ca2+ before Ca2+ add-back. Example traces for a. CRACR2A 
siRNA 1 (CR2A.si.1; N=4), b. CRACR2A siRNA 2 (CR2A.si.2.; N=4), c. Orai 1 siRNA 
(Orai1.si.; N=7) and d. STIM1 siRNA (STIM1.si.; N=2). e-h. Summary data (Mean ± 
SEM) for the experiments of the type illustrated in a-d showing measurements for the 
Ca2+ release and Ca2+ entry effects with: e. CR2A.si.1 (n/N=6/28; *P<0.05), f. 
CR2A.si.2 (n/N=5/23; NS, non-significant), g. Orai1.si. (n/N=2/9) and h. STIM1.si. 
(n/N=2/8).   
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3.4. EFCAB4B-a contains a putative Rab domain  
 
CRACR2A and EFCAB4B-a have identical N-termini, encoding 2 EF-hand 
domains and a coiled-coil region. However EFCAB4B-a also contains a putative 
Rab domain located at its C-terminus at 542-731 residues (Figure 3-8). Since 
knocking-down EFCAB4B-a using siRNA had no effect on SOCE, the C-
terminus of EFCAB4B-a must influence its function. Sequence analysis showed 
that the putative Rab domain encoded by EFCAB4B-a contains all of the 
conserved Rab motifs (Figure 3-8) (Colicelli, 2004). EFCAB4B-a is therefore a 
putative Rab protein expressed in endothelial cells. The aims of the project from 
this point were to investigate whether it is a novel Rab protein, and to 
investigate its role in endothelial cells.  
 
In order to obtain unbiased insight into the significance of EFCAB4B-a in 
endothelial cells, the subcellular localisation of EFCAB4B-a was investigated. 
To examine the endogenous localisation of EFCAB4B-a, HUVECs were seeded 
onto glass coverslips, fixed and labelled with the commercially available anti-
CRACR2A antibody (1:50) and visualised using a fluorescent anti-rabbit 
secondary antibody. Immunofluorescence was visualised using the Delta Vision 
microscope. The images showed staining in the cell cytoplasm and nuclei 
(Figure 3-9). Since this antibody did detect other protein bands by Western blot 
(Figure 3-3), the staining observed could not be attributed purely to EFCAB4B-
a. Since no EFCAB4B-a-specific antibodies were available it was decided to 
clone EFCAB4B-a from HUVECs and to generate an overexpression construct 
in order to further investigate its localisation.  
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Figure 3-9 Staining observed with the anti-CRACR2A antibody. 
 HUVECs were fixed and permeabilised then incubated with the anti-CRACR2A antibody at 
1:50, 1:100 and 1:200 dilutions. Secondary antibody (2º) was Alexa Fluor 488 donkey anti-
rabbit. Nuclei are stained with DAPI. Cells were imaged by Bing Hou on the Delta Vision 
microscope.   
1:50 1:100
1:200 2° only
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3.5. Cloning EFCAB4B-a from HUVECs confirms its expression 
 
EFCAB4B-a was cloned from HUVEC cDNA that had been enriched using a 
EFCAB4B-a gene specific primer (Crac2rainsertR; Table 2-5) for reverse 
transcription. Nucleotide sequencing confirmed its identity as the predicted long 
isoform of EFCAB4B, although the sequencing results indicated that EFCAB4B-
a cloned from HUVECs had 3 extra nucleotides in its sequence (encoding an 
additional amino acid between serine424 and glutamamine425) compared to 
the published sequence (NM_001144958.1). This most likely represents a 
genuine variation from the sequence published, since the same insertion was 
detected in human pulmonary artery, human dermal microvascular and human 
colonic microvascular endothelial cells, by RT-PCR. EFCAB4B-a was then 
cloned into an eGFP-C1 expression vector by Infusion reaction. Two different 
constructs were generated, one that expressed GFP tagged to the N-terminus 
of EFCAB4B-a (GFP-EFCAB4B-a), and one that expressed untagged 
EFCAB4B-a.  
 
In order to compare the intracellular localisation of EFCAB4B-a with CRACR2A, 
a CRACR2A construct (clone ID 3531511) was purchased. Using the same 
cloning methods as described for EFCAB4B-a, CRACR2A was inserted into the 
same eGFP-C1 vector, plus and minus expression of GFP at the N-terminus 
and constructs were verified by sequencing. 
 
In order to confirm the expression and detection of each gene product by the 
anti-CRACR2A antibody, the constructs were transfected into HUVECs, and 
lysates from transfected cells were probed by Western blotting. The results are 
shown in Figure 3-10 – in untransfected cells (lane 1), only endogenous 
EFCAB4B-a is detected; in transfected cells, both the endogenous protein and 
the overexpressed recombinant proteins (CRACR2A, lane 2; EFCAB4B-a, lane 
3; GFP-EFCAB4B-a, lane 4) are detected. These data confirm that the high 
molecular weight band detected by this antibody is the predicted long isoform 
EFCAB4B-a.   
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Figure 3-10 The anti-CRACR2A antibody cross reacts with EFCAB4B-a protein.  
Constructs expressing either CRACR2A (lane 2), EFCAB4B-a (lane 3) or GFP-
EFCAB4B-a (lane 4) were transiently transfected into HUVECs, and Western blotting 
was performed on cell lysates. The anti-CRACR2A antibody (1:800) detected both 
endogenous and overexpressed CRACR2A and EFCAB4B-a proteins. Lane 1: control 
transfected cells with pcDNA3.1. Lane 2: red arrow shows overexpressed 46 kDa 
CRACR2A. Lane 3: shows overexpressed EFCAB4B-a (blue arrow). Lane 4: Green 
arrow shows overexpressed GFP-EFCAB4B-a. Bottom blot shows actin loading 
controls. 
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3.6. EFCAB4B-a localises to endothelial cell-specific Weibel-Palade 
Bodies 
 
To determine the localisation of EFCAB4B-a, EFCAB4B-a constructs were 
transiently transfected into HUVECs using Lipofectamine 2000™ in a 6-well 
dish.  After 24 hours, cells were transferred onto glass coverslips and 
immunostaining was performed at 48 hours post-transfection. Constructs 
expressing CRACR2A were also transfected into separate cells to compare its 
localisation with that of EFCAB4B-a. Overexpressed proteins were visualised 
either by the GFP-tag or by staining with the anti-CRACR2A antibody and 
fluorescently labelled secondary antibodies.  
 
CRACR2A, as expected, showed a cytosolic localisation with some plasma 
membrane expression (Figure 3-11). EFCAB4B-a showed a very different 
localisation to CRACR2A. Immediately obvious was a strong expression in the 
peri-nuclear region. A similar localisation had previously been observed for 
Rab45 (also known as RASEF), a Rab protein with a very similar structure to 
EFCAB4B-a with 2 EF-hands, a coiled-coil region and a Rab domain (Shintani 
et al., 2007). Since the Golgi has a peri-nuclear localisation, transfected cells 
were immunostained with the cis-Golgi marker GM130, in order to determine 
whether EFCAB4B-a was present in the Golgi. No co-localisation occurred 
between the Golgi marker and EFCAB4B-a (Figure 3-12).  No co-localisation 
occurred with the trans-golgi marker, anti-TGN-46 either. Instead, EFCAB4B-a 
appeared to disrupt the Golgi (Figure 3-12). 
 
Although the majority of cells displayed this peri-nuclear localisation, in some 
cells, EFCAB4B-a was found in small rod-shaped vesicles clustered around the 
peri-nuclear region. These rod-shaped vesicles resembled endothelial-cell 
specific Weibel-Palade bodies (WPBs) (Weibel and Palade, 1964). WPBs are 
secretory-like vesicles involved in exocytosis (Valentijn et al., 2011). WPBs can 
be 0.1-0.3 µm in diameter and 1-5 µm in length and the main constituent of 
these vesicles is the prothrombotic agent, von Willebrand Factor (vWF) 
(Valentijn et al., 2011). To investigate whether these rod-shaped vesicles 
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containing EFCAB4B-a were WPBs, HUVECs overexpressing EFCAB4B-a 
were fixed and immunostained with a primary anti-vWF antibody. vWF staining 
was visualised using a fluorescently tagged anti-mouse secondary antibody. 
The cells were then imaged on the DeltaVision microscope.  
 
vWF staining, as expected, appeared in rod-shaped structures resembling 
WPBs. The dimensions of these structures were measured using Image J 
software (http://uhnresearch.ca/wcif/imagej). A total of 150 structures in cells 
from 6 images were measured and the results were plotted in a frequency 
histogram (Figure 3-13). The dimensions of the structures were consistent with 
those previously described for WPBs (Valentijn et al., 2011). 
 
To investigate any potential colocalisation between EFCAB4B-a and vWF, 
HUVECs were transfected with non-tagged EFCAB4B-a, fixed and stained with 
the anti-CRACR2A and anti-vWF antibodies. Across four independent 
experiments, a total of eighteen images of cells expressing EFCAB4B-a in the 
field of view were analysed. Of those 18 images, eleven (65%) included cells 
showing evidence of colocalisation between vWF (red stain) and EFCAB4B-a 
(green stain). The degree of this colocalisation was quantified using Image J 
software and the Colocalisation Threshold PlugIn 
(http://uhnresearch.ca/wcif/imagej). This software generates an Rcolocalisation 
(Rcoloc) value, which is a measure of the linear correlation between the red 
(vWF) and green (EFCAB4B-a) channels. A value of 1 represents a complete 
positive correlation and zero indicates no correlation. The mean Rcoloc value 
across the images analysed was 0.8, indicating a strong correlation between 
EFCAB4B-a and vWF localisation. Seven of eighteen images analysed (41%) 
showed co-localisation of EFCAB4B-a and vWF in structures that resembled 
WPBs (Figures 3-14 and 3-15). In addition to these structures, the 
colocalisation was frequently observed in the peri-nuclear region. The 
significance of this peri-nuclear staining remains to be determined. 
 
Although up to 97% of EFCAB4B-a was found to colocalise with vWF 
(Rcoloc=0.88), the extent of colocalisation varied widely between cells (5-97%). 
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Similar results were also obtained when cells transfected with GFP-tagged 
EFCAB4B-a were costained with anti-vWF (Figure 3-16). 
 
Whilst 65% of cells showed colocalisation of EFCAB4B-a with vWF, the 
remaining 35% of EFCAB4B-a-expressing cells showed no detectable vWF 
staining (Figure 3-17) suggesting that overexpression of EFCAB4B-a reduces 
the total amount of cellular vWF.  
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Figure 3-11 CRACR2A has a cytoplasmic and plasma membrane localisation in 
HUVECs.  
HUVECs were transfected with a CRACR2A expressing plasmid. 48 hours later cells 
were fixed, stained with the anti-CRAC2A antibody and analysed by Delta Vision 
microscopy. The nuclei were stained with DAPI. The figures are representative  images 
from 2 experiments showing CRACR2A expression in the cytoplasm and at the plasma 
membrane (arrow heads). 
b
a
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Figure 3-12 EFCAB4B-a does not localise to the Golgi.  
HUVECs were transfected with a GFP-EFCAB4B-a expressing plasmid. 48 hours later 
cells were fixed, stained with a primary cis-Golgi marker, anti-GM130 antibody (1:50) 
and analysed by Delta Vision microscopy. DyLight594-conjugated anti-mouse IgG was 
used for visualisation of the Golgi (red). The nuclei were stained with DAPI (blue). The 
figures are representative images showing GFP-EFCAB4B-a (green) and cis-Golgi 
(red).  
b 
a 
92 
 
1 2 3
0
10
20
 
 
Co
un
t
WPB length (µm)
Figure 3-13 Frequency distribution of WPBs in HUVECs. 
150 WPBs were counted from a total of 6 images. The length of 
each WPB was measured using Image J software. Data were 
plotted in a statistical histogram.  
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Figure 3-14 EFCAB4B-a localises to WPBs.  
HUVECs were transfected with the EFCAB4B-a construct. Two days later cells were 
fixed, immunostained with primary monoclonal anti-vWF (shown in red) and primary 
polyclonal anti-CRACR2A (shown in green) antibodies and analysed by Delta Vision 
microscopy. DyLight594-conjugated anti-mouse IgG was used for visualisation of vWF 
(red). Nuclei were stained with DAPI (blue). The figure is a representative image from 4 
independent experiments showing a. EFCAB4B-a expression (green) b. anti-vWF 
expression (red) and c. merged image, showing co-localisation (yellow) of EFCAB4B-a 
with vWF. Colocalisation was measured using Image J software and the ‘Colocalisation 
Threshold’ Plugin. The grey colour shown in d highlights the mask applied to generate 
the Rcoloc. Rcoloc=0.9.   
 
a b
d
Rcoloc =&0.9
c
94 
 
 
Figure 3-15 EFCAB4B-a localises to WPBs.  
HUVECs were transfected with a EFCAB4B-a expressing plasmid. 48 hours later cells 
were fixed, stained with a primary anti-vWF antibody (1:200) and primary anti-
CRACR2A antibody and analysed by Delta Vision microscopy. DyLight594-conjugated 
anti-mouse IgG (red) was used for visualisation of vWF. The nucleus was stained with 
DAPI (blue). The figure shows representative images from 3 experiments showing a. 
EFCAB4B-a expression (green) b. anti-vWF expression (red) and c. merged image, 
showing co-localisation (yellow) of EFCAB4B-a with vWF. The image in panel d shows 
an enalarged image of the highlighted section in panel c. arrows indicate colocalisation. 
Rcoloc=0.9.  
 
b!a!
c!
  
  
  
  d!
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Figure 3-16 GFP-EFCAB4B localises to WPBs. 
HUVECs were transfected with the GFP-EFCAB4B-a construct and immunostained with anti-
vWF. Cells were imaged on the Delta Vision microscope. Nuclei are stained with DAPI (blue). 
a. expression of GFP-EFCAB4B-a (green). b. anti-vWF staining (red). c. colocalisation of 
GFP-EFCAB4B-a and vWF (yellow). d. colocalisation analysis was performed using ImageJ 
PlugIn : Correlation Threshold. Rcoloc = 0.8. 
a b 
c d 
Rcoloc%=%0.8% 
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Figure 3-17 Over-expression of EFCAB4B-a reduces vWF expression.  
HUVECs were transfected with a EFCAB4B-a expressing plasmid. 48 hours later cells 
were fixed, stained with a primary anti-vWF antibody and primary anti-CRACR2A antibody 
and analysed by Delta Vision microscopy. DyLight594-conjugated anti-mouse IgG was 
used for visualisation of vWF (red). The nuclei were stained with DAPI (blue). The figures 
are 2 representative images from 3 experiments showing strong EFCAB4B-a over-
expression reduced vWF expression.  
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3.7. A conserved GTP-binding motif is important for the localisation 
of EFCAB4B-a. 
 
Rab proteins function by cycling between an active GTP-bound state and an 
inactive GDP-bound state (Colicelli, 2004). When Rab proteins are in their GTP-
bound conformation they are often membrane bound, whilst when they are in 
their GDP-bound confirmation they often reside in the cytoplasm (Colicelli, 
2004). Conserved motifs in Rab GTPase sequences are responsible for GTP 
binding and hydrolysis. Rab proteins have 5 conserved “G box” motifs (Figure 
3-8) (Colicelli, 2004). The G1 box is important for purine nucleotide binding; the 
G2 box is important for downstream effector binding; the G3 box is important in 
binding nucleotide-associated Mg2+ ions; the G4 box is important for direct 
interaction with the nucleotide and the residues in the G5 box are less well 
conserved but are primarily important for indirect associations with the guanine 
nucleotide (Colicelli, 2004). One of the most widely-used Rab mutations 
involves mutating the conserved catalytic glutamine in the G3 box residue to 
leucine, which prevents GTP hydrolysis and locks the protein in a permanently 
active state (Lee et al., 2009). On the other hand, mutations in the G4 box lead 
to a constitutively inactive protein that has reduced affinity for guanine 
nucleotides (Knop et al., 2004). In light of this information, two GFP-EFCAB4B-
a mutant constructs were generated to determine whether GTP binding was 
important for the localisation of EFCAB4B-a. The first mutation in the G3 box 
was GFP-EFCAB4B-aQ604L and the second mutation in the G4 box was GFP-
EFCAB4B-aN658I. The mutations were made by site-directed mutagenesis on 
the GFP-EFCAB4B-a construct using the primers shown in Table 2-8. Both 
constructs were sequenced to confirm the successful mutagenesis.  
 
Mutated constructs were transiently transfected into HUVECs and 24 hours 
later, the cells were fixed and immunostained with the anti-vWF antibody to 
label the WPBs and then analysed on the confocal microscope. Results from 
five images across three independent experiments suggested that the GTP-
98 
 
locked GFP-EFCAB4B-aQ604L mutant had a peri-nuclear localisation, but no co-
localisation with vWF was observed. In contrast, the GTP-deficient mutant 
(GFP-EFCAB4B-aN658I) showed a more diffuse, cytosolic distribution (n=9 
images from 3 independent experiments) (Figure 3-18). These findings suggest 
that the conserved GTP-binding motif is important for EFCAB4B-a function.  
 
At the C-termini of Rab proteins is a prenylation motif, which acts as a 
localisation signal and is important for the insertion of the protein into the 
membrane (Gomes et al., 2003). The putative prenylation motif in EFCAB4B-a 
consists of two cysteine residues (–SCCG; Figure 3-8). It has been shown for 
other Rab proteins that disrupting this prenylation motif prevents membrane 
insertion and function (Gomes et al., 2003). In line with this, it has been shown 
that tagging fusion proteins, such as GFP, to the C-termini of Rab proteins can 
mask their localisation signal and result in mislocalisation (Wink, 2006). In this 
study, another EFCAB4B-a construct was made but this time GFP was tagged 
to the C-terminus of EFCAB4B-a. When this construct was transfected into 
HUVECs, it had a general cytosolic distribution (Figure 3-19), similar to that 
observed with the GFP-EFCAB4B-aN658I mutation construct (Figure 3-18a). This 
may have occurred because the C-terminal disrupted a prenylation event that is 
important for WPB association.  
 
Together these data suggest that the Rab domain and prenylation motif are 
important for the localisation of EFCAB4B-a to WPBs. 
 
At a late stage in this thesis work it was appreciated that the sequence of 
EFCAB4B-a, cloned from HUVEC cells contained a nucleotide resulting in a 
single amino acid substitution (L532P).  This substitution was outside the EF-
hand and Rab domains but could have had an effect on function. Therefore, in 
order to determine whether the substitution had an effect, a construct 
expressing GFP-tagged gene containing the EFCAB4B-a sequence as 
deposited in the gene database (L532) was generated by site-directed 
mutagenesis, overexpressed in HUVECs and visualised using the DeltaVision 
microscope.       
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The overexpression pattern observed for the L532 construct was consistent 
with that observed for the constructs containing P532. A total of 19 images were 
taken of HUVECs expressing EFCAB4B-aL532. Of those images, eight (42%) 
showed colocalisation with vWF and four (21%) showed co-localisation with 
vWF in structures that resembled WPBs (R=0.6; Figure 3-20). These 
experiments suggest that this amino acid (L532) is not important for the 
localisation of EFCAB4B-a.    
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Figure 3-18 Mutating a conserved GTP-binding region in EFCAB4B-a results in 
a cytoplasmic localisation.  
HUVECs were transfected with plasmids encoding GFP-EFCAB4B-a mutants. 24 
hours later cells were stained with a primary anti-vWF antibody  and visualised using 
the confocal microscope. Nuclei were stained with DAPI (blue). HUVECs expressing 
the GTP-deficient mutant GFP-EFCAB4B-aN658I showed a cytoplasmic distribution (a) 
whereas the constitutively active mutant GFP-EFCAB4B-a Q604L showed a peri-
nuclear and localisation (b). Images are representative images from 3 experiments.  
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Figure 3-19 EFCAB4B-a-GFP has a cytosolic localisation.  
HUVECs were transfected with EFCAB4B-a-GFP. 48 hours later cells were 
fixed then analysed by Delta Vision microscopy. The nuclei were stained with 
DAPI (blue). The figures are 2 representative images from 1 experiment 
showing EFCAB4B-a -GFP has a cytoplasmic localisation in HUVECs (green).  
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Figure 3-20 Amino acid substitution at position 532 does not affect the sub-
cellular localisation of EFCAB4B-a. 
HUVECs were transfected with GFP-EFCAB4B-a expressing Lysine at position 532. 48 
hours post-transfection, cells were fixed and stained with the anti-vWF antibody (red) 
and colocalisation with GFP-EFCAB4B-a (green) was visualised using the Delta Vision 
microscope. The nuclei were stained with DAPI (blue). Rcoloc=0.75. 
a b
c d Rcoloc =&0.75
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3.8. Knockdown of EFCAB4B-a has no effect on VEGF-A165-
stimulated vWF secretion  
 
A major role of Rab proteins is in vesicle trafficking (Diekmann et al., 2011). 
Several other Rab proteins including Rab3, Rab33, Rab37, Rab27 and Rab15 
have been found expressed in WPBs (Zografou et al., 2012) and 3 of these 
Rabs (Rab3d, Rab27a and Rab15) have reported roles in the trafficking and 
secretion of vWF (Bierings et al., 2012, Knop et al., 2004, Nightingale et al., 
2009, Zografou et al., 2012). To determine if EFCAB4B-a was involved in the 
secretion of vWF,  vWF ELISA assays were performed.  
 
The secretion of vWF occurs mostly in a Ca2+-regulated manner by exocytosis. 
Many different factors have been shown to activate WPB exocytosis including 
endogenous chemicals such as ATP and histamine; polypeptides such as 
thrombin and VEGF, and lipids such as ceramide and sphingosine-1-phosphate 
(Lowenstein et al., 2005).  In this study, VEGF-A165 was used to stimulate 
secretion of vWF since it is a major signalling cytokine involved in driving 
endothelial cell migration, proliferation and tube formation, although it also 
promotes vascular inflammation (Matsushita et al., 2005).  
 
A concentration response curve to VEGF-A165 was performed to determine a 
sub-maximal concentration to stimulate vWF secretion (Figure 3-21). HUVECs 
treated with either scrambled or EFCAB4B-a siRNA were incubated in growth 
factor- and serum- free media for 30 minutes at 37°C 4% CO2. Thirty minutes 
later the cell medium was exchanged for medium containing 30 ng/ml VEGF-
A165. A previous study showed that 30 minutes treatment evoked a significant 
increase in secreted vWF (Matsushita et al., 2005). After this time two 100 µl 
supernatant samples were removed, and vWF levels were measured using a 
vWF ELISA assay. To determine the constitutive secretion of vWF, control 
experiments were performed where water was substituted for VEGF-A165.  
 
As confirmation that EFCAB4B-a had been knocked down in these 
experiments, the cells used in these experiments were lysed and Western 
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blotting was performed using the anti-CRACR2A antibody. The results showed 
that siRNA treatment had no significant effect on basal (constitutive) or 
regulated (VEGF-stimulated) vWF secretion (Figure 3-21), despite a significant 
reduction in EFCAB4B-a protein levels (Figure 3-22 a and b). However, the 
basal levels of intracellular vWF were significantly increased (Figure 3-22). 
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Figure 3-21 siRNA-mediated knockdown of EFCAB4B-a has no significant effect 
on constitutive or VEGF-stimulated vWF secretion.  
a. Standard curve showing absorbance at 450 nm increases with increasing vWF 
concentrations. b. HUVECs were stimulated with a range of concentrations of VEGF-
A165 for 30 minutes. Samples of cell media were removed and the amount of vWF was 
measured by ELISA assay. c. HUVECs treated with scrambled or EFCAB4B-a siRNA 
for 72 hours were treated with 30 ng/ml VEGF-A165 or water control (basal). The 
amount of vWF released was quantified by ELISA. The histogram shows the mean 
absorbance at 450 nm for control and knockdown cells. n numbers are shown in the 
histogram bars. No significant difference was observed between scrambled and 
knockdown treated cells.   
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Figure 3-22 Knockdown of EFCAB4B-a increases the amount of cellular vWF.  
HUVECs were transfected with scrambled or 2 different EFCAB4B-a siRNA (EF.si.1 
and EF.si.2). 72 hours post-transfection, cells were lysed and Western blotting 
performed using an anti-CRACR2A/EFCAB4B-a antibody to confirm knockdown, anti-
actin to confirm equal protein loading and anti-vWF to determine if knock-down of 
EFCAB4B-a had any effect on cellular vWF levels. a. Representative Westen blot 
showing successful knockdown of EFCAB4B-a and increased amount of vWF in 
EFCAB4B-a siRNA-treated cells. b. Quantification of knockdown results, showing 
EFCAB4B-a abundance is significantly reduced following siRNA treatment (n=3; 
P<0.05). c. Quantification of Western blot results showing increased expression of 
vWF when EFCAB4B-a is knocked down with two different siRNAs (n=3; *P<0.05).  
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3.9. Knockdown of EFCAB4B-a suppresses VEGFR2 receptor 
expression and function 
 
As a separate investigation to explore other roles of EFCAB4B-a in endothelial 
cells, the effect of EFCAB4B-a knockdown on the VEGF-A165-induced Ca2+ 
response was investigated. HUVECs transfected with either scrambled or 
CRACR2A siRNA were loaded with the Ca2+ indicator dye Fura-2 AM and Ca2+ 
responses were measured on the FlexStation. In the presence of extracellular 
Ca2+, VEGF-A165 evoked a transient Ca2+ elevation followed by a sustained 
Ca2+ response (Figure 3-23). siRNA mediated knockdown of EFCAB4B-a 
significantly reduced the transient and sustained VEGF-A165-induced Ca2+ 
responses (Figure 3-23 a-c). The effect of EFCAB4B-a on VEGF-A165-induced 
Ca2+ release in the absence of extracellular Ca2+ was also tested. The data 
showed that knockdown of EFCAB4B-a also inhibited the Ca2+ release 
response (Figure 3-23d). The data suggest that EFCAB4B-a has a positive 
impact on VEGF responsiveness without effect on the CRAC channel, which is 
in line with the studies discussed above with thapsigargin (Figure 3-7). 
 
Because EFCAB4B-a knockdown inhibited the Ca2+ release response, it was 
hypothesised that this could be due to the EFCAB4B-a knockdown suppressing 
VEGF receptor 2 (VEGFR2; also known as KDR/Flk-1) expression, which could 
be responsible for the reduced Ca2+ signal observed in the EFCAB4B-a siRNA 
transfected cells. In endothelial cells VEGFR2 can be detected as an immature 
form with a molecular mass of around 200 kDa and a mature fully glycosylated 
230 kDa form which is expressed on the cell surface (Takahashi and Shibuya, 
1997). Western blot experiments using an anti-VEGFR2 antibody on HUVEC 
lysates were performed to confirm VEGFR2 expression. The Western blots 
consistently showed expression of the mature form, with less reliable detection 
of the immature form, possibly due to a difference in antibody recognition 
between the two forms. To investigate if EFCAB4B-a affected VEGFR2 
expression, HUVECs were treated with two different EFCAB4B-a siRNAs 
(CR2A.si.1 or CR2A.si.2) and 72 hours post-transfection the cells were lysed 
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and Western blotting was performed with the anti-VEGFR2 antibody. The blots 
showed that the 2 different siRNAs reduced VEGFR2 protein abundance by 48 
and 55% respectively (Figure 3-24). The data suggest that EFCAB4B-a 
positively affects VEGFR2 expression and function.  
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Figure 3-24 EFCAB4B-a enhances VEGFR2 protein expression.  
a and b. Example Western blots of HUVEC lysates after transfection with control 
(sc.ci.) or CRACR2A (CR2A.si.1 a or CR2A.si.2 b) siRNAs. The blots were probed with 
an anti-VEGFR2 antibody c and d. Quantification of VEGFR2 expression comparing 
scrambled (sc.si.) and CRACR2A siRNAs (CR2A.si.1 c; n=6 or CR2A.si.2 d; n=3, both 
*P<0.05) relative to actin loading controls. 
 
anti-VEGFR2 
anti-actin 43 
55 
95 
130 
72 
sc. 
si. 
CR2A. 
si.1. 
0
20
40
60
80
100
CR2A.
si.1.
sc.
si.
 VE
G
FR
2 
ex
pr
es
si
on
 (%
 s
c.
si
.)
*
kDa 
130 
95 
55 
43 
anti-VEGFR2 
anti-actin 
sc. 
si. 
CR2A. 
si.2. 
kDa 
0
20
40
60
80
100
sc.
si.
VE
G
FR
2 
ex
pr
es
si
on
 (%
 s
c.
si
.)
CR2A.
si.2.
*
a 
b 
c 
d 
111 
 
3.10. Knockdown of EFCAB4B-a inhibits histamine-evoked Ca2+ entry 
in HUVECs 
 
The aim of this section was to investigate the role of EFCAB4B-a on histamine-
induced Ca2+-responses in endothelial cells. HUVECs were treated with 
CRACR2A siRNA and 72 hours later, cells were loaded with Fura-2 AM and 
Ca2+ imaging was performed on the FlexStation. The results showed that siRNA 
mediated knockdown of EFCAB4B-a inhibited histamine-evoked Ca2+ entry, 
with no effect on Ca2+ release, compared to scrambled controls (Figure 3-25). 
The results suggest that EFCAB4B-a does not affect histamine receptor levels, 
but does affect Ca2+ entry through Ca2+ permeable ion channels, the identity of 
which has not been determined in this study.  
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Figure 3-25 EFCAB4B-a knockdown inhibits histamine-evoked Ca2+ 
entry.  
a. siRNA transfected HUVECs loaded with Fura-2 AM were treated with 
histamine (10 µM) in the absence of extracellular Ca2+ before Ca2+ add-
back. Example trace for CRACR2A siRNA 1 (CR2A.si.1; N=11). b. 
Summary data (Mean ± SEM) for the experiments of the type illustrated 
in a showing measurements for the Ca2+ release and Ca2+ entry effects 
with CR2A.si.1 compared to scrambled controls (n/N=3/22; *P<0.05; 
NS, non-significant). 
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3.11. Impact of EFCAB4B-a on EC migration and tube formation 
 
To investigate if there were any wider effects of EFCAB4B-a on EC function, the 
effect of EFCAB4B-a knockdown on EC tube formation and migration in vitro 
was investigated. 
 
An in vitro co-culture assay was performed. For this assay HUVECs, which had 
been pre-treated with scrambled siRNA (sc.si.) or CRACR2A siRNA 
(CR2A.si.1) were seeded onto a layer of confluent fibroblasts. Over the course 
of 8 days, the endothelial cells formed tubular-like structures (white arrows, 
Figure 3-26), which are thought to mimic vessel growth in vivo. The tubes were 
quantified by measuring the mean tube length or area. Typically tubes 
measured approximately 4 mm/mm2 in length and 0.11 mm2/mm2 in area in 
control cells. EFCAB4B-a knockdown significantly reduced both tube length and 
area by 10-12%. The data suggest that EFCAB4B-a positively modulates tube 
formation, which may be a function of its enhancing effect on VEGFR2. 
 
To examine the effect of EFCAB4B-a on endothelial cell migration alone, 
HUVECs were transfected with either scrambled or 2 different CRACR2A 
siRNAs and seeded into 96 well plates. Forty-eight hours post-transfection a 
wound was made using the ‘Wound-maker’ (Essen) and migration was imaged 
using phase-contrast imaging software on the IncuCyte (Essen). Images were 
taken every 2 hours for 18 hours and the relative wound density was calculated. 
A small but significant effect was observed for si.2. but no effect was observed 
with si.1. (Figure 3-27).  
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Figure 3-26 EFCAB4B-a enhances tube formation.  
a. Representative example images showing HUVEC tube formation with CRACR2A 
(CR2A.si.1) or scrambled (sc.si.) siRNA. HUVECs are labelled in green by Alexa 488 
anti-CD31 antibody. b−d. Summary histograms for 3 independent experiments (1-3; 
n=9 wells for sc.si. and 9 wells for CR2A.si.1. for each experiment) showing the effect 
of CRACR2A knockdown on mean tube length, branch points and mean tube area. 
Arrows point to tubes. *P<0.05. Data generated by Dr Jing Li.  
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0 3
2
 
Tu
be
 le
ng
th
 (m
m
/m
m
2 )
***
CR2A.
si.1.
CR2A.
si.1.
sc.
si.
sc.
si.
sc.
si.
 CR2A.
si.1.
 
1
0.00
0.02
0.04
0.06
0.08
0.10
0.12 3
 
***
 T
ub
e 
ar
ea
  (
m
m
2 /m
m
2 )
CR2A.
si.1.
CR2A.
si.1.
sc.
si.
sc.
si.
sc.
si.
 
CR2A.
si.1.
1 2
0
1
2
3
4
5
6
3
2
CR2A.
si.1.
CR2A.
si.1.
sc.
si.
sc.
si.
sc.
si.
 
 
*
*
*
  B
ra
nc
h 
po
in
ts
   
(n
um
be
r/m
m
2 )
CR2A.
si.1.
1
sc.si CR2A.si.1. 
a 
b c 
d 
400uM 400uM 
115 
 
Figure 3-27 EFC
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3.12. Discussion and Conclusions 
 
The aim of this study was to investigate the role of CRACR2A as a regulator of 
SOCE in endothelial cells. In contrast to immune cells, endothelial cells did not 
express CRACR2A. However, this result led to discovery of a novel splice 
variant of the CRACR2A gene, EFCAB4B-a, which has distinct function from 
the previously described CRACR2A. The data from this study provide evidence 
that EFCAB4B-a is a previously unidentified Rab protein that is expressed on 
endothelial cell-specific WPBs and negatively influences the abundance of 
intracellular vWF, without effect on vWF release. Data also showed that 
EFCAB4B-a could regulate VEGFR2 and its downstream effectors.  
3.12.1. CRACR2A gene 
This study has revealed for the first time, experimental evidence that a longer 
splice variant of the CRACR2A gene exists. In fact, according to the Ensembl 
database, the CRACR2A gene contains a possible seven splice variants 
(ENSG00000130038). Two of the variants (46 kDa CRACR2A and 83 kDa 
EFCAB4B-a), which have been described in this thesis, have had their 
sequences confirmed and exist in the Consensus Coding DNA Sequence 
(CCDS) database. The CCDS database is one that contains human and mouse 
protein coding regions that have been consistently annotated and are of high 
quality (http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi). However, 
according to Ensembl, another five transcripts may exist, two of which, are 
predicted to be protein coding. One of these has an incomplete CDS but the 
other has a predicted length of 462 amino acids and shares the identical N 
terminal sequence with CRACR2A and EFCAB4B-a, which encodes the Ca2+-
binding EF-hands domains. The predicted molecular mass of this variant is 53.8 
kDa, which may explain one of the extra bands (approximately 60 kDa) 
observed on the Western blot with the anti-CRACR2A antibody (Figure 3-3). 
Since the 46 kDa CRACR2A protein was not detected, subsequent Western 
blots in this study were cut in half so that one half could be used with the anti-
CRACR2A antibody and the other half with the anti-actin antibody as a loading 
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control. For this reason it could not be determined from these data whether or 
not the intermediate bands were suppressed by the CRACR2A siRNA. It would 
be interesting to address this since this protein may be involved in endothelial 
cell Ca2+ signalling. Another point regarding this 53.8 kDa variant is that the 
region in which its sequence differs from EFCAB4B-a, is where the extra serine 
was identified in the EFCAB4B-a sequence, suggesting that this may be an 
important splicing site. Further studies would be needed to determine if this 
predicted variant is really expressed and what its function is.  
 
Previous data showed that CRACR2A is a binding partner for Orai1 and STIM1 
in immune T cells and HEK293 cells (Srikanth et al., 2010) but in this study the 
46 kDa CRACR2A protein could not be detected in endothelial cells. This 
finding raises the possibility that the regulation of CRAC channels differs 
according to cell type. It also suggests that the CRACR2A gene may be 
alternatively spliced in different cell types and it would be an interesting to 
determine how this occurs and whether the expression of the different variants 
can be controlled and switched on/off.  
3.12.2. EFCAB4B-a runs with a greater mass than predicted 
 
In this study, the protein band ascribed to EFCAB4B-a appeared larger than the 
predicted size of 83 kDa. Rab45, which has the same molecular mass also 
appeared larger than expected (Oshita et al., 2013a). This could be explained 
by the acidic nature of these proteins (EFCAB4B-a pI = 5.15; Rab45 pI = 4.83), 
since it has previously been demonstrated that acidic proteins can negatively 
affect SDS binding, resulting in a slower migration and an apparent greater 
mass (Armstrong and Roman, 1993). In this study, the data showed that the 
band could be significantly reduced following knockdown by two different 
siRNAs, generating confidence that it really was EFCAB4B-a. 
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3.12.3. EFCAB4B-a is a novel putative Rab protein 
 
Sequence analysis showed that EFCAB4B-a differed from CRACR2A at its C-
terminus where it contained a Rab domain. Several lines of evidence from this 
study suggest that EFCAB4B-a is a previously undiscovered Rab protein; firstly, 
Rab proteins contain conserved motifs and the EFCAB4B-a sequence contains 
all of these conserved Rab motifs including the GTP-binding motifs and the 
double cysteine (prenylation) motif at its C terminus, a region important in 
membrane targeting (Colicelli, 2004, Horgan and McCaffrey, 2011). Secondly, 
GTP binding is important for the localisation and function of Rab proteins and in 
this study, imaging data showed that by making a mutation in a conserved GTP 
binding motif (N658I) meant EFCAB4B-a no longer localised to WPBs but 
instead showed a general cytosolic distribution. Thirdly, the prenylation motif at 
the C terminus of Rab proteins is critical for their association with intracellular 
membranes and the data showed that tagging GFP to the C terminus of 
EFCAB4B-a, resulted in a cytosolic distribution with no localisation to WPBs. 
Should future biochemical experiments (which will be discussed in detail later) 
on EFCAB4B-a demonstrate that it has GTP-binding ability, then EFCAB4B-a 
may be renamed as Rab46.  
3.12.4. EF-hand Rab proteins 
 
Whilst EFCAB4B-a is larger than most of the 60 human Rab proteins (around 
200-300 amino acids), it is a similar size to Rab44 and Rab45, which have 
predicted masses of 108 and 83 kDa respectively. Structurally, Rab44, Rab45 
and EFCAB4B-a are predicted to be similar in that they all contain two EF-
hands at their N termini and a Rab domain at their C termini. Currently no 
studies have investigated Rab44, only four publications exist for Rab45 
(Nakamura et al., 2011, Oshita et al., 2013b, Shintani et al., 2007, Maat et al., 
2008) and this is the first account of EFCAB4B-a.  
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3.12.5. EFCAB4B-a localises to WPBs and a peri-nuclear region: is there a 
connection? 
 
A key finding from this study was the localisation of EFCAB4B-a on WPBs as 
revealed by the strong co-localisation between EFCAB4B-a and vWF. This 
colocalisation of EFCAB4B-a and vWF occurred in fewer than 50% of cells, 
however when it did occur, the mean Rcoloc value of 0.8 suggested the 
correlation or relationship between the two proteins was strong. Interestingly, 
phylogenetic analysis groups EFCAB4B-a protein with other Rab proteins that 
have been associated with WPBs: Rab3a-d and Rab27a (Figure 3-28). Five of 
these Rabs (Rab3a, 3d, 27a, 27b and 15) have reported roles in vWF secretion 
(reviewed in (Nightingale and Cutler, 2013), however I did not find a role for 
EFCAB4B-a in this process. Some caution is needed in interpreting these data 
however, since vWF is released from cells as long strings that remain cell 
attached, which means collecting samples of supernatant, may not accurately 
reflect the amount of vWF that has been released.  
 
EFCAB4B-a is the first large EF-hand-containing Rab protein to be localised to 
WPBs and the significance of the Ca2+ binding domain would be an interesting 
future investigation.  
 
EFCAB4B-a also colocalised with vWF in the peri-nuclear region. vWF has 
been observed in a cluster at the peri-nuclear region before (Rondaij et al., 
2006, Vinogradova et al., 2000). Two previous publications have shown that 
when endothelial cells are stimulated with cAMP raising agents, WPBs travel 
along microtubules from the cell periphery to accumulate in a peri-nuclear 
cluster. The region where the WPBs were accumulating was identified as the 
microtubule organising centre (MTOC) (Rondaij et al., 2006). Interestingly, in a 
preliminary study looking at the localisation of EFCAB4B-a in endothelial cells, 
just 24 hours post transfection, I noticed that EFCAB4B-a localised to 
microtubule-like structures (Figure 3-29).  
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I hypothesise that the peri-nuclear location observed in this study is therefore 
the MTOC. This hypothesis is supported by staining results from this study that 
showed that EFCAB4B-a localised very close to the Golgi but was not 
colocalised with it, a finding that is consistent with reports that the MTOC is 
often found closely associated with the Golgi (Sutterlin and Colanzi, 2010). 
 
Microtubules are involved in the transport of cargo around the cell – this cargo 
can travel in either direction along the microtubules, depending on the balance 
of activity of the motor proteins kinesin (outward, toward the cell periphery) and 
dynein (retrograde, toward the cell interior; (Bryantseva and Zhapparova, 2012). 
In the previous study by Rondaij et al it was found that the retrograde transport 
of WPBS towards the MTOC was dependent on the motor protein dynein 
(Rondaij et al., 2006).  
 
If this peri-nuclear localisation observed in this study is indeed the MTOC, this 
suggests that overexpression of EFCAB4B-a favours retrograde transport of 
WBPs along microtubules and this may involve dynein. In support of this 
hypothesis, the EFCAB4B-a localisation observed at 24h post-transfection 
closely resembled the staining that has previously been observed with dynein-
GFP (Ma and Chisholm, 2002).  
 
In recent years interactions between microtubule motor proteins and Rab 
GTPases have been identified and these motor proteins are recognised as Rab 
effector molecules (Horgan and McCaffrey, 2011). For example, Rab6, which is 
a regulator in the retrograde transfer of endosomes from the Golgi to the 
endoplasmic reticulum, has been found to interact with dynein in the Golgi 
(Wanschers et al., 2008).  Given further time, it would be interesting to 
investigate potential functional interactions between EFCAB4B-a and dynein. 
Figure 3-30 shows a schematic to illustrate the putative role of EFCAB4B-a in 
the trafficking of WPBs.  
 
As an interesting side note, images in the Human Protein Atlas show that 
endogenous Rab45 (structurally very similar to EFCAB4B-a) is also localised to 
microtubules (http://www.proteinatlas.org/ENSG00000165105/subcellular) 
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whilst overexpression was identified in a peri-nuclear region (Shintani et al., 
2007). These data suggest that EFCAB4B-a and Rab45 may have similar 
functions.  
3.12.6. Could a possible interaction of EFCAB4B-a with dynein affect VEGFR2? 
 
Dynein is also important for the transport of transcription factors to the nucleus. 
In this study, I found that in cells where EFCAB4B-a had been knocked down, 
VEGFR2 levels were suppressed. If EFCAB4B-a interacts with dynein, and 
dynein is responsible for the transport of transcription factors necessary for 
VEGFR2 expression then it is possible that knockdown of EFCAB4B-a would 
negatively influence the expression of VEGFR2.  
 
3.12.7. Could EFCAB4B-a effects on VEGFR2 be due to regulation of 
membrane trafficking in the biosynthetic pathway? 
 
In this study, EFCAB4B-a was found localised in a peri-nuclear localisation 
close to the Golgi. When EFCAB4B-a was knocked down, total VEGFR2 levels 
were suppressed. A similar observation was reported with one of the t-SNARE 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor) 
proteins, syntaxin-6 (Manickam et al., 2011). SNARE proteins are important for 
vesicle fusion and syntaxin-6 is localised predominantly in the Golgi and 
facilitates trans Golgi and post-Golgi vesicle fusion processes. Manickham et al 
(2011) found that in quiescent endothelial cells, around 25% of VEGFR2 is 
localised to the Golgi and colocalises with the trans-Golgi marker TFN46. They 
found that when they suppressed syntaxin-6 either by siRNA or by 
overexpressing the inhibitory cytosolic domain of syntaxin-6, then total cellular 
VEGFR2 levels were reduced by approximately 75% and VEGF-stimulated 
endothelial cell proliferation, migration and tube formation were all inhibited. 
Further to this they found that if they blocked lysosome function but not 
proteasome function, then this could reverse the inhibitory effect, suggesting 
that the VEGFR2 is being targeted to lysosome for degradation (Manickam et 
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al., 2011). It may therefore be possible that EFCAB4B-a is regulating the 
biosynthetic pathway of VEGFR2 in a similar manner to syntaxin-6 and this 
could offer another explanation as to why knocking down EFCAB4B-a 
suppresses total VEGFR2 levels.  
 
3.12.8. Conclusions 
 
This study has identified a novel putative Rab protein, EFCAB4B-a that is a 
product of the CRACR2A gene, but has distinct function from CRACR2A. 
EFCAB4B-a colocalised with vWF in endothelial WPBs but also in a peri-
nuclear region, hypothesised to be the MTOC. Overexpression of a predicted 
GTP-deficient mutant showed a general cytosolic localisation suggesting that 
GTP-binding was important for EFCAB4B-a localisation to WPBs and the 
MTOC. I speculate that EFCAB4B-a interacts with the minus-end microtubule 
motor protein, dynein and favours the reverse trafficking of WPBs.  
 
3.12.9. Future studies 
 
Several lines of evidence suggest that EFCAB4B-a is a novel Rab protein, 
however the defining feature of Rab proteins is their ability to bind and 
hydrolyse GTP. The GTP binding ability of EFCAB4B-a has so far not been 
investigated but the fact that mutations in conserved GTP binding motifs 
changed the localisation of EFCAB4B-a from WPB expressing to cytosolic, 
suggests that binding GTP is important for the localisation and function of 
EFCAB4B-a. Future studies would involve generating a purified EFCAB4B-a 
protein and performing a GTP binding assay, which may be a colorimetric assay 
or a radioligand binding assay. Should EFCAB4B-a bind and hydrolyse GTP as 
predicted, it could be renamed as Rab46. 
 
The exchange between GDP and GTP in vivo requires other regulatory 
proteins. Enzymes termed GEFs (guanine nucleotide exchange factors) and 
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GAPs (GTPase activating proteins) facilitate the inter-conversion by stimulating 
the release of bound GDP or the hydrolysis of bound GTP respectively (Pfeffer 
and Aivazian, 2004). Currently it is not known what the GEFs and GAPs are 
necessary for EFCAB4B-a so screening approaches and pull-down assays 
would be needed to determine these. It would certainly be interesting to 
investigate if there is any relationship between EFCAB4B-a and microtubule 
motor proteins such as dynein.  
 
For Rabs to effectively bind their respective membranes they undergo post-
translational modification in the form of prenylation. Prenylation involves the 
covalent addition of either a farnesyl (15 carbon) or geranylgeranyl (20 carbon) 
pyrophosphate and is critical for the function of the modified protein in cellular 
responses (Leung et al., 2006). EFCAB4B-a has the motif XXXCC, which is one 
of 6 different carboxyl-terminal motifs on human Rab proteins. To determine if 
prenylation is important for membrane targeting of EFCAB4B-a, cells would be 
treated with a statin and these cells should show a more diffuse distribution and 
only localise to the WPBs on washout of the drug. 
 
To date, only 2 other Rab proteins have EF-hands and the role of these 
remains unknown. It will be interesting to investigate the role of the EF-hand in 
the function of EFCAB4B-a.  
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Figure 3-28 Phylogenic tree of Rab family members including the putative Rab 
family member EFCAB4B-a. 
Rab protein sequences were aligned using Clustal Omega online software. The 
generated Newick tree file was uploaded to Phy.fi (Fredslund, 2006) to generate the 
phylogenic tree. Rab proteins that have been identified on WPBs are highlighted in the 
red boxes. 
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Figure 3-29 Localisation of EFCAB4B-a 24 hours post transfection. 
HUVECs were transfected with EFCAB4B-a, fixed and immunostained 24 hours post-
transfection with the anti-CRACR2A antibody (green). Nuclei were stained with DAPI 
(blue).  
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CHAPTER 4. GOLLI-MYELIN BASIC PROTEIN IS A POSITIVE 
REGULATOR OF VEGFR2 EXPRESSION 
4.1. Introduction  
 
Myelin basic proteins (MBPs), encoded by the MBP gene on chromosome 18, 
are important structural proteins that make up the myelin sheath surrounding 
oligodendrocytes and Schwann cells in the central nervous system (CNS). The 
MBP transcription unit however is part of a complex genetic locus that is highly 
conserved in mouse and human called Golli, which stands for gene expressed 
in the oligodendrocyte lineage-MBP (Campagnoni et al., 1993, Pribyl et al., 
1993). Figure 4-1 shows a diagrammatic representation of the golli-MBP gene 
and the products of its alternative splicing. The golli-MBP gene is found 
upstream of the MBP gene and gives rise to at least 2 splice variants. In mouse 
these splice variants are called BG21 and J37 (Campagnoni et al., 1993). 
Humans have an identical splice variant to mouse BG21 called HOG5 or variant 
8 and a splice variant which is clearly related to J37 but contains 2 additional 
exons and is called HOG7 or variant 7 (Pribyl et al., 1993). Mouse and human 
golli-MBP peptides share 79% amino acid similarity (Pribyl et al., 1993). Unlike 
the classic MBP peptides that are found almost exclusively in the CNS, the golli-
MBPs are also expressed in cells and organs of the immune system, including 
the thymus and spleen, which suggests that golli-MBPs have a different 
biological role to the classic MBPs (Feng et al., 2000, Pribyl et al., 1993).  
4.1.1. Golli-MBP as a negative regulator of SOCE 
 
Whilst the physiological role of golli-MBP is still largely unknown, there is 
mounting evidence to suggest that golli-MBP regulates intracellular Ca2+. In T 
lymphocytes, golli-MBP has been identified as a negative regulator of store-
operated Ca2+ influx (Feng et al., 2004, Feng et al., 2006). A study using golli-
deficient mice, showed that ablation of the golli-MBP gene in T cells resulted in 
hyper-proliferation, which could be attributed to an enhanced store-operated 
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Ca2+ entry (SOCE; (Feng et al., 2006). Furthermore, over-expression of golli-
MBP inhibited SOCE and mutation of the myristolylation site disrupted its ability 
to associate with the plasma membrane, thereby reversing its inhibitory action 
on Ca2+ influx (Feng et al., 2006). In line with this study, golli-MBP was found 
associated with the ER Ca2+ sensor STIM1 in HeLa cells (Walsh et al., 2010). A 
bimolecular fluorescence complementation assay using HeLa cells and tagged 
golli-MBP and STIM1 showed that upon thapsigargin stimulation, golli-MBP and 
STIM1 came together, but this did not occur in the absence of cell stimulation 
(Walsh et al., 2010) suggesting that golli-MBP may regulate SOCE. In addition, 
co-localisation of STIM1 and golli-MBP was observed at the plasma membrane 
and overexpression of golli-MBP reduced the thapsigargin-induced SOCE, an 
effect that could be rescued by over-expression of STIM1 (Walsh et al., 2010).  
4.1.2. Golli-MBP as a positive regulator of Ca2+ entry in oligodendrocytes 
 
Golli-MBP also plays a role in regulating Ca2+ influx in oligodendrocyte 
precursor cells (OPCs) where over-expression resulted in enhanced Ca2+ influx 
with no effect on Ca2+ release from intracellular stores (Paez et al., 2007). As 
observed in studies on T cells, the myristoylation site of golli-MBP was 
important for its ability to modulate Ca2+ homeostasis (Paez et al., 2007). Using 
golli-overexpressing mice (JOE mice) it was shown that golli-MBP could 
increase Ca2+ entry, both through store-operated Ca2+ channels and voltage-
operated Ca2+ channels (Paez et al., 2009). Another study showed that SOCE 
was greater in OPCs derived from JOE mice compared to control mice and that 
this SOCE was dependent on TRPC1, since suppression of TRPC1 using 
siRNA or a blocking antibody abolished SOCE (Paez et al., 2011).  
4.1.3. Aims 
 
SOCE is an important Ca2+ entry mechanism for endothelial processes such as 
migration, proliferation and angiogenesis. STIM1 and Orai1 underlie the main 
Ca2+ entry mechanism in endothelial cells, and Ca2+ entry through Orai1 
channels is important for endothelial cell migration and angiogenesis (Li et al., 
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2011). TRPC1 is also important in angiogenesis (Yu et al., 2010). It is currently 
unknown if golli-MBPs are expressed and functional in endothelial cells. The 
aim of this chapter was therefore to investigate golli-MBP in endothelial cells. 
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4.2. Golli-MBP is expressed in human endothelial cells 
 
Two variants of human golli-MBP, variant 7 and variant 8 have previously been 
detected in cells and tissues outside of the CNS. To determine if golli-MBP was 
expressed in endothelial cells, RT-PCR primers were designed in a region that 
would detect both the long (variant 7) and short (variant 8) transcripts. RT-PCR 
was performed on cDNA from a range of micro- and macro-vascular endothelial 
cells and electrophoresis gel images confirm mRNA expression of golli-MBP in 
all endothelial cells tested (Figure 4-2).  
 
As a first step to determining the functional significance of golli-MBP, the role of 
golli-MBP in Ca2+ influx in response to the major physiological agonist, VEGF-
A165, was investigated. HUVECs were transfected with either scrambled or 2 
different golli-MBP siRNAs. Knockdown was quantified by RT-PCR and results 
from 3 independent experiments showed a mean knockdown of golli-MBP at 
the mRNA level of 75 ± 2%. Cells were loaded with the Ca2+ indicator dye Fura-
2 AM and Ca2+ responses were measured on the FlexStation. In the presence 
of extracellular Ca2+, VEGF-A165 evoked a transient Ca2+ elevation followed by a 
sustained Ca2+ response. Both the transient and sustained responses were 
inhibited in golli-MBP deficient cells compared to controls (Figure 4-3). The next 
step was therefore to investigate the mechanism underlying this response.  
4.3. Golli-MBP is a mild negative regulator of SOCE in HUVECs 
 
Previous studies on immune T cells and HeLa cells showed that golli-MBP had 
a negative regulatory role on SOCE (Feng et al., 2004, Feng et al., 2006, Walsh 
et al., 2010) and studies on OPCs showed a positive regulatory role on Ca2+ 
influx (Paez et al., 2011, Paez et al., 2009, Paez et al., 2007). To investigate 
whether the inhibition of VEGF-A165-induced Ca2+ response observed in golli-
MBP deficient cells was due to an effect on SOCE, Ca2+ imaging experiments 
were performed as follows. Two different golli-MBP siRNAs and a scrambled 
control siRNA were individually transfected into HUVECs. Seventy-two hours 
post-transfection, cells were loaded with the Ca2+ indicator dye Fura-2-AM and 
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SOCE was measured in multi-well intracellular Ca2+ ([Ca2+]i) measurement 
experiments using the FlexStation. To measure SOCE, cells were treated with 
the SERCA inhibitor TG in the absence of extracellular Ca2+ to evoke a release 
of Ca2+ from intracellular stores. Extracellular Ca2+ was then added back and 
the Ca2+ entry response measured. The results showed that golli-MBP had no 
effect on Ca2+ release from stores but knockdown of golli-MBP had a small 
potentiating effect on the Ca2+ entry response (Figure 4-4).  As a control, STIM1 
siRNA-transfected cells showed a significant inhibition of the SOCE response 
(Figure 4-4).  
 
4.4. Golli-MBP is strong positive regulator of VEGF-A165-induced Ca2+ 
responses 
 
Since golli-MBP had only a mild effect on SOCE, another mechanism must exist 
to explain the large inhibition of the VEGF-A165-induced Ca2+ response. To 
investigate the VEGF-A165 response in more detail, VEGF-A165 was applied in 
the absence of extracellular Ca2+ followed by Ca2+ add-back to see individually 
the effect on Ca2+ release and Ca2+ entry. In golli-MBP deficient cells, the 
VEGF-A165-induced Ca2+ release response was reduced compared to control 
cells (Figure 4-5). As a control, Ca2+ responses in STIM1 deficient cells showed 
no change in the Ca2+ release response compared to scrambled controls 
(Figure 4-5). On re-addition of extracellular Ca2+, mimicking SOCE, a rise in 
intracellular Ca2+ was observed in control cells but this response was 
significantly smaller in golli-MBP deficient cells (Figure 4-5). As expected, 
STIM1 deficient cells showed a significant inhibition of the Ca2+ entry response 
(Figure 4-5c).  
 
To determine whether the knockdown of golli-MBP specifically inhibited VEGF-
A165-evoked Ca2+ release from stores, a second agonist, histamine was used. 
No significant inhibition of histamine-evoked Ca2+ release was observed in golli-
MBP deficient cells compared to controls (Figure 4-6) suggesting that golli-MBP 
preferentially affects VEGF-A165-induced Ca2+ responses.  
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4.5. Golli-MBP is a strong positive regulator of VEGFR2 expression  
 
A possible reason why VEGF-A165-evoked Ca2+ release was reduced in cells 
deficient in golli-MBP could be that golli-MBP regulates VEGFR2 expression. To 
test this, Western blotting was performed with an anti-VEGFR2 (anti-KDR) 
antibody on HUVEC lysates from cells treated with scrambled or golli-MBP 
siRNAs. Results showed that cells deficient in golli-MBP had significantly 
reduced expression of VEGFR2 compared to controls (Figure 4-7). Therefore it 
is suggested that the reason for the inhibition of Ca2+ release was lower 
expression of VEGFR2.  
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Figure 4-2 Expression of golli-MBP in human endothelial cells.  
Gel electrophoresis showing golli-MBP products from RT-PCR analysis of RNA 
isolated from endothelial cells derived from 1. HPAEC (pulmonary artery), 2. HUAEC 
(umbilical artery), 3. HDBEC (dermal blood), 4. HDLEC (dermal lymphatic), 5. HUVEC 
(umbilical vein), 6. HBdMEC (bladder microvascular), 7. HPMEC (pulmonary 
microvascular), 8. HDMEC (dermal microvascular), 9. HCMEC (cardiac microvascular), 
10. HCoMEC (colonic microvascular). Reactions were performed with (+) or without (-) 
reverse transcriptase (RT). Expected size of golli-MBP product was 232 bp. 
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Figure 4-3 Knockdown of golli-MBP inhibits VEGF-A165-induced Ca2+ response.  
a. Example trace showing 30 ng/ml VEGF-A165-induced Ca2+ response in 1.5 mmol/L 
extracellular Ca2+ with golli siRNA (golli.si.1) or scrambled (sc.si) siRNA (N=7). b. 
Summary data for the experiment of the type illustrated in a. showing measurements 
for the transient and sustained effects of VEGF-A165 with golli.si. (n/N=4/24; *P<0.05) c. 
Example trace showing 30 ng/ml VEGF-A165-induced Ca2+ response in 1.5 mmol/L 
extracellular Ca2+ with STIM1 siRNA (STIM1.si.) or scrambled (sc.si) siRNA (N=6). d. 
Summary data for the experiment of the type illustrated in c. showing measurements 
for the transient and sustained effects of VEGF-A165 with STIM1.si. (n/N=5/36; *P<0.05; 
NS, non-significant). 
 
 
0.0
0.2
0.4
0.6
0.8
1.0
*
Golli.
si.
Golli.
si.
sc.
si.
 
 V
EG
F 
Δ
C
a i
2+
 re
sp
on
se
 (Δ
 F
 ra
tio
)
sc.
si.
*
transient
sustained
0 2 4 6 8 10
1.4
1.6
1.8
2.0
2.2
2.4
2.6
transient golli.si.ΔC
a i
2+
 (Δ
F 
ra
tio
)
Time (min)
sc.si.
VEGF
HUVECs
sustained
a. b. 
0.0
0.2
0.4
0.6
0.8
1.0
sc.
si.
stim1.
si.
stim1.
si.
 
Δ
C
a2
+ i
 (Δ
F 
R
at
io
)
sc.
si.
HUVECs
NS
transient
*
sustained
0 2 4 6 8 10
1.2
1.6
2.0
2.4
stim1.si.
Δ
C
a2
+ i
 (Δ
F 
R
at
io
)
Time (min)
VEGF
HUVECs
sc.si.
c. d. 
136 
 
 
Figure 4-4 Golli-MBP has a small negative effect on SOCE in HUVECs.    
a - c. Examples of Ca2+ imaging traces showing 1 µmol/L thapsigargin (TG) induced 
store-depletion in zero mmol/L Ca2+ followed by 2 mmol/L Ca2+ add-back. Traces show 
responses in cells treated with scrambled siRNA (sc.si) plus one of the following: golli-
MBP siRNA 1 (golli.si.1; a; N=11), golli-MBP siRNA 2 (golli.si.2; b; N=6) or STIM1 
siRNA (STIM1.si; c; N=2). (c) is repeated from Fig.3.7b. d – f.  Summary data for the 
experiments of the type illustrated in a - c. showing measurements for the TG-induced 
Ca2+ release and Ca2+ entry effects in cells treated with golli.si.1 (n/N=5/26; d), golli.si.2 
(n/N=4/20; e) or STIM1.si. knockdown (n/N=2/8; f) where *P<0.05 and NS, non-
significant).
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Figure 4-5 Knockdown of golli-MBP inhibits VEGF-A165-induced Ca2+ response.  
a - c. Example traces showing 30 ng/ml VEGF-A165-induced store-depletion in zero 
mmol/L Ca2+ followed by 2 mmol/L Ca2+ addback. Traces showing cells treated with 
scrambled siRNA (sc.si) with either golli-MBP siRNA 1 (golli.si.1; a; N=4), golli-MBP 
siRNA 2 (golli.si.2; b; N=4) or STIM1 siRNA (STIM1.si.;c; N=4). d – f.  Summary data 
for the experiments of the type illustrated in a - c. showing measurements for the 
VEGF-A165-evoked Ca2+ release and Ca2+ entry effects with golli.si.1 (d; n/N = 5/27), 
golli.si.2 (e; n/N = 3/16) or STIM1.si (f; n/N = 3/11) where *P<0.05 and NS, non-
significant.
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Figure 4-6 Knockdown of golli-MBP has an insignificant effect on histamine-
evoked Ca2+ response.  
a. Example trace showing 10 µM histamine-evoked Ca2+ release and Ca2+ entry in cells 
treated with either scrambled siRNA (sc.si) or golli-MBP siRNA (golli.si. N=11) b. 
Summary data for the experiment of the type shown in a showing measurements for 
the histamine-evoked Ca2+ release and Ca2+ entry (n/N=3/22; NS, non-significant).  
 
0.0
0.4
0.8
1.2
1.6
entry
golli.
si
golli.
si
sc.
si
 
NSΔ
C
a i
2+
(Δ
 F
 ra
tio
) NS
sc.
si
HUVECs
release
-2 0 2 4 6 8 10 12 14 16
1.2
1.6
2.0
2.4
golli.si.ΔC
a i
2  (
Δ
 F
 ra
tio
) 
Time (min)
 Histamine
 2 mM Ca2+
HUVECs
sc. si.
0 mM Ca2+a. b. 
139 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Knockdown of golli-MBP reduces VEGFR2 expression.  
a. Western blot showing the expression of VEGFR2 in HUVECs treated with scrambled 
siRNA (sc.si) or golli-MBP siRNA (golli.si). Actin was used as a loading control. b. 
Quantified Western blot data showing VEGFR2/Actin ratio in cells treated with sc.si or 
golli.si. (n=4; *P<0.05).  
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4.6. Discussion and Conclusions 
 
The main findings from this study are that golli-MBP is expressed in human 
endothelial cells; that golli-MBP positively regulates VEGFR2 and that golli-MBP 
has a small negative effect on SOCE. 
 
Golli-MBP was discovered in the early 1990s and one of the main 
characteristics distinguishing it from the classic MBPs was its expression in a 
number of different cell types. However, this is the first study to demonstrate 
expression of golli-MBP in endothelial cells.  
 
There remains an incomplete understanding regarding the functional role of 
golli-MBPs but a large number of studies point to a role in regulating Ca2+ 
homeostasis. In T cells and HeLa cells it was found that golli-MBP negatively 
regulated SOCE (Feng et al., 2004, Feng et al., 2006, Walsh et al., 2010). The 
data presented in this chapter demonstrate a small but significant enhancement 
of TG-evoked SOCE in HUVECs with one of the golli-MBP siRNAs. The small 
enhancement compared to that observed in T cells is likely due to methodology, 
since this study used siRNA to reduce golli-MBP gene expression compared to 
T cells derived from a golli-knockout mouse. The mechanism by which golli-
MBP regulates SOCE is not entirely clear but a recent study showed that golli-
MBP can interact with STIM1 complexes at the plasma membrane. The main 
Ca2+ entry pathway in HUVECs is through CRAC channels where STIM1 is the 
ER Ca2+ sensor that triggers activation of Orai1 channels (Li et al., 2011). It is 
therefore possible that golli-MBP negatively regulates CRAC channels in 
endothelial cells. Further studies are needed to determine if this is the case. 
This would not be the first account of a protein regulating CRAC channels as 2 
other proteins: the EF-hand proteins CRACR2A and junctate have both been 
found to regulate CRAC channel activity (Srikanth et al., 2012, Srikanth et al., 
2010). 
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VEGF is a major signalling cytokine in endothelial cells and VEGF-stimulated 
Ca2+ entry occurs through Orai1 ion channels (Li et al., 2011). If golli-MBP was 
a negative regulator of SOCE in endothelial cells, then an enhancement of 
VEGF-evoked Ca2+ entry might also have occurred. Instead however, 
knockdown of golli-MBP reduced both the VEGF-induced Ca2+ release and 
subsequent Ca2+ entry response. This was in contrast to STIM1 that, as 
expected, only inhibited the SOCE response. Knockdown of golli-MBP had no 
effect on histamine-evoked Ca2+ release, which suggested that golli-MBP could 
be involved in the regulation of VEGFR2, the primary receptor for VEGF in 
endothelial cells. In line with this, the Western blot data showed that the 
VEGFR2 protein was suppressed in cells that had been treated with golli-MBP 
siRNA. It remains to be determined whether this suppression occurs at the 
transcriptional or translational level.  
 
In conclusion, golli-MBP may be an important regulator of endothelial cell Ca2+ 
entry and VEGFR2 expression. Any mechanism that results in reduced 
VEGFR2 could be relevant for potential new cancer therapies, since this would 
impair VEGF-driven angiogenesis. 
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CHAPTER 5. IDENTIFYING NOVEL TRPC6 CHANNEL 
BLOCKERS 
5.1. Introduction  
 
TRPC6 is a 931 amino acid protein that is a member of the TRPC subfamily of 
TRP ion channels, which comprises TRPC1 – 7. TRPC6 shares around 70-80% 
sequence homology with TRPC3 and TRPC7 (Trebak et al., 2003). Human and 
mouse TRPC6 channels share 93% sequence similarity (Hofmann et al., 1999). 
TRPC6 is widely expressed in the central nervous system and cardiovascular 
system, and expression has also been detected in the lungs, ovaries and testis 
(Dietrich and Gudermann, 2007, Garcia and Schilling, 1997, Onohara et al., 
2006, Reiser et al., 2005, Riccio et al., 2002, Sours et al., 2006, Zhou et al., 
2008).  
5.1.1. Structural and biophysical properties of TRPC6 
 
Like other TRPC channels, TRPC6 is predicted to have 6 transmembrane 
spanning segments with a cation-permeable ion pore located between 
transmembrane segments 5 and 6 (TM5 and 6) (Dietrich and Gudermann, 
2007). TRPC6 has 2 TRP box domains, an ankyrin repeat domain, a coiled-coil 
domain and a calmodulin and IP3R binding site (Dietrich and Gudermann, 2007) 
(Figure 5-1). To form an ion channel, four TRPC6 proteins come together 
around a central ion channel pore (Beech, 2013). Alternatively, TRPC6 can also 
form ion channels with TRPC3 and TRPC7 subunits, or indeed other ion 
channel family subunits, for example Orai1 generating ion channels with distinct 
biophysical and functional properties (Beech, 2013, Liao et al., 2008, Liao et al., 
2007). The native composition of these channels will differ from tissue to tissue 
and the physiological and pathophysiological relevance of these various 
compositions remains to be determined (Eder and Groschner, 2008). This 
chapter will focus on homomeric TRPC6 channels only.  
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Biophysically TRPC6 currents are both inwardly- and outwardly-rectifying and 
show a typical S-shaped current-voltage (I-V) relationship with a reversal 
potential near 0 mV, constituting a non-selective cation channel (Boulay et al., 
1997, Hofmann et al., 1999). Human TRPC6 channels have a single channel 
conductance of around 35 pS as observed in symmetrical 120 mM Cs+ 
solutions (Hofmann et al., 1999). TRPC6 channels are permeable to Ca2+, Cs+, 
Na+ and K+ and show greatest selectivity for Ca2+ with a PCa/PNa in the order of 
4-5 (Hofmann et al., 1999).  
5.1.2. TRPC6 channel modulation 
 
One of the first observations made following the cloning of TRPC6 in 1997 was 
that TRPC6 is not activated by store-depletion (Boulay et al., 1997, Hofmann et 
al., 1999). Electrophysiological studies on both mouse and human TRPC6 
showed that currents were not induced with the SERCA inhibitor thapsigargin, 
the Ca2+ ionophore ionomycin, PIP2 or IP3 (Boulay et al., 1997, Hofmann et al., 
1999). TRPC6 is therefore not considered a store-operated Ca2+ channel. 
Instead, TRPC6 is activated following G-protein coupled receptor stimulation, 
and a number of receptors have been linked to TRPC6 including muscarinic 
(Boulay et al., 1997), adrenergic (Inoue et al., 2001) and purinergic receptors 
(Inoue et al., 2001). Stimulation of tyrosine kinase receptors by growth factors, 
for example VEGF, has also been shown to activate TRPC6 (Ge et al., 2009, 
Hamdollah Zadeh et al., 2008). Receptor-activated TRPC6 currents are blocked 
with the phospholipase C (PLC) inhibitor U73122, but are not blocked with 
inhibitors of PKC, suggesting that TRPC6 is mainly coupled to PLC activation of 
diacylglycerol (DAG) and less so to IP3 or the IP3Rs (Hofmann et al., 1999, 
Jung et al., 2002). On this note, TRPC6 can be directly activated by the 
membrane-permeable analogue of DAG, 1-oleoyl-2-acetyl-sn-glycerol (OAG; 
(Jung et al., 2002) or by the DAG lipase inhibitor RHC80267 (Inoue et al., 
2001). Other lipid activators for TRPC6 include: arachidonic acid and its 
metabolites 20-HETE and 11,12-EET (Basora et al., 2003, Fleming et al., 2007, 
Inoue et al., 2009), lysophosphatidylcholine (LPC; (Chaudhuri et al., 2008), 
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lipopolysaccharide (Tauseef et al., 2012) and c2-ceramide (Samapati et al., 
2012). PIP3 and Ca2+/calmodulin have also been suggested as modulators of 
TRPC6 channel activity (Kwon et al., 2007). TRPC6 is also modulated by 
oxidative stress: a study by Graham et al (2010) showed that currents through 
TRPC6 could be augmented by H2O2 in a concentration-dependent manner, 
suggesting that TRPC6 may be more active in an oxidative environment 
(Graham et al., 2010). Finally, TRPC6 is modulated by intracellular Ca2+ 
concentrations and high concentrations have a negative effect on channel 
activity, while low concentrations enhance activity (Shi et al., 2004). Figure 5-1 
highlights some of the positive and negative modulators of TRPC6. 
5.1.3. TRPC6 function in endothelial cells 
 
TRPC6 is important in VEGF-stimulated angiogenesis, as evidenced by two 
independent studies which overexpressed dominant negative TRPC6 and 
showed a significant inhibition of VEGF-stimulated tube formation in vitro with 
both micro- and macrovascular endothelial cells (Ge et al., 2009, Hamdollah 
Zadeh et al., 2008). A recent study has shown that TRPC6 is important for 
mediating lipopolysaccharide/Toll-like receptor 4–stimulated lung vascular 
permeability and lung inflammation through NF-κB (Tauseef et al., 2012).  
5.1.4. Therapeutic potential 
 
TRPC6 knockout mice are viable, have a broadly normal phenotype, are fertile 
and produce normal litters (Dietrich et al., 2005), which suggests that the 
TRPC6 gene is not essential for life. However, overexpression of TRPC6 has 
been linked to idiopathic pulmonary arterial hypertension, a disease 
characterised by excessive smooth muscle cell proliferation due to overload of 
Ca2+ (Yu et al., 2004). In addition, a mutation in the TRPC6 gene (P112Q), 
which results in enhanced Ca2+ entry, has been linked to focal segmental 
glomerulosclerosis (FSG), a disease affecting the kidneys (Winn et al., 2005). 
The fact that complete loss of TRPC6 is not lethal, but overexpression or 
mutations are detrimental, suggests that pharmacological manipulation of 
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TRPC6 may offer a new avenue for therapeutic intervention for the treatment 
these diseases. 
5.1.5. Pharmacology 
 
Flufenamate, a known cation channel blocker, has been to shown to activate 
TRPC6, but has no effect on TRPC3 or TRPC7 (Inoue et al., 2001). The active 
ingredient of St John’s wort, hyperforin also activates TRPC6 (Leuner et al., 
2007). Inhibitors of TRPC6 include lanthanum (La3+), gadolinium (Gd3+) and 
cadmium (Cd2+) ions, which have IC50s of 4, 1.9 and 253 µM respectively (Inoue 
et al., 2001). The non-selective cation channel blockers, SKF-96365 and 2-
APB, also block TRPC6 channels along with the PLC inhibitor U73122 
(Clapham, 2007b, Inoue et al., 2001).  
5.1.6. Identifying novel TRPC6 channel blockers 
 
Accumulating evidence including the gene mutation information, in vitro and in 
vivo studies suggests that TRPC6 is an important ion channel in vasculature 
physiology and pathophysiology. However, there remains a lack of selective 
and potent channel blockers. Identifying novel TRPC6 channel blockers would 
be beneficial both to fundamental research, to learn and understand more about 
the functioning of this channel and may also lead to the development of new 
therapeutics for cardiovascular disease, cancer or other conditions such as 
FSG. High throughput screening is one approach for the identification of novel 
channel blockers. Another approach is to mine the literature for molecules, 
which have shown efficacy in vivo or in the clinic but where the mechanism of 
action or target of the drug remains unknown. One advantage of the latter 
approach is that the compound will have already passed safety screens. A 
compound of this type is carboxyamidotriazole. A third approach is to 
investigate the mechanism of action of herbal or dietary substances that have 
beneficial effects on health, for example flavonoids found in fruits, vegetables 
and wine, which are associated with a decreased risk for the development of 
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cardiovascular disease (Hertog et al., 1993, Knekt et al., 1996, Rimm et al., 
1996, Yochum et al., 1999).  
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Figure 5-1 TRPC6 channel structure showing positive and negative modulators.  
TRPC6 contains 6 transmembrane domains (TM1-TM6) with the channel pore between 
TM5 and 6. The amino terminal of TRPC6 is cytosolic and contains 4 ankyrin repeat 
domains and a coiled-coil region. The carboxy terminus is also cytosolic and contains 2 
TRP boxes and a calmodulin and IP3 receptor binding domain (CIRB). Shown in the 
top left is a list of positive TRPC6 modulators and in the top right, a list of negative 
TRPC6 modulators.  
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5.1.7. Carboxyamidotriazole 
 
Carboxyamidotriazole (CAI; Figure 5-4a), also known as L-651,582, was 
identified in a large pharmaceutical screen that was set up to find novel anti-
cancer drugs (Kohn and Liotta, 1990). Initial studies showed that CAI could 
prolong the life of mice bearing ovarian cancer by 220% compared to untreated 
mice (Kohn and Liotta, 1990). A large number of studies followed which showed 
that CAI was effective at inhibiting the development, growth and spread of 
cancer in vivo (Kohn et al., 1995, Kohn and Liotta, 1990, Kohn et al., 1992, 
Luzzi et al., 1998, Perabo et al., 2005, Qin et al., 1999). Because of the good 
safety profile and low toxicity effects observed with CAI, this compound was 
investigated in clinical trials. A large number of trials have taken place, looking 
at the effects of CAI alone or in combination with other anti-cancer therapies, 
and the overall results so far have shown some disease stabilisation in various 
cancers including pancreaticobiliary carcinomas, renal cell carcinoma, 
melanoma, ovarian cancer and non-small cell lung cancer (Hussain et al., 2003, 
Kohn et al., 1996).  
 
The mechanism of action for CAI remains incompletely understood but several 
lines of evidence suggest that CAI affects intracellular Ca2+. Firstly, one of the 
initial studies on CAI showed that low micromolar concentrations of CAI could 
block Ca2+ entry that is stimulated either by muscarinic receptor agonists or by 
the Ca2+ ionophore A23187 (Felder et al., 1991). Secondly, VEGF-A165-induced 
Ca2+ responses in endothelial cells could be blocked by pre-treatment with CAI 
(Faehling et al., 2002). Thirdly, CAI blocked fMet-Leu-Phe-stimulated Ca2+ entry 
into leukocytes (Hupe et al., 1991). Fourth, CAI was able to block L-type Ca2+ 
channels in guinea-pig atrial cells (Hupe et al., 1991). In addition, Wu et al 
(1997) showed that CAI caused a generalised inhibition of receptor-mediated 
Ca2+ elevation to epidermal growth factor and bradykinin (Wu et al., 1997). 
Finally, CAI has been shown to inhibit Ca2+ entry and mitochondrial Ca2+ uptake 
(Mignen et al., 2005).  
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There is also substantial evidence that CAI, through the inhibition of Ca2+ influx, 
can inhibit endothelial cell proliferation and angiogenesis: several groups have 
shown that CAI can strongly inhibit VEGF- and fibroblast growth factor (FGF)-
induced endothelial cell proliferation and tube formation (Afzal et al., 2010, 
Bauer et al., 2000, Faehling et al., 2002, Fiorio Pla et al., 2008). In addition, 
studies by Fiorio-Pla et al (2008 and 2010) showed that CAI caused complete 
inhibition of arachidonic acid induced Ca2+ entry in endothelial cells, and that 
pre-treatment of breast cancer derived endothelial cells (BTECs) with 1 µM CAI 
completely abolished BTEC motility in a wound healing assay (Fiorio Pla et al., 
2010, Fiorio Pla et al., 2008). 
 
Exactly how CAI inhibits Ca2+ influx is not clear. One study shows evidence that 
CAI works by inhibiting IP3 formation with no effect on PLC activation (Faehling 
et al., 2002), whilst another suggests that CAI has no effect on IP3 formation 
and may therefore act by blocking Ca2+ through receptor-operated ion channels 
(Hupe et al., 1991). In the recent study by Fiorio-Pla et al (2010), it was 
suggested that CAI may exert its inhibitory effects by blocking endothelial Ca2+ 
permeable channels and the authors postulate that the channel could be 
TRPV1, TRPV4, TRPC3 or TRPC6 (Fiorio Pla et al., 2010). In guinea-pig atrial 
cells, it has been shown by patch clamp technique that CAI can block L-type 
Ca2+ channels (Hupe et al., 1991). There has been no study to date that has 
investigated whether CAI directly blocks any of the endothelial cell Ca2+ 
permeable channels. Owing to the evidence that TRPC6 is involved in 
angiogenesis, the aim of the first part of this chapter was to investigate if CAI 
inhibits TRPC6 channels. TRPC5 and TRPV4 were also investigated. Ca2+ 
imaging and whole cell patch clamp recordings on HEK cells overexpressing 
TRPC6 or TRPC5 or CHO cells overexpressing TRPV4 were used to address 
these aims.  
5.1.8. Galangin 
 
Galangin is a flavonoid found in high concentrations in honey (Kim et al., 2006). 
Several studies have suggested that galangin has several health benefits 
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including anti-cancer and anti-inflammatory effects and also decreases the risk 
for developing cardiovascular disease including stroke and hypertension 
(Hertog et al., 1993, Knekt et al., 1996, Rimm et al., 1996, Yochum et al., 1999). 
Studies have suggested that galangin works by modulating intracellular Ca2+. In 
one study looking at contractile responses of pig bladder it was found that 
galangin inhibited carbachol- and electrical field stimulated contractions in a 
concentration-dependent manner (Dambros et al., 2005). In this study they 
observed that galangin could inhibit responses in the absence of extracellular 
Ca2+, suggesting that galangin may exert its effect via ryanodine receptors 
(Dambros et al., 2005). In another study it was found that galangin could inhibit 
voltage-gated Cav1.2 channels with an IC50 of 13.4 µM (Saponara et al., 2011) 
whereas the structurally related flavonoids kaempferol and myricetin stimulated 
Cav1.2 channels with EC50s of 4.4 and 16 µM, respectively, with the differences 
in responses being attributed to small changes in the chemical structures of 
these compounds (Saponara et al., 2011). The second part of this chapter 
investigates whether galangin and structurally related compounds have any 
effect on TRPC6 channels.  
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5.2. TRPC6-mediated Ca2+ entry in overexpressing HEK cells 
 
HEK cells stably expressing mouse TRPC6 (mTRPC6) were used in Ca2+ 
measurement experiments on the FlexStation. TRPC6 channels were activated 
with either the membrane-permeable analogue of DAG, OAG or with carbachol, 
a muscarinic receptor agonist that stimulates TRPC6 indirectly through 
activation of PLCβ and production of DAG. In Ca2+ measurement experiments, 
OAG evoked a concentration-dependent increase in intracellular Ca2+ (Figure 5-
2 a,b). A concentration of 100 µM OAG also evoked a Ca2+ response in wild-
type HEK cells (Figure 5-2 c,d), which suggests that wild-type HEK cells 
express endogenous TRPC6 or related channels. However, the response in 
these cells was smaller and lower concentrations had no effect (Figure 5-2 c,d), 
indicating that the OAG-evoked Ca2+ entry in the TRPC6 expressing cells was 
primarily through TRPC6 channels.  
 
Carbachol also evoked a concentration-dependent rise in intracellular Ca2+. 
However, unlike OAG, which evoked a gradual Ca2+ entry response, the 
response to carbachol was rapid and transient, followed by a sustained 
elevation of the intracellular Ca2+ concentration (Figure 5-3a). The EC50 
generated from the maximal carbachol response was 1.2 µM (Figure 5-3b). In 
the absence of extracellular Ca2+, only the transient response was observed, 
with no sustained component. This was likely due to carbachol-evoked Ca2+ 
release from stores following activation of PLCβ and increased levels of IP3. 
Carbachol also evoked a Ca2+ response in wild-type HEK cells, but this 
response was transient and showed no sustained component (Figure 5-3d), 
indicating that the sustained increase in Ca2+ concentration in Figure 5-3a was 
due to carbachol-induced activation of TRPC6 channels.  
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Figure 5-2 OAG induces Ca2+ entry through TRPC6 channels.  
a. Example time-series graph showing the effect of OAG (0, 3, 30 and 100 µM) in 
HEK293 cells overexpressing mTRPC6 (N=6). b. Summary data for experiments of the 
type illustrated in a (n/N = 4/23; *P<0.05). c. Example time-series graph showing the 
effect of OAG (0, 3, 30 and 100 µM) in wild-type HEK293 cells (N=6). d. Summary data 
for experiments of the type illustrated in c, normalised to the 100 µM OAG response in 
a (n/N = 2/11).  
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Figure 5-3 Carbachol induces Ca2+ entry through TRPC6 channels.  
a. Example time-series graph showing the effect of carbachol (0.1, 1, 10 and 100 µM) 
in HEK293 cells overexpressing mTRPC6 (N=6). b. Concentration-response curve 
showing % maximum carbachol response, EC50 = 1.2 µM (N=6). c. Example of 
carbachol-induced Ca2+ response in 0 mM extracellular Ca2+ d. Example of carbachol-
induced Ca2+ response in wildtype HEK cells compared to 100 µM carbachol response 
in TRPC6 cells (N=6).  
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5.3. CAI inhibits TRPC6-mediated Ca2+ entry 
 
To determine if CAI (Figure 5-4a) could block TRPC6 channels, cells were pre-
treated with CAI or vehicle control for 30 minutes before FlexStation recordings. 
Pre-treatment of TRPC6 cells with 10 µM CAI significantly inhibited the OAG-
induced Ca2+ entry compared to DMSO controls (Figure 5-4b,c). CAI also 
inhibited the carbachol-evoked Ca2+ entry in a concentration dependent 
manner, with an IC50 of 1.89 µM for the sustained Ca2+ response, compared to 
vehicle control (Figure 5-5 a-b). 
 
5.4. CAI inhibits TRPC6-mediated ionic currents 
 
To further investigate the blocking effect of CAI on TRPC6-mediated Ca2+ 
responses, electrophysiological studies were performed.  TRPC6 channels 
were activated by 10 µM OAG in a 1.5 mM Ba2+ containing extracellular solution 
in the whole cell patch clamp experiment (Figure 5-6a). Ba2+ has a similar 
permeability to Ca2+ through mTRPC6 (Inoue et al., 2001). OAG activated large 
but transient inward and outward currents (mean current = 1.16 ± 0.21 nA at -80 
mV; mean current = 3 ± 0.35 nA at +80 mV; n=11), and the resulting current 
voltage relationship (I-V) was doubly rectifying, S shaped and reversed close to 
0 mV as reported previously (Figure 5-6b) (Hofmann et al., 1999, Boulay, 
2002). A high concentration (100 µM) of Gd3+ completely inhibited the current. 
Since OAG-induced currents were of a transient nature, it meant it was not 
possible to bath-apply CAI to the open channel in the conventional manner. 
Therefore cells were pre-treated with 10 µM CAI (or vehicle control) for 10 
minutes prior to OAG application. Cells that were pre-treated with CAI showed 
significantly smaller current amplitudes in response to OAG compared to cells 
pre-treated with DMSO alone (Figure 5-6 c-e).  
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Figure 5-4 CAI inhibits OAG-induced Ca2+ entry through TRPC6 channels.  
a. chemical structure for CAI. b. Example time-series trace showing inhibition of OAG-
induced Ca2+ entry by 10 µM CAI (n/N=4/10). c. Summary data for the experiments of 
the type illustrated in b (n/N=4/10; *P<0.05).  
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Figure 5-5 CAI inhibits carbachol-stimulated Ca2+ responses through TRPC6 
channels.  
a. Example time-series trace showing concentration-dependent inhibition of CAI on 
carbachol-induced Ca2+ response (N=6). c. Concentration-response curve for CAI 
measuring the sustained Ca2+ response (IC50 = 1.89 µM; n/N=3/24).  
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Figure 5-6 CAI inhibits OAG-induced TRPC6 currents.  
Recordings were made by whole-cell voltage-clamp from mTRPC6 expressing HEK 
cells. a. Example time course of current sampled at +80 mV and -80 mV during a 
voltage-ramp protocol, showing bath-application of vehicle control followed by 10 µM 
OAG and 100 µM Gd3+. b. Typical I-V relationship for the experiment shown in a. c. 
Example time course of current sampled at +80 mV and -80 mV during a voltage ramp 
protocol following, showing bath-application of 10 µM CAI followed by 10 µM OAG and 
100 µM Gd3+. d. Typical I-V relationship for the experiment shown in c. e. Mean data 
for OAG-induced TRPC6 current following pretreatment with either vehicle (DMSO; 
n=9) or CAI (n=10; *P<0.05). 
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5.5. CAI does not inhibit TRPC5-mediated ionic currents or TRPV4-
mediated Ca2+ entry 
 
To investigate if the block observed with CAI was specific for TRPC6, whole cell 
patch clamp recordings were performed on TRPC5 expressing HEK 293 cells. 
Ca2+ entry through TRPC5 channels was evoked by 30 µM Gd3+. Gd3+ evoked 
large and sustained inward and outward currents and the resulting I-V showed 
the TRPC5 signature, S shaped, doubly rectifying and crossing at close to 0 
mV. In the continued presence of Gd3+, TRPC5 channels remained open, which 
meant it was possible to bath-apply CAI to determine if it could block the 
channels. CAI applied to the open channels had no effect on the inward or 
outward current compared to vehicle controls (Figure 5-7).  
 
TRPV4 is a TRP family member from the vanilloid family and is expressed and 
functional in endothelial cells (Nilius et al., 2003). In breast cancer derived 
endothelial cells, arachidonic acid (AA) stimulated Ca2+ entry, which was 
blocked by CAI (Fiorio Pla et al., 2008). TRPV4 is activated by AA, and 
therefore Fiorio-Pla et al (2008) suggested that TRPV4 may be the target for 
CAI. To determine if this is the case, CHO cells stably expressing TRPV4 were 
used for Ca2+ imaging experiments. 4αPDD (a potent activator of TRPV4) 
evoked a large and sustained Ca2+ response that was absent in wild-type CHO 
cells. Pre-treatment for 30 minutes with CAI had no significant effect on the 
4αPDD-evoked Ca2+ entry into TRPV4 cells (Figure 5-7). 
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5.6. Structure-activity relationship of galangin compounds and 
TRPC6-mediated Ca2+ responses 
 
Previous studies in our lab showed that galangin was an effective blocker of 
TRPC5 channels, with an IC50 of 400 nM generated from Ca2+ imaging 
FlexStation experiments (Ben Green, Yasser Majeed, Jacqueline Naylor, Jing 
Li, unpublished data). It was found that making substitutions at the R1 position 
generated compounds that were effective TRPC5 channel blockers though the 
potency was not as great as that for galangin (Figure 5-8). Conversely, making 
substitutions at positions R2-R4 generated compounds that were ineffective 
TRPC5 channel blockers (Figure 5-8). The present study sought to determine 
the effects of these compounds against TRPC6. TRPC6 cells were seeded into 
96 well plates and loaded with the Ca2+ indicator dye Fura-2 AM. OAG (100 µM) 
was used to evoke a Ca2+ response through TRPC6 channels. To test the effect 
of galangin and its derivatives against TRPC6, cells were pre-treated with 10 
µM of each compound and OAG was applied in the presence of the compound. 
The percentage inhibition of the OAG-induced TRPC6 response was measured.  
Galangin inhibited the OAG-induced response by 65 ± 15.0%. The data for the 
galangin derivatives with for R1 – R4 substitutions are shown in Tables 5-1 – 5-
4 respectively. The data showed that all of the compounds tested had some 
inhibitory effect on TRPC6 ranging from 21-87% inhibition. However, there was 
no pattern to suggest any one of the R group substitutions generates better 
blockers than others. Further experiments would be needed to generate IC50 
values for these compounds in order to determine how efficacious these 
compounds really are.   
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Figure 5-8 Galangin derivatives as TRPC5 inhibitors.  
Galangin derivatives with an R1 substitution were effective inhibitors of TRPC5 
whereas derivatives with R2, R3 or R4 substitutions were mostly inactive. Unpublished 
data generated by Ben Green, Yasser Majeed, Jacqueline Naylor, Jing Li. Chemistry 
by Robin Bon (Leeds University). 
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5.7. Discussion and conclusions 
 
The results from this chapter showed that pre-treatment of TRPC6-expressing 
cells with CAI inhibited Ca2+ entry and ionic currents through TRPC6 channels 
suggesting that CAI is a novel TRPC6 channel blocker. In contrast, CAI had no 
effect on TRPC5-mediated ionic currents or on TRPV4-mediated Ca2+ influx. 
Galangin, a flavonoid found in honey and derivatives of galangin showed 
inhibitory effects ranging from 21-87% on TRPC6-mediated Ca2+ influx. 
However, there was no pattern to suggest that certain chemical groups made 
better or worse blockers which is in contrast to previous data generated in the 
lab showing structure activity relationships for galangin and its derivatives 
against TRPC5.  
 
Carbachol, a muscarinic receptor agonist, is widely used to stimulate TRPC6 
channels and the resulting Ca2+ response is composed of a transient Ca2+ 
response followed by a sustained Ca2+ entry response. In the absence of 
extracellular Ca2+ only the transient response remained, which suggested that 
this was due to Ca2+ release from intracellular stores following muscarinic 
receptor activation followed by PLC activation and IP3 formation. Importantly, 
when cells were pretreated with CAI, only the sustained response to carbachol 
was maximally inhibited, which suggests that CAI was blocking Ca2+ entry 
through TRPC6 and having little effect on Ca2+ release which would likely be 
due to IP3 formation. Faehling et al found that CAI inhibited IP3 formation, but 
Hupe et al found CAI had no effect on IP3 levels in leukocytes (Faehling et al., 
2002, Hupe et al., 1991). The IC50 for CAI on carbachol-evoked Ca2+ entry was 
2.5 µM. This value is comparable to IC50s generated in in vitro and in vivo 
angiogenesis studies where CAI was efficacious at concentrations of 1-10 µM 
(Felder et al., 1991, Kohn and Liotta, 1990, Kohn et al., 1992). In the clinic, 
cancer patients dosed with CAI maintained steady-state plasma concentrations 
of approximately 4-10 µM. CAI at these concentrations was well tolerated with 
adverse events graded 1-2, which included fatigue, depression, nausea, 
headache and constipation being the common ones (Hussain et al., 2003). 
Whole cell patch clamp experiments validated the Ca2+ imaging experiments 
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showing that pretreatment of TRPC6 cells with CAI resulted in a significant 
inhibition of the OAG-evoked ionic currents compared to the vehicle controls, 
confirming the Ca2+ measurement data that CAI inhibits TRPC6 channels at 10 
µM, a concentration that is efficacious against cancer and non-toxic.  
 
Under the experimental conditions used in this study, OAG evoked a large and 
transient current. The conventional method to investigate ion channel blockers 
is to apply them after channel activation and this is the method that was used to 
test the effect of CAI on TRPC5 ionic currents. However, the transient nature of 
the OAG response made this very difficult, therefore cells were pretreated with 
CAI prior to channel activation and this resulted in a significant inhibition of the 
OAG response observed in the vehicle control treated cells. The data generated 
do not entirely support that CAI directly blocks TRPC6 channels and to get this 
answer, photo-affinity labelling studies could be performed or outside-out patch 
clamp experiments. 
 
Previous studies in our lab showed that the flavonoid galangin could block 
TRPC5-mediated Ca2+ entry with an IC50 of 400 nM. In the present study, 
galangin had an inhibitory effect on TRPC6 but the block was not as good as for 
TRPC5, suggesting that galangin has selectivity for TRPC5 over TRPC6. 
Galangin R1-substituted compounds were also blockers of TRPC5, but the R2-
R4 substituted compounds were mostly inactive. For TRPC6 however, there 
was no pattern to the degree of block measured with the different R group 
substituted compounds. IC50 measurements would be needed to determine the 
efficacy of these compounds at the TRPC6 channel. The fact that galangin has 
been found to have health benefits and be anti-cancer suggests that blocking 
TRPCs may be a good therapeutic strategy for anti-cancer drugs. This fits in 
with accumulating data showing overexpression of TRPC6 in cancer.  
 
In conclusion, CAI and galangin (and its derivatives) are able to block TRPC6 
channels. Whether they directly block the channel remains to be determined but 
the data so far suggest that TRPC6 may be a good therapeutic target.  
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CHAPTER 6. FINAL SUMMARY AND CONCLUSIONS 
 
The overall objective of this thesis was to gain further insight into molecular 
mechanisms and pharmacology of Ca2+ entry mechanisms and their 
downstream signalling in endothelial cells. This was achieved using a range of 
molecular, biochemical and electrophysiology techniques and cell functional 
assays.   
 
The first objective was to investigate the putative Ca2+ channel regulator 
proteins, CRACR2A and golli-MBP. Unexpectedly these proteins had functions 
that were independent of Ca2+ channels, this finding lead to alternative 
hypotheses about their roles in endothelial cells. The second objective was to 
generate new information about pharmacology targeted to a Ca2+ channel 
subunit, TRPC6, which has been suggested to be important in endothelial cell 
biology. 
 
In Chapter 3 the putative Ca2+ channel regulator protein CRACR2A was 
investigated. A major finding was that CRACR2A, which had previously been 
identified as a novel interacting partner for Orai1 and involved in CRAC channel 
regulation, was not detected in endothelial cells. Instead a longer splice variant 
arising from the same gene, EFCAB4B isoform a (EFCAB4B-a), was detected. 
CRACR2A and EFCAB4B-a have the same putative Ca2+ binding domains at 
their N termini but EFCAB4B-a, unlike CRACR2A, had no role in the regulation 
of Ca2+ release-activated Ca2+ (CRAC) channels. Instead, EFCAB4B-a 
contained a predicted Rab domain in its C terminus and was therefore a 
putative monomeric G protein. The results showed that it localised to 
endothelial cell specific Weibel-Palade bodies (WPBs) where it influenced the 
abundance of the pro-thrombotic agent von Willebrand factor (vWF). Results 
also showed that depletion of EFCAB4B-a reduced VEGFR2 protein expression 
and histamine-stimulated Ca2+ entry into endothelial cells. It is therefore 
possible that EFCAB4B-a is involved in the biosynthetic pathway of VEGFR2 
and Ca2+ channel subunits, for example TRPC6. This is the first study to show 
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expression and function of this novel putative Ca2+ regulated Rab protein. This 
discovery is therefore a significant advancement in the field of monomeric G 
proteins. In addition, this important finding means EFCAB4B-a could be a novel 
therapeutic target in diseases involving vWF which include von Willebrands 
disease (VWD), atherosclerosis and cancer.  
 
Chapter 4 investigated golli-MBP and the results unexpectedly showed that 
golli-MBP had little effect on SOCE in endothelial cells. Instead, the results 
showed that golli-MBP was a positive regulator of VEGFR2 and suggests that 
golli-MBP may have a role in the biosynthetic pathway of VEGFR2. Since 
VEGFR2 is most important for its role in VEGF induced vascular permeability 
and angiogenesis, golli-MBP may be an important protein in tumour progression 
by stimulating angiogenesis.  
 
In Chapter 5 the results showed that the small-molecule carboxyamidotriazole 
(CAI), reported to have anti-cancer activity, was identified as an inhibitor of 
TRPC6 channels without effect on TRPC5 or TRPV4 channels. Since the first 
report of CAI as an anti-cancer agent, research has been on-going to try and 
elucidate the mechanism underlying its effects. The discovery in this study that 
CAI can inhibit TRPC6 channels at therapeutic concentrations will be of great 
interest to the field. It also strengthens existing evidence that TRPC6 may be an 
important ion channel in cancer progression. Not only that, since CAI showed 
selectivity for TRPC6 over TRPC5 and TRPV4, this finding will also be of 
interest to the TRP field, where there is a constant interest to find novel TRP 
channel blockers that can be used as research tools. A range of flavonol 
compounds was also identified as TRPC6 inhibitors, which will also be of 
interest to the TRP field in addition to the cardiovascular field where flavonols 
are continuing to be investigated for their cardiovascular health benefits. 
 
In summary, this research has generated new information and hypotheses 
about a putative Ca2+-regulated Rab protein of Weibel-Palade bodies, a novel 
regulator of a key endothelial growth factor receptor, and a molecular target for 
CAI. It has, therefore, led to understanding of molecular mechanisms and 
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pharmacology in endothelial cells which may be useful for devising strategies to 
treat major problems such as cardiovascular disease and cancer. 
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Figure 6-1 Cartoon summarising new hypotheses around EFCAB4B-a, Golli-MBP 
and the small molecule Ca2+ inhibitor, carboxyamidotriazole in endothelial cells, 
based on the results from this thesis.   
A novel Rab protein, EFCAB4B-a has been identified in endothelial cells. EFCAB4B-a 
localises to Weibel-Palade bodies (WPBs) along with Rabs 3a, 3b, 3d, 27a, 27b, 15, 
33a and 37. Rabs 3a, 3d, 15, 27a and 27b have reported roles in vWF secretion 
(reviewed in (Nightingale and Cutler, 2013). WPBs travel along microtubules using the 
motor proteins kinesin and dynein, for forward and retrograde traffic respectively. 
Increases in intracellular Ca2+ stimulate the forward trafficking and release of von 
Willebrand factor (vWF) from the cell, which is particularly important for blood clotting. 
Increases in intracellular Ca2+ or cAMP can result in WPBs travelling in the reverse 
direction and accumulating at the microtubule organising centre (MTOC). Based on 
results from this thesis, one hypothesis is that EFCAB4B-a is involved in the retrograde 
trafficking of WPBs through an interaction with dynein. Since depletion of EFCAB4B-a 
resulted in a suppression of total VEGFR2 in the cell, another hypothesis may be that 
EFCAB4B-a is involved in the biosynthetic pathway of VEGFR2, in a similar way to 
syntaxin-6. The role of the Ca2+-binding EF-hand remains to be determined. Depletion 
of Golli-MBP had little effect on store-operated Ca2+ entry in endothelial cells. Instead 
depletion of Golli-MBP suppressed total VEGFR2 protein levels, suggesting that Golli-
MBP is also involved in the trafficking or biosynthetic pathway of VEGFR2. The role of 
Ca2+ is unknown at present. Finally, the small molecule Cra2+ inhibitor, 
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carboxyamidotriazole (CAI) was found to inhibit TRPC6 channels in HEK293 cells. 
Expression of TRPC6 has previously been identified on endothelial cells and it has 
been shown that TRPC6 is involved in VEGF-evoked Ca2+ responses that underlie 
angiogenesis in vitro. The hypothesis is therefore that CAI inhibits endothelial TRPC6 
channels that are important for VEGF-evoked angiogenesis. Results from this thesis 
also showed that depletion of EFCAB4B-a using siRNA, resulted in a reduced Ca2+ 
entry following histamine stimulation. It is possible that at least part of this Ca2+ entry is 
through TRPC6 channels. Another hypothesis is therefore that EFCAB4B-a is involved 
in the biosynthetic pathway of TRPC6 channel subunits. WPB: Weibel-Palade Body; 
H1: histamine receptor 1; MTOC: microtubule organising centre; CAI: 
carboxyamidotriazole; vWF: von Willebrand factor; VEGF: vascular endothelial growth 
factor; VEGFR2: vascular endothelial growth factor receptor 2; DAG: diacylglycerol; 
PLC: phospholipase C; PM: plasma membrane. 
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